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Abstract 	  
Right ventricular dysfunction is the most frequent cause of death in patients with 
pulmonary arterial hypertension. Although abnormal energy substrate use has been 
implicated in the development of chronic left heart failure, data describing such 
metabolic remodeling in failing right ventricular tissue remain incomplete. In the present 
dissertation we sought to characterize metabolic gene expression changes and 
mitochondrial dysfunction in functional and dysfunctional RV hypertrophy.  
Two different rat models of RV hypertrophy were studied. The model of right ventricular 
failure (SU5416/hypoxia) exhibited a significantly decreased gene expression of 
peroxisome proliferator-activated receptor- coactivator-1α, peroxisome proliferator- 
activated receptor-α and estrogen-related receptor-α. The expression of multiple 
peroxisome proliferator-activated receptor- coactivator-1α target genes required for fatty 
acid oxidation was similarly decreased. Decreased peroxisome proliferator-activated 
receptor- coactivator-1α expression was also associated with a net loss of mitochondrial 
protein and oxidative capacity. Reduced mitochondrial number was associated with a 
downregulation of transcription factor A, mitochondrial, and other genes required for 
mitochondrial biogenesis. Electron microscopy demonstrated that, in right ventricular 
failure tissue, mitochondria had abnormal shape and size. Lastly, respirometric analysis 
demonstrated that mitochondria isolated from right ventricular failure tissue had a 
significantly reduced ADP- stimulated (state 3) rate for complex I. Conversely, functional 
right ventricular hypertrophy in the pulmonary artery banding model showed normal 
expression of peroxisome proliferator-activated receptor- coactivator-1α, whereas the 
expression of fatty acid oxidation genes was either preserved or unregulated. Moreover, 
	   vi	  
pulmonary artery banding-right ventricular tissue exhibited preserved transcription factor 
A mitochondrial expression and mitochondrial respiration despite elevated right 
ventricular pressure-overload. We conclude that right ventricular dysfunction, but not 
functional right ventricular hypertrophy in rats, demonstrates a gene expression profile 
compatible with a multilevel impairment of fatty acid metabolism and significant 
mitochondrial dysfunction, partially independent of chronic pressure-overload. 	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Chapter 1: General introduction to pulmonary hypertension and right ventricular 
failure. Rationale and outline of the thesis 
 
Segments of this chapter have been previously published in: 
Voelkel NF, Gomez-Arroyo J, et al. Pathobiology of pulmonary arterial hypertension 
and right ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565. 
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CHAPTER 1 
 
 
“Further research is essential in order that the etiology of the disease to be discovered. 
Once the mechanism is known, perhaps it can be arrested or reversed […] Thus, the 
ultimate hope is for a discovery of the basic mechanisms which now are unknown” 
 
N.F Voelkel and J.T. Reeves, 1979 
 
 
1. 1 General introduction to pulmonary hypertension  
 
 Pulmonary hypertension (PH) or high blood pressure in the lung circulation, 
occurs in a broad spectrum of diseases of the lung and is defined as an elevation of the 
mean pulmonary artery pressure > 25 mmHg(210). Because many lung and systemic 
diseases can be associated with pulmonary hypertension, five World Heath Organization 
(WHO) meeting groups have worked to categorize PH, since the first classification of the 
disease in 1973. Indeed, nowadays the different etiologies of PH have been classified into 
5 different groups (Table 1). Understanding the differences between the WHO groups is 
critical not only for medical management of the patient with PH but also for the 
understanding of the pathogenesis. For the purposes of this dissertation, one could 
simplify the causes of PH in two broad groups: 1) Diseases affecting the arterial  (pre-
capillary) component of the lung circulation, that is, lung vessels that take deoxygenated 
	   3	  
blood from the right side of the heart (right ventricle) to the lungs and 2) Diseases 
affecting the venous (post-capillary) component of the lung circulation, which carries 
oxygenated blood to the left ventricle ready to be pumped into the systemic circulation. 
In addition to the hemodynamic criterion of a high mean pulmonary artery pressure 
(mPAP), the diagnostic definition of WHO Group 1, or pulmonary arterial hypertension 
(PAH), adds the criterion of a pulmonary arterial wedge pressure <15 mmHg, which 
largely rules out the presence of left heart disease. Although Groups 3, 4 and 5 include 
diseases or conditions associated with arterial lung vascular disease, the pathobiology of 
the diseases included in these groups is significantly distinct from Group 1. The reader 
should be aware that the entire dissertation is focused on Group 1, or pulmonary 
arterial hypertension (PAH).  
As noted in Table 1, PAH includes conditions that range from congenital heart disease 
(different from WHO Group 2 which lists acquired left heart disease), infections, drug-
induced, hepatopulmonary syndrome, as well as sporadic idiopathic (unknown) and 
hereditary idiopathic forms. All forms of PAH are characterized by elevated pulmonary 
arterial pressure and elevated blood flow resistance due to a precapillary pulmonary 
microangiopathy(243). However, although PAH is a disease originated in the lungs, 
patients with the disease die from right ventricular failure(49, 197).  
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Table 1. Classification of Pulmonary Hypertension 
 
 
 
 
like kinase 1 or endoglin) and familial cases with or without
identified germline mutations (13,14). The new category of
“heritable PAH” does not mandate genetic testing in
patients with IPAH or in familial cases of PAH. Genetic
testing, when called for, should be performed as a part of a
comprehensive program that includes genetic counseling
and discussion of the risks, benefits, and limitations of such
testing (15).
1.3. Drug- and toxin-induced PAH. A number of risk
factors for the development of PAH have been identified
and were included in the previous Evian and Venice
classifications (3,5). Risk factors for PAH include “any
factor or condition that is suspected to play a predisposing
or facilitating role in the development of the disease. Risk
factors may include drugs and chemicals, diseases, or phe-
notype (age, gender).” Risk factors were categorized as
definite, very likely, possible, or unlikely, based on the
“strength of their association with PH and their probable
causal role.” In the current classification, the categorization
of risk factors and the likelihood of developing PAH have
been modified. Updated risk factors and associated condi-
tions for PAH are presented in Table 3. A “definite”
association is defined as an epidemic, such as occurred with
appetite suppressants in the 1960s, or large, multicenter
epidemiologic studies demonstrating an association between
a drug and PAH. A “likely” association is defined as a
single-center, case-control study demonstrating an associa-
tion or a multiple-case series. “Possible” is defined as drugs
with similar mechanisms of action as those in the “definite”
or “likely” categories but which have not yet been studied
(e.g., drugs used to treat attention-deficit disorder). Lastly,
an “unlikely” association is defined as one in which a drug
has been studied in epidemiologic studies and an association
with PAH has not been demonstrated.
Aminorex, fenfluramine derivatives, and toxic rapeseed
oil represent the only identified “definite” risk factors for
PAH (3,5). A recent retrospective analysis of more than 100
cases of PAH associated with fenfluramine exposure showed
that this category shares clinical, functional, hemodynamic,
and genetic features with IPAH, suggesting that fenflura-
mine exposure represents a potential trigger for PAH
without influencing its clinical course (16).
The most recent surveillance study of PH, Surveillance of
Pulmonary Hypertension in America (SOPHIA), enrolled
1,335 subjects at tertiary PH centers in the U.S. between
1998 and 2001 (17). This study confirmed the association of
fenfluramine and dexfenfluramine intake with the develop-
ment of PAH. The average monthly number of IPAH cases
did not change during the study, which was, however,
conducted after fenfluramine and its derivates had been
withdrawn from the U.S. market. A novel finding was that
St. John’s Wort (odds ratio [OR]: 3.6, vs. thromboembolic
PH) and over-the-counter antiobesity agents containing
phenylpropanolamine (OR: 5.2, vs. thromboembolic PH)
also increased the risk of developing IPAH.
The SOPHIA study examined intake of a variety of
nonselective monoamine reuptake inhibitors, selective sero-
tonin reuptake inhibitors, antidepressants, and anxiolytics,
and found no increased risk for developing PAH (17).
However, a recent case-control study of selective serotonin
Updated Risk Factors foran Assoc ated Conditi ns of PAH
Table 3 Updated Risk Factors forand Associated Conditions of PAH
Definite Possible
Aminorex Cocaine
Fenfluramine Phenylpropanolamine
Dexfenfluramine St. John’s Wort
Toxic rapeseed oil Chemotherapeutic agents
SSRI
Likely Unlikely
Amphetamines Oral contraceptives
L-tryptophan Estrogen
Methamphetamines Cigarette smoking
PAH ! pulmonary arterial hypertension; SSRI ! selective serotonin reuptake inhibitor.
Updated Clinical Classification ofPulmonary Hyperten ion (Dana Point, 2008)
Table 2 Updated Clinical Classification ofPulmonary Hypertension (Dana Point, 2008)
1. Pulmonary arterial hypertension (PAH)
1.1. Idiopathic PAH
1.2. Heritable
1.2.1. BMPR2
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic
telangiectasia)
1.2.3. Unknown
1.3. Drug- and toxin-induced
1.4. Associated with
1.4.1. Connective tissue diseases
1.4.2. HIV infection
1.4.3. Portal hypertension
1.4.4. Congenital heart diseases
1.4.5. Schistosomiasis
1.4.6. Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn
1=. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary
hemangiomatosis (PCH)
2. Pulmonary hypertension owing to left heart disease
2.1. Systolic dysfunction
2.2. Diastolic dysfunction
2.3. Valvular disease
3. Pulmonary hypertension owing to lung diseases and/or hypoxia
3.1. Chronic obstructive pulmonary disease
3.2. Interstitial lung disease
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4. Sleep-disordered breathing
3.5. Alveolar hypoventilation disorders
3.6. Chronic exposure to high altitude
3.7. Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell
histiocytosis: lymphangioleiomyomatosis, neurofibromatosis, vasculitis
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid
disorders
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure
on dialysis
Main modifications to the previous Venice classification are in bold.
ALK1! activin receptor-like kinase type 1; BMPR2! bone morphogenetic protein receptor type
2; HIV ! human immunodeficiency virus.
S45JACC Vol. 54, No. 1, Suppl S, 2009 Simonneau et al.
June 30, 2009:S43–54 Classification and Epidemiology
 by Miguel Beltran on June 22, 2009 content.onlinejacc.orgDownloaded from 
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Table 1. Updated clinical classification of pulmonary arterial hypertension groups 
according the World Health Organization. ALK1 = activin receptor-like kinase type 1; 
BMPR2 = bone morphogenetic protein receptor type 
2; HIV = human immunodeficiency virus. Reproduced from Simonneau G, et al. Updated 
clinical classification of pulmonary hypertension. Journal of the American College of 
Cardiology. 2009 Jun 30;54(1 Suppl):S43–54. Copyright 2009, with permission from 
Elsevier.  
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1.2 Brief historical and current perspective of the disease 
 
Idiopathic pulmonary arterial hypertension (IPAH), formerly known as primary 
pulmonary hypertension, is the best-characterized form of PH. The term idiopathic refers 
to a disease of unexplained etiology and therefore patients diagnosed with IPAH do not 
have a coexisting cardiac or pulmonary disease(209). In other words, the diagnosis of 
IPAH remains a ‘diagnosis of exclusion’. The disease was first described in 1891 by 
Romberg and later on by Ayerza in 1901 who reported patients with heart failure and 
severe cyanosis (‘negros cardiacos’) associated with ‘brochopulmonary sclerosis’(247). 
The first systematic description was not reported until 1935 by Brenner(29) and did not 
become a clinical entity until 1951, when Dresdale and collaborators described its clinical 
and hemodynamic features(247). All forms of PAH, including IPAH, are characterized 
by a common histopathological feature: the presence of plexiform-like lesions (Figure 1) 
(243), hence the former name of ‘unexplained plexogenic pulmonary arteriopathy’. This 
concept was further developed by Heath and Edwards who, in 1958, defined the 
structural vascular changes in the lungs of patients with PAH(247). After first 
anorexigen-induced (aminorex fumarate) epidemic of pulmonary hypertension in Europe 
in 1967-1970, the husband and wife Wagenvoort and Wagenvoort reported the largest 
series of autopsied patients providing the structural criteria for the diagnosis of PAH and 
its separation from other forms of pulmonary hypertension, which now are included in 
WHO Groups 2-5.  
It should be noted that unlike other diseases, including infectious diseases, cancer or 
even pulmonary or cardiovascular (myocardial infarction, atherosclerosis, stroke) 
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diseases, PAH was a relatively unrecognized medical condition until rather recently. 
As reviewed by Voelkel and Reeves, until the year 1979(241), researchers and clinicians 
knew that PAH was a lung vascular disease predominantly affecting women (5:1), that it 
could affect patients of any age but the highest incidence occurred between the ages of 25 
and 29 years and perhaps, most importantly, it was well recognized that the disease had 
no cure or treatment and therefore, upon diagnosis, the prognosis of the patient was 
dismal. Indeed, the mean survival time of patients was 2 to 3 years after diagnosis(247). 
Because of the heterogeneity of the data collected from rather small patient cohorts, in 
1981, the Patient Registry for the Characterization of Primary Pulmonary Hypertension 
was established by the National Heart, Lung, and Blood Institute of the National 
Institutes of Health. This was the first prospective collection of data based on 
standardized protocols, which included a initial diagnostic catheterization(49). A total of 
194 patients from 32 medical centers in the United States were recruited and followed-up 
in order to define survival patterns based on hemodynamic parameters. The data of this 
registry provided for the first time a solid hemodynamic description of IPAH and 
demonstrated that survival strongly correlated with the function of RV. 
Five World Symposia on pulmonary hypertension have taken place in the past two 
decades (the last in 2013) and scientists as well as clinicians have thoroughly categorized 
the diverse forms of PH and have consolidated the data produced in many laboratories 
and clinical centers around the world. Today, almost a quarter of a century after first NIH 
national registry, the data from the Registry to Evaluate Early and Long Term PAH 
Disease Management (REVEAL), the largest registry in the United States, indicate that 
the phenotype of idiopathic PAH, has significantly changed. Today, up to 79% of patients 
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are obese women close to menopausal age (69). However, there is an apparent 
discrepancy in the PAH phenotype between US and European registries(62, 105, 169), 
suggesting, perhaps, currently unidentified regional environmental factors that could 
contribute to the development and progression of the disease. Furthermore, PAH is no 
longer an orphan disease(102). Unlike 20 years ago, three classes of drugs have been 
developed and an increasing number of patients are being treated with a single drug or a 
combination therapy (22, 104). The advent of PAH-specific therapies has improved the 
survival of PAH patients in comparison the survival published in historic registries. 
However, in spite of treatment, the mortality remains unacceptably high, as the 
survival for incident patients continues to be as low as 54.9% at 3 years after diagnosis 
(95% CI, 41.8 to 68.0)(107). In other words, although new therapies improve 
survival, PAH remains an incurable and rapidly progressive disease. Indeed, 
although the structural changes that explain the “fixed pulmonary hypertension” of PAH 
patients have been described in recent decades (13, 181, 250) and new pathobiological 
concepts of PAH have been described(199, 232), current PAH-specific drugs are 
predominantly vasodilators(106) and do not stop the progression of the disease(213). 
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Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
B 
replicative potential. The complex vascular lesions of severe
PAH are governed by some, but not all, of these traits. Thus,
although the lesions are not cancer in the true sense of the word,
they are certainly neoplasms in that there is a process of
abnormal and uncontrolled growth of cells. The lesions are
angiogenic (7), there are no apoptotic cells found in the lesions
(24, 37, 38), and antiapoptotic proteins are expressed in the
lesion cells (20). Impaired transforming growth factor (TGF)-b
signaling may make the lesional endothelial cell insensitive to
the endothelial cell growth–controlling effects of TGF-b (39),
and speculating further, abnormal endothelial cells with a hyper-
proliferative potential could be released from the complex
vascular lesions and recirculate into the lung where they are
then trapped within partially obliterated lung vessels. The pro-
liferating endothelial cells of the complex vascular lesions ap-
pear to proceed ‘‘via a process formally analogous to Darwinian
evolution, in which a succession of genetic changes, each confer-
ring one or another growth advantage, leads to the progressive
Figure 2. Hematoxylin-and-eosin–stained section from
a lung of a patient with idiopathic pulmonary arterial
hypertension demonstrating the intraluminal proliferation
of endothelial cells that occurs in severe angioproliferative
pulmonary hypertension. Arrows indicate the bland, flat-
tened endothelial cells lining the lumen of newly formed
vessels. The upper right inset shows a higher power view of
the endothelial cells that comprise these lesions.
Figure 3. A panel of plexiform lesions demonstrates the expression pattern of several markers of malignancy. (A) Expression of p16 in the central
part of two plexiform lesions (in proximal portions of bifurcating vessels). (B) Highly expressed b-catenin. (C) Luminal endothelial cell expression of
multiple drug resistance protein (MDRP) in a plexiform lesion. (D) Increased expression of survivin in central portion of plexiform lesion. (E) Dense
expression of chemokine receptor (CXCR)-4 in a plexiform lesion. (F) Expression of epithelial growth factor receptor (EGFR)-3 in a plexiform lesion.
560 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 178 2008
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Figure 1. Comparison between a plexiform-like lesion from the lung of a patient 
with pulmonary arterial hypertension and a renal glomerulus. Micrographs obtained 
with a light-microscope illustrate the similarities between a classic plexiform-like lesion 
in a patient with pulmonary arterial hypertension (A) and a normal renal glomerulus (B). 
Complex vascular remodeling, as illustrated in panel A, is not present in the lung under 
normal conditions. Panel A figure was reprinted with permission of the American 
Thoracic Society. Copyright © 2013 American Thoracic Society from Rai PR, et al. The 
cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 
2008,15;178(6):558–564 (Ref. (178, 183)).  
Official Journal of the American Thoracic Society. Panel B was reproduced from Pontén 
F et al. A global view of protein expression in human cells, tissues, and organs. Mol Syst 
Biol. 2009 5:337 (Ref (49, 178)).  
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1.3 Outline of the dissertation, justification and general hypothesis  
The entire dissertation consists of seven chapters. CHAPTER 2 is a compendium of the 
current literature discussing the pathobiology of PAH, which has significantly evolved 
from the early concepts proposed by many experts two decades ago. Although the data 
derived from cell-based models and human samples have provided the basis for the 
generation of novel hypotheses about the genesis of the disease, many questions remain 
unanswered. Because, animal models of the disease are fundamental not only to the better 
understanding of the disease but also for pre-clinical testing of new pharmacotherapies, in 
CHAPTER 4 we broadly discuss the existing literature, as well as our own data, 
regarding the current animal models utilized to study PAH. Given that an ‘ideal’ animal 
model of pulmonary is not yet available, we sought to characterize the problems and 
prospects of the most prevalent animal model of pulmonary hypertension, the 
monocrotaline-injury and the SU5416/hypoxia rat models, as well as several transgenic 
mouse models reported in the literature and studied in our laboratory. This chapter is of 
particular importance to the reader because it provides the necessary rationale for 
the use of the SU5416/hypoxia rat model of PH, the principal animal model used for 
the studies described in this dissertation.   
The direct consequence of the lung vascular remodeling present in patients with PAH are 
restricted blood flow and increased vascular resistance, all of which translates into 
increased right ventricular afterload (Figure 2)(246). Although, right ventricular failure 
(RVF) is the most frequent cause of death of patient with PAH(22, 49, 104, 197), the 
interactions between the remodelled lung circulation and the right ventricle (RV) are only  
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Figure 2.  
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Figure 2.  Pulmonary Arterial Hypertension: Natural history of disease. Schematic 
representation of the natural history of pulmonary arterial hypertension. Pulmonary 
vascular remodeling will be directly translated into increased blood flow resistance and 
therefore, increased pulmonary pressure. Right ventricular dysfunction and failure will be 
the direct consequence of increased pulmonary pressure (also known as RV after load). 
Image of lung vascular lesion was reproduced from Rai PR, et al. The cancer paradigm 
of severe pulmonary arterial hypertension. Am J Respir Crit Care Med. 
2008,15;178(6):558–564 (Ref. (183)). 
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partially understood(246). Furthermore, a detailed description of the cellular and 
molecular mechanistic elements that explain RV failure (“RV failure program”) is 
incomplete.  
Given the prognostic importance of RV dysfunction/failure in PAH, understanding 
the mechanisms underlying the transition from adaptive (functional) to maladaptive 
(dysfunctional) right ventricular hypertrophy is critical, particularly if any to these 
mechanisms can be prevented or reversed. 
 
CHAPTER 3 discusses pertinent data highlighting unmet needs based on our current 
concepts of the pathobiology of RVF and provides an overall justification for the study of 
RV failure mechanisms. Chapter 3 also provides the basic cardiac physiology concepts 
that underlie the experimental approaches taken. As part of a preliminary project, we 
studied explanted hearts obtained from autopsy material of two different groups with 
pulmonary arterial hypertension and analyzed the differences in RV hypertrophy. These 
data are presented as part of Chapter 3.   
Indeed, our knowledge of the pathobiology and pathophysiology of RVF has evolved 
from the state available two decades ago. New concepts such as fibrosis, capillary 
rarefaction, cardiac hibernation and cardiomyocyte apoptosis now complement the 
classical theory of load-dependent, wall stress-induced RV dysfunction. Because left 
ventricular failure, in the setting of chronic pressure overload (i.e systemic hypertension) 
is characterized by changes in energy substrate utilization and abnormal mitochondrial 
biology, we sought to characterize the changes in mitochondrial energy metabolism 
during RV failure.  
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We hypothesized that maladaptive RV hypertrophy, but not functional/adaptive RV 
hypertrophy would be characterized by abnormal cardiac metabolism and 
mitochondrial dysfunction.   
 
To begin to address our research question, we utilized 2 different animal models of 
chronic RV pressure overload, the SU5416/hypoxia and the pulmonary artery banding 
models. CHAPTER 5 provides a detailed description of the methodology used 
throughout the studies and the results are presented in CHAPTER 6. Lastly, CHAPTER 
7 includes published and unpublished data regarding additional therapeutic strategies 
utilized to reverse the metabolic changes and RV failure described in Chapter 6. 
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Chapter 2: Pathobiology of Pulmonary Arterial Hypertension 
 
Segments of this chapter have been previously published in: 
Voelkel NF, Gomez-Arroyo J, et al. Pathobiology of pulmonary arterial hypertension 
and right ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565. 
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CHAPTER 2 
 
 
 
“Mexiform lesion” - © Jose Gomez-Arroyo 
 
 
2.1 Introduction 
As briefly stated in Chapter 1, our knowledge of the pathobiology of PAH has 
significantly changed from what was initially proposed two decades ago(243). Early 
hypotheses derived from autopsy studies and animal models of hypoxia-induced 
pulmonary hypertension postulated that 1) vasoconstriction, 2) vascular remodeling and 
3) thrombosis in situ were the main components contributing to the development of the 
disease. Indeed these three components became the main targets for the therapies 
designed to treat patients with PAH(106). However, whereas it is true that 
vasoconstriction plays a role in the disease, that a small group of patients have a highly 
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vasorreactive (perhaps, completely different) form of PAH, and that thrombosis is 
frequently observed in small vessels(71), the use of vasodilator therapy and 
anticoagulants has not had a great impact on disease progression(72, 213). Therefore, 
new hypotheses based on human samples, cell-based and animal models have been 
developed.  Although some of these concepts have been previously considered as part of 
the disease (Figure 3), mechanistic studies addressing the role of genetics, epigenetics 
and immune dysregulation in the pathogenesis of the PAH had not been reported until 
rather recently. This chapter intends to put in perspective the newly postulated 
pathobiological concepts of PAH, which reflect the progress made in the understanding 
of this complex pulmonary vascular disease.  
 
2.2 Genetic influences and epigenetics in PAH 
The pathogenesis of PAH is based on more than one hits, and genetic factors conferring a 
predisposition for the development or progression of severe PAH may be required as one 
of the hits (Figure 4)(136, 157, 175). Mutations of the Bone Morphogenic Type II 
Receptor (BMPR2) gene, a member of the transforming growth factor (TGF-β) 
superfamily, were first described in patients with familial/hereditary PAH (HPAH)(157). 
Although BMPR2 mutations in HPAH have a high prevalence (70%), limited numbers of 
patients with IPAH have mutations(136), and only 20% of the carriers ever develop PAH 
during their lifetime(136).  BMPR2 mutation carriers at the time of PAH-diagnosis are 
younger (77, 175) and less likely have a vasoreactive component(59). A large number of 
mutations have  
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Figure 3. Early postulated hypothesis of the pathogenesis of pulmonary arterial 
hypertension.  
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Figure 3. Data derived from the analysis of human samples and from the study of animal 
models of hypoxic pulmonary hypertension lead to the generation of early hypotheses 
that considered vasoconstriction a central component of the pathogenesis of pulmonary 
hypertension. Copyright 1979. Reproduced with permission of the publisher. The image 
was obtained from Voelkel N, Reeves JT. Chapter 10: Primary Pulmonary Hypertension. 
In: Moser KM, editor. Pulmonary Vascular Diseases. New York: Marcel Dekker, Inc; 
1979. 
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been reported and the majority translate into a loss of function (137) or reduced BMPR2  
expression(14). It has been reported that the disease appears to be more severe when 
patients carry a truncating BMPR2 mutation(15) however, this appears not to be the case 
in the French patients (77).  Mechanistic studies indicate that BMPR2 mutations are 
permissive but not necessary for the development of severe PAH. BMPR2 may be one of 
the guardians of lung vessel homeostasis, as gene knockout and silencing experiments 
have clearly demonstrated that both apoptosis and cell proliferation of pulmonary 
vascular smooth muscle and endothelial cells are controlled by BMPR2(150). Intact 
BMPR2 signaling may be necessary for the execution of a normal lung vascular wound-
healing program, preventing apoptosis-induced compensatory cell proliferation. BMPR2 
loss makes cells more susceptible to apoptosis(226), however, vascular cell-apoptosis 
alone, is insufficient for angioproliferation to occur. BMPR2 signaling appears to define 
the cellular identity during reparative responses(230). BMP signaling is regulated at 
many different levels and each level could potentially contribute to abnormal BMPR2 
function, without necessarily involving a mutation in the BMPR2 gene(150). For 
example, mutations in the type I TGF-β receptor, ALK-1(76, 218, 229), have been 
observed in patients with severe PAH occurring in families with hereditary hemorrhagic 
telangiectasia. Moreover, although infrequent, mutations in the BMPR2-downstream 
mediators, the smad proteins, have also been described in PAH patients(155). In the 
aggregate the data indicate that BMP/TGF-β signalling plays an important role in the 
maintenance of the normal lung arteriolar structure.  
Epigenetic mechanisms influence gene expression via modifications of the chromatin, 
histones and regulatory micro RNAs(95). At present, there is no firm evidence that PAH  
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Figure 4. Hallmarks of severe angioproliferative pulmonary arterial hypertension. 
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FIGURE 1. Hallmarks of severe angioproliferative pulmonary arterial hypertension. Genetic determinants, epigenetic factors and other conditions synergise and result in
the injury and apoptosis of pulmonary arteriolar endothelial cells. Endothelial cell apoptosis triggers compensatory proliferation of phenotypically abnormal endothelial cells.
Apoptosis may also be the initiating event, activating the bone marrow to release precursor and stem cells and eliciting a local immune response of the vascular wall. The end
result is the complex vascular lesion, the plexiform lesion. These complex lesions obliterate the lumen of small arteries, predominantly localised to vessel bifurcations. The
mature lesions are composed of endothelial cells (dark purple), smooth muscle cells (yellow), apoptotic cells (purple) and phenotypically altered apoptosis-resistant
endothelial cells (red). These cells, together inflammatory cells, populate a microenvironment of exuberant cell growth. BMPR2: bone morphogenic type II receptor; ALK-1:
activin A receptor type-II like-1; HSC: hematopoietic stem cell; EPC: endothelial progenitor cell.
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Figure 4. Genetic determinants, epigenetic factors and other conditions synergise and 
result in the injury and apoptosis of pulmonary arteriolar endothelial cells. Endothelial 
cell apoptosis triggers compensatory proliferation of phenotypically abnormal endothelial 
cells. Apoptosis may also be the initiating event, activating the bone marrow to release 
precursor and stem cells and eliciting a local immune response of the vascular wall. The 
end result is the complex vascular lesion, the plexiform lesion. These complex lesions 
obliterate the lumen of small arteries, predominantly localised to vessel bifurcations. The 
mature lesions are composed of endothelial cells (dark purple), smooth muscle cells 
(yellow), apoptotic cells (purple) and phenotypically altered apoptosis-resistant 
endothelial cells (red). These cells, together inflammatory cells, populate a 
microenvironment of exuberant cell growth. BMPR2: bone morphogenic type II receptor; 
ALK-1: activin A receptor type-II like-1; HSC: hematopoietic stem cell; EPC: 
endothelial progenitor cell. Copyright 2012. Reproduced with permission of the publisher 
from Voelkel NF et al, et al. Pathobiology of pulmonary arterial hypertension and right 
ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565. 
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has an epigenetic component(119). Downregulation of BMPR2 expression has been  
explained by activation of a STAT3/miRNA-17-92 microRNA axis in normal human 
lung endothelial cells after interleukin-6 exposure(31). Interestingly, mice overexpressing 
IL-6 develop severe pulmonary hypertension(214) and, unlike other PH mice models , 
also develop angioobliterative vascular remodelling and robust RV hypertrophy(82). 
Overexpression of miR-17 also increases proliferation of human pulmonary artery 
smooth muscle cells and inhibition with an specific miR-17 antagomir ameliorated PH in 
two experimental models(180). Another microRNA, miRNA-204, has been found 
downregulated in pulmonary artery smooth muscle cells isolated from patients with 
PAH(44). Upregulation of miR204 seems to induce an apoptosis-resistant phenotype in 
smooth muscle cells.  
2.3 The paradigm shift: From vasoconstriction to cell growth.   
Terms like “cell phenotype switch,” “apoptosis-resistance” and “angiogenic niche” have 
introduced a new vocabulary which can be used to explain the pathobiology of 
PAH(183). The early pioneers of PH research focused their attention on hypoxic 
vasoconstriction(254), and because the arachidonic acid-derived prostacyclin is a 
powerful inhibitor of hypoxic pulmonary vasoconstriction(242), it was thus intuitive to 
establish prostacyclin infusion as the first treatment for severe PAH(17). Since then, rapid 
progress has been made. Our knowledge of the cellular and molecular components 
involved in the pathobiology of PAH has expanded and these new insights are likely to 
change our future approach to the treatment of PAH. We now regard the plexiform 
pulmonary vascular lesions as a product of an angioproliferative process leading to 
vascular occlusion (angioobliteration)(183, 232) and we appreciate that these lesions are 
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composed of a multitude of cell types, among them, actively dividing and phenotypically 
abnormal apoptosis-resistant endothelial cells with a monoclonal origin(129), progenitor 
cells(148) and immune cells(40, 171, 172). Immunohistochemistry, using antibodies 
directed against cell surface epitopes and nuclear markers of cell activation, identifies 
different cell phenotypes with their expressed genes and proteins(183). Hallmarks of 
cancer in angioproliferative PAH have been described, in particular angiogenesis(232), 
metabolic changes(262) and apoptosis-resistant cells(193). Based also on the therapy 
refractoriness of PAH, a hypothesis of “quasi-malignancy” has been proposed(183): 
apoptosis may be the initiating event followed by the selection of  proliferating  
apoptosis-resistant cells –some of which may be stem cells (Figure 4). PAH plexiform 
lesions also show decreased expression of the tumor-suppressor protein peroxisome 
proliferator activated receptor (PPAR) gamma(9), while exhibiting increased expression 
of β-catenin, CXCR4 (a receptor that mediates metastatic cell homing), and survivin, 
among other(183). Survivin, an inhibitor of apoptosis, is expressed in essentially all 
cancers, and cultured cells isolated from the lungs of PAH patients exhibit a markedly 
increased expression of survivin. Moreover, experimental gene therapy targeting this 
protein suppresses proliferation and ameliorates PAH in rats(141). Another hallmark of 
cancer is the metabolic switch towards glycolysis (Warburg effect, perhaps as a defense 
against oxidative damage). Pulmonary arterial endothelial cells from IPAH patients 
cultured in vitro, demonstrate reduced oxygen consumption, reduced mitochondrial 
respiration and increased glycolytic metabolism(262).  
The “quasi-malignancy” disease model also accommodates the concept of a cancer stem 
cell/angiogenic niche(183). Precursor cells can be transported into the pulmonary 
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vascular adventitia via vasa vasorum(263), stem cells can divide and migrate from a 
niche at the media-adventitia border zone(61) and pulmonary microvascular endothelial 
cell stem cells of small arteries(8) may proliferate to the point of lumen obliteration. It is 
presently unclear whether stem- and precursor cells are friends or foes. For example, 
autologous endothelial progenitor cells transplantation therapy for PAH has reported 
positive results(252). However, this early trial has been criticized(228) because the cells 
utilized for the clinical trial were not “true” progenitors. Conversely, anti c-Kit (a stem 
cell marker) treatment for PAH with the tyrosine kinase inhibitor imatinib mesylate, has 
demonstrated anectodal positive results(75). Stem cell-based gene therapy is currently 
being investigated in a clinical trial (NCT00469027). 
Growth factors and receptor tyrosine kinases 
Many potent cell growth factors are overexpressed in IPAH vascular lesions, and it is 
likely that these growth factors and their receptor tyrosine kinases contribute to cell 
growth and vessel obliteration. The Platelet Derived Growth Factor (PDGF) has been 
extensively studied in PAH(173), and it has been shown that PDGF can induce the 
proliferation and migration of SMCs and fibroblasts. PDGF has been proposed as a key 
mediator in the progression of several fibroproliferative disorders. It was postulated that 
PDGF receptor blockers could reverse PAH, based on the case report of a patient with 
end-stage IPAH, treated with imatinib mesylate. Subsequently, a clinical safety trial 
evaluating imatinib mesylate as a treatment of advanced forms of PAH was 
performed(74). The data showed a significant decrease in pulmonary vascular resistance 
(PVR) and a moderate increase in cardiac output, but no significant change in pulmonary 
artery pressures, leading to the conclusion that imatinib mesylate may have a limited role 
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in the treatment of IPAH patients. Other tyrosine kinase inhibitors for PAH are being 
studied(78, 160). It is important that the tyrosine kinase inhibitors imatinib, sorafenib and 
nilotinib were shown in animal studies to be acute pulmonary vasodilators(2). However, 
the vasodilator effect in clinical studies of PAH was not prominent. This is an example, 
that identifying highly specific molecular targets in PAH animal models that do not 
reproduce the salient features of human PAH, may be misleading and the drug effect may 
be lost in translation(81, 82). Paradoxically, dasatinib, a multi-tyrosine kinase inhibitor, 
has been associated with the development of PAH(94, 147).   
2.4 Inflammation and Immune Response  
The association of autoimmune disorders with PAH and the presence of antinuclear and 
antiphospholipid antibodies in the serum of patients with IPAH has been appreciated for 
many years(158). There is more evidence that lymphoid neogenesis occurs in IPAH; 
macrophages, mast cells, T- and B- lymphocytes, plasma cells and anti-endothelial cell 
antibodies are present in and around the complex pulmonary vascular lesions in IPAH 
patients(171, 232). Serum levels of IL-1 and IL-6 are high in IPAH patients(103), and 
serum IL-6 levels negatively predict patient survival(211). However, whether 
inflammation and aberrant immune responses in IPAH are cause or consequence remains 
unknown. Likely PH occurs when an inflammatory pulmonary arteriolar injury is not 
resolved by (normally) protective, innate anti-inflammatory mechanisms. Regulatory T-
cells (Tregs) control not only other T-cells but also regulate monocytes, macrophages, 
dendritic cells, natural killer cells and B-cells(192), and recent evidence suggests that 
decreased Treg cell number or function may favour the development of PH(221). For 
example, conditions associated with PAH, such as HIV, systemic sclerosis, systemic 
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lupus erythematosus, Hashimoto’s thyroiditis, Sjogren’s Syndrome and the 
antiphospholipid syndrome are characterized by abnormal CD4+ T-cell number and 
function(28, 45, 139, 167, 182, 212). At the experimental level, athymic rats, lacking T-
cells, develop pronounced PH after vascular injury with a vascular endothelial growth 
factor receptor blocker. The lungs in these animals are populated by infiltrating 
macrophages, mast cells and B cells, similar to human PAH lesions(221, 224). Most 
importantly, PH is prevented by immune reconstitution of Tregs prior to the induction of 
vascular injury(221). All together, it is a possibility that aberrant Treg-cell function in the 
face of vascular injury can result in heightened innate and adaptive immune responses 
that could initiate and/or propagate the development of PH (120)(Figure 5). Despite the 
increasing evidence suggesting a role for immune deregulation in PAH, there is only 
limited anecdotal evidence suggesting that PH associated with connective tissue disorders 
–such as systemic lupus erthyematosis and systemic sclerosis or viral infections, such as 
human herpes virus-8 – can respond to gluococorticoids or targeted B cell depletion(93, 
116). Sanchez et al(196) and Jais et al(111) reported on treatment of patients with mixed 
connective tissue disease - or systemic lupus erythematosus – associated PH, where 
corticosteroid and cyclophosphamide has been used as first-line drugs. The effectiveness 
of B cell depletion is currently being put to test with an NIH-trial examining the 
effectiveness of rituximab – a chimeric monoclonal antibody against the protein CD20, 
primarily expressed by B-cells – for systemic sclerosis-associated PH (NCT01086540).   
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Figure 5. Participation of the immune system in pulmonary vascular remodelling. 
 
 
 
 
PAH patients, in comparison to normal subjects [88, 89].
However, increased, 18FDG uptake does not seem to correlate
with disease severity. A recent study showed no difference in
18FDG uptake between NYHA class II and class III PAH patients,
even when there was a clear-cut difference in cardiac output [90].
Moreover, this study found no correlation between RV 18FDG
uptake and RVmechanical efficiency. It is important to remember
that 18FDG uptake studies have limitations and that the
physiological interpretation is not straightforward. Tracer uptake
can be influenced by multiple factors [91]. Moreover, 18FDG
avidity represents the total amount of 18FDG present in the tissue
at the time of image acquisition [92], which is not necessarily
equal to the total amount of 18FDG absorption by the cell. Instead,
the scan also captures the 18FDG present in the blood and
intercellular spaces. Perhaps the most prominent limitation of
18FDG study interpretation is explained by its chemical structure.
18FDG lacks the functional hydroxyl group that is required for the
enzyme phosphoglucose isomerase (the second enzymatic step of
glycolysis) to function properly [93]. Briefly, 18FDG cannot be
further metabolised inside the cells. Thus, 18FDG uptake studies
are too crude to identify a ‘‘metabolic switch’’ in the failing RV.
Whereas, experimental studies have demonstrated that RVF
exhibits increased expression of glycolysis-related genes [94] and
increased enzymatic glycolysis rates [95], a complete character-
isation of RV ‘‘metabolic remodelling’’ in human PAH-associated
RVF is still lacking.
Noninvasive imaging technologies, in particular echocardio-
graphy and cardiac magnetic resonance imaging (CMRI), are
now providing a more complete assessment of the structural
and functional changes of the failing and non-failing RV in the
setting of chronic PAH. Whereas changes in longitudinal
shortening (tricuspid annulus plane systolic excursion) have
been the standard measure to evaluate RV dysfunction [96],
other changes in RV morphology have been shown to correlate
with survival. For example, a large RV volume and impaired
left ventricular filling, assessed by CMRI, are strong indepen-
dent predictors of mortality and treatment failure [97]. It has
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FIGURE 2. Participation of the immune system in pulmonary vascular remodelling. The initial arteriolar endothelial cell injury can be due to mechanical stress, toxins or
antibodies. The ‘‘two-hit’’ hypothesis considers that defective immune regulation, such as in HIV/AIDS and scleroderma, participates in the lumen-obliterating cell growth [1]
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facilitate the angio-obliteration. HSC: hematopoietic stem cell.
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Figure 5. The initial arteriolar endothelial cell injury can be due to mechanical stress, 
toxins or antibodies. The ‘‘two-hit’’ hypothesis considers that defective immune 
regulation, such as in HIV/AIDS and scleroderma, participates in the lumen-obliterating 
cell growth [1] and in the impaired injury resolution [2]. The disease model depicted here 
reflects the complexity of multicellular interactions within and around the vascular wall 
and the active role of the bone marrow and inflammatory and immune cells in the 
pathobiology of pulmonary arterial hypertension. The multi-growth factor-producing 
mast cell was the first of several immune cells to be identified in the perivascular space of 
pulmonary arterioles in lungs from patients with severe pulmonary hypertension. It may 
populate these vessels because of hyperplasia (in situ expansion of mast cell number) or 
after being recruited from the bone marrow. An impaired activity of regulatory T-cells 
may facilitate the angio-obliteration. HSC: hematopoietic stem cell. Copyright 2012. 
Reproduced with permission of the publisher from Voelkel NF et al, et al. Pathobiology 
of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012 
Dec;40(6):1555–1565 
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It is becoming apparent that circulating factors can likely amplify lung vascular injury, 
attract immune cells and/or repair cells which respond to a variety of chemotactic stimuli, 
suggesting perhaps, a systemic disease component contributing to the development or  
progression of PAH. In the “modern era” of PAH treatments, where standard vasodilation 
therapies have failed to reverse or stop the progression of PAH, novel targets such as 
discrete immune pathways hold promise. However, new drugs and clinical trials will 
require to assess which patients may respond to anti-inflammatory treatment strategies. 
2.5 Summary and Conclusions 
PAH is increasingly recognized not as one disease but as a group of diseases where 
genetic susceptibility renders patients vulnerable to a chronic pulmonary 
microangiopathy. Further explorations of the molecular mechanisms of cell 
reprogramming in PAH, in both the lung vessels and the heart, should lead to a better 
understanding of this group of diseases. The classical pathophysiology of PAH which 
operates with the mechanical concepts of pressure, flow, shear stress, RV wall stress and 
impedance, should be complemented with the new pathobiological concepts of cell injury 
and repair and interactions of complex multicellular systems (Figure 6). Precursor-and 
stem cells derived from the bone marrow and resident lung vascular stem cells should 
also be considered as active players in the process of pulmonary vascular wound healing 
“gone awry”. Integrating the new pathobiological concepts will become critical as we 
design new medical therapies in order to change the prognosis of the patients with this 
fatal group of diseases. 
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Figure 6. Integration of haemodynamic and cellular events that characterise the 
cardiopulmonary disease of severe pulmonary arterial hypertension (PAH). 
 
 
 
criticised due to the fact that many of the studies assessed were
underpowered to determine mortality [108]. A later meta-
analysis by GALIE` et al. [108], which included 23 randomised
controlled trials performed exclusively in PAH patients,
reported that a reduction of 43% in overall mortality was
observed in the groups randomised to active treatments when
compared with those randomised to placebo. However, the
average duration of the trials assessed was limited (14.3 weeks)
and, with the exception of the first epoprostenol trial [43], none
of the trials defined survival as a primary end-point. 3) Future
therapeutic strategies face one particular critical paradox: while
the remodelled lung circulation in PAH is characterised by
angiogenesis, apoptosis resistance and cell proliferation, the
failing RV suffers from ischaemia [109], capillary rarefaction and
cardiomyocyte apoptosis [86], conditions that could be wor-
sened by pharmacotherapy targeting pulmonary vascular
remodelling. One example could be the tyrosine kinase inhi-
bitors, which are known to be cardiotoxic [110].
CONCLUSIONS
PAH is increasingly recognised not as one disease but as a
group of diseases where genetic susceptibility renders patients
vulnerable to a chronic pulmonary microangiopathy. It appears
that increased afterload of the RV is insufficient to explain right
heart failure, as it is best illustrated by the better prognosis and
longer survival of patients with Eisenmenger’s physiology.
Further explorations of the molecular mechanisms of cell
reprogramming in PAH, in both the lung vessels and the heart,
should lead to a better understanding of this group of diseases.
The classical pathophysiology of PAH, which operates with the
mechanical concepts of pressure, flow, shear stress, RV wall
stress and impedance, should be complemented with the new
pathobiological concepts of cell injury and repair and interac-
tions of complex multicellular systems (fig. 4). Precursor and
stem cells derived from the bone marrow and resident lung
vascular stem cells should also be considered as active players in
the process of pulmonary vascular wound healing ‘‘gone awry’’.
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FIGURE 4. Integration of haemodynamic and cellular events that characterise the cardiopulmonary disease of severe pulmonary arterial hypertension (PAH). The
pathophysiology of PAH, which operates via mechanical concepts, is complemented with concepts of cell injury and repair and interactions of complex multicellular systems.
The model is built on the principle of abnormal pulmonary blood flow. Regional blood flow abnormalities underlie the pulmonary vascular remodelling, which in turn causes
further alterations of the regional blood flow, perpetuating a cycle of cell death and cell proliferation. Vascular rarefaction occurs in the form of pruning of the small lung
vessels, and in the right ventricle in the form of myocardial capillary rarefaction.
N.F. VOELKEL ET AL. REVIEW: PATHOBIOLOGY OF PAH
c
EUROPEAN RESPIRATORY JOURNAL VOLUME 40 NUMBER 6 1561
	   33	  
Figure 6. The pathophysiology of PAH, which operates via mechanical concepts, is 
complemented with concepts of cell injury and repair and interactions of complex 
multicellular systems. The model is built on the principle of abnormal pulmonary blood 
flow. Regional blood flow abnormalities underlie the pulmonary vascular remodelling, 
which in turn causes further alterations of the regional blood flow, perpetuating a cycle of 
cell death and cell proliferation. Vascular rarefaction occurs in the form of pruning of the 
small lung vessels, and in the right ventricle in the form of myocardial capillary 
rarefaction. Copyright 2012. Reproduced with permission of the publisher from Voelkel 
NF et al, et al. Pathobiology of pulmonary arterial hypertension and right ventricular 
failure. Eur Respir J. 2012 Dec;40(6):1555–156 
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Chapter 3: Function and Dysfunction of The Right Ventricle 
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Voelkel NF, Gomez-Arroyo J, et al. Mechanisms of right heart failure-A work in 
progress and a plea for failure prevention. Pulm Circ. 2013 Jan;3(1):137–143. 
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CHAPTER 3 
 
 
"Severe damage of right ventricle free wall (of the dog) had no apparent effect on 
hemodynamics.” 
Starr I., et al. 
American Heart Journal, 1943 
 
 
3. 1 Introduction 
The right ventricle (RV) of the heart, which pumps blood through a low pressure, low 
resistance “lesser” circulation, is now receiving more attention by researchers and 
clinicians, after many years of benign neglect(23, 30, 85, 246).  Some of the many 
reasons for neglecting the RV assumed that 1) In the context of global cardiac 
performance the RV was not very important (246) and 2) That the cellular and molecular 
mechanisms of RV failure (RVF) were not different from those responsible for LV 
failure. Perhaps the biggest knowledge gap originated from the lack of experimental 
studies modeling the development of RVF, and from attempts to extrapolate mechanisms 
of chronic RVF from studies originally designed to study acute RVF. These likely 
explain why “pressure overload” is the most frequent – and sometimes exclusively – 
quoted mechanism of RVF. Indeed, patients with chronic, progressive pulmonary 
vascular disease, most frequently die of RV failure(249). However, as we increment our 
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knowledge in the pathobiology of RVF, we should also begin to consider RVF as a 
“progressive,” but not necessarily “chronic” phenomenon.  
3.2 The case for investigating the Right Ventricle 
We propose that the outcome of the patient with pulmonary arterial hypertension (PAH) 
is not only determined by pathophysiological characteristics germane to the lung disease 
– vasoconstriction and pulmonary vascular remodeling – but rather by the response of the 
RV to increased afterload and to additional mechanistically important factors imposed on 
the RV such as neuroendocrine system activation (23, 26) and perhaps, factors released 
from a “sick-lung circulation” (243)(Figure 7). In the management of patients with 
severe PAH we still face (as a barrier) the fact that prevention of RV failure is not a 
realized treatment goal.  For the past 15 years, clinical studies have utilized vasodilator 
drugs expecting to significantly reduce pulmonary arterial pressure, halt or delay the 
progression of the lung vascular disease, reduce RV afterload and prevent the 
development of RVF. However, this goal is not often accomplished in the clinical setting, 
as a recent meta-analysis of PAH clinical trials reported a weighted mean reduction in 
mean pulmonary arterial pressure of 3 mmHg after treatment(72). Moreover, it has been 
demonstrated that even after many years of vasodilator therapy (at least with 
epoprostenol treatment), pathological lung vascular remodeling does not stop(213). 
Lastly, a recent cardiac MRI study from the Netherlands’ pulmonary hypertension center 
reported that the survival of medically treated patients with PAH was not determined by a 
vasodilator-induced decrease of the pulmonary vascular resistance, but rather by an 
improved RV ejection fraction (RVEF) (237). 
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Figure 7: The sick lung circulation–right heart failure axis. 
 
 
also been reported that decreased RV longitudinal shortening
and free-wall motion at the time of diagnosis do not
significantly change over time, whereas RV transverse short-
ening continues to decline over time in non-survivor PAH
patients [98]. RV transverse shortening could be particularly
valuable for the monitoring of treatment success or failure, as
we move forward with clinical trials for RV-targeted therapies.
Measurement of RV free wall longitudinal deformation (strain)
and the rate of deformation by speckle-tracking strain echocar-
diography have been shown to identify patients with greater
severity of RV dysfunction [99]. Most importantly, changes in
RV strain correlate significantly with functional class and can
predict mortality. Finally, the prognostic importance of RVF in
patients with PAH has recently been revisited. VAN DE
VEERDONK et al. [100] reported that although elevated PVR (in
treated PAH patients) is associated with higher mortality, the
RV ejection fraction (measured by CMRI) is the strongest
predictor of survival, even after a response to vasodilator
therapy has been established. Other noninvasive imaging tools
to evaluate RV dysfunction in PAH patients have been
described previously [101–104].
CHALLENGES OF PAH TREATMENT
The future of the medical management of PAH faces multiple
obstacles. 1) In spite of improved screening tools, PAH is not
discovered during its early stage and treatment is often
delayed. Data from the REVEAL registry indicate that the
lag-time from the onset of symptoms to right heart catheter-
isation has not changed compared with the data published
based on the first National Institute of Health registry [105]. 2)
Although improvements in survival have been demonstrated
in clinical trials, the overall patient survival in the ‘‘modern
era’’ remains low and the survival of ‘‘incident’’ PAH patients
appears to be similar to that of the idiopathic PH patients
enrolled in the first National Institute of Health registry [8].
Indeed, the concept of vasodilator drug treatment for PAH has
become controversial in the last decade (for reasons discussed
previously). In one meta-analysis, MACCHIA and co-workers
[106, 107] called PAH ‘‘a clinical condition looking for new
drugs and research methodology’’ and stated ‘‘whether current
therapies of PAH improve long-term survival has never been
demonstrated in a randomised clinical trial’’. However, the
meta-analysis of MACCHIA and co-workers [106, 107] was
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FIGURE 3. The sick lung circulation–right heart failure axis. Increased pulmonary vascular resistance generates a significant afterload for the right ventricle resulting in
right ventricular hypertrophy. The structural and functional changes during the development of right ventricular failure can be characterised clinically [2]. Right ventricular
dysfunction is probably associated with multiple cellular changes [3], such as oxidative stress, apoptosis, inflammation, fibrosis and metabolic remodelling. These factors
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Figure 7: Increased pulmonary vascular resistance generates a significant afterload for 
the right ventricle resulting in right ventricular hypertrophy. The structural and functional 
changes during the development of right ventricular failure can be characterized 
clinically(249). Right ventricular dysfunction is probably associated with multiple 
cellular changes(23), such as oxidative stress, apoptosis, inflammation, fibrosis and 
metabolic remodelling. These factors also contribute to right ventricle (RV) dysfunction 
and failure. The cellular changes are either the result of chronic RV pressure overload or 
the effect of circulating factors released from the sick lung circulation. RVF: right 
ventricle failure; LV: left ventricle. Copyright 2012. Reproduced with permission of the 
publisher from Voelkel NF et al, et al. Pathobiology of pulmonary arterial hypertension 
and right ventricular failure. Eur Respir J. 2012 Dec;40(6):1555–1565. 
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Thus, if current vasodilator drugs have failed to reverse the vascular disease, should we 
not start thinking about RV-targeted therapies while we wait for new PAH lung-specific 
therapies to get in the pipeline? 
 
The prevailing paradigm holds that increased RV afterload is sufficient as an explanation 
of RV failure, but there are several conflicts with this view: 
 
• Under most circumstances the RV adequately adapts to chronic pressure overload 
(in contrast to acute pressure overload). In average, at least 55% of incident 
patients with PAH live (with chronic progressive pressure overload) for 3 
years(22).  
• Even in the pre-pulmonary hypertension “drug era” (prior to 1991) there were 
long-term PAH patient survivors(241), most prominently patients diagnosed with 
aminorex- (appetite suppressant) induced PAH(127). 
• There are patients with severe PAH that remain highly functional (NYHA 
functional class I) for many years without developing RV failure(22). 
• Experimental studies show that after pulmonary artery banding (PAB), the RV 
develops adaptive hypertrophy which is more resistant to pressure overload and 
does not necessarily develop failure(25). 
Perhaps, the best example to argue against pressure-overload as the unique insult 
responsible for the development of RVF are the patients with Einsemenger Syndrome. 
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3.3 Differences in Right Ventricular Remodeling Secondary to Pressure-Overload in 
Patients with Pulmonary Hypertension: The ‘Unique’ Right Ventricle of Patients 
with Eisenmenger Syndrome 
 
Patients with Eisenmenger Syndrome (EMS), develop PAH secondary to a systemic-to-
pulmonary shunt. In other words, a congenital heart defect (mainly nonrestrictive post-
tricuspid defects) initially allows blood to shunt the left side compartment to shunt 
towards the right ventricle or pulmonary artery, either by means of a ventriculoseptal 
defect or a patent ductus arteriosus. If not corrected a certain age, the shunt allows large 
amounts of blood to be pumped into the lung circulation (volume-overload) and this 
overload eventually leads vascular remodeling and pulmonary hypertension(97). Once 
PH has developed, the pressure in the right ventricle will eventually be high enough to 
reverse the shunt and pump venous (deoxygenated) blood into the left (systemic) 
circulatory compartment, explaining the remaining features of the Eisenmenger 
syndrome: Cyanosis, chronic hypoxemia, polycythemia and finger clubbing(97)..   
Most importantly, the ‘resilient’ RV of EMS patients appears to be better adapted to 
increased pressure-overload compared to the RV of patients with idiopathic PAH (IPAH) 
or other forms of PAH(98). Indeed, whereas most patients with IPAH frequently present 
with decreased cardiac output at the time of diagnosis(22), patients with EMS maintain a 
normal cardiac output and right atrial pressure in spite of a similar degree of pressure 
overload(96), at least until later stages of the disease(96). Interestingly, whereas the 
hemodynamic differences between IPAH and EMS patients have long been 
recognized(96), and some structural differences of the RV have been described by 
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cardiac tomography(98), an anatomo-pathological comparison between the hearts of 
patients with EMS and IPAH has so far not been reported.  
As a preliminary project, we performed a post-mortem morphometric analysis of the left 
and right ventricles of patients with IPAH (n=6) or EMS (n=6) who died from RV 
failure, and sought to characterize the differences in RV hypertrophy.  
3.3.1 Patient’s characteristics and methods 
 
All patients with EMS included in this study had a patent ductus arteriosus as the 
systemic-to-pulmonary shunt. Age-matched patients who died from non-cardiac, non-
pulmonary disease where used a controls (n=6). The majority of patients died before any 
PAH-specific therapies were available. However, we excluded any patient that had been 
treated with PAH-specific drug later in time. Informed consent was obtained from the 
family of each patient. The study protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki and was approved by the Instituto Nacional de Cardiología 
"Ignacio Chávez” Institutional Review Board.  
We measured the anterior-to-posterior and septum-to-free-wall diameters, as well as RV 
and LV wall thickness at the base, middle and apex levels (Figure 8A-B). Annular 
dimensions of tricuspid and mitral valves were also measured. Utilizing the RV diameters 
we estimated the RV-chamber area using the formula A= (π * dAP * dSW)/4, were A 
represents the RV-chamber area, ChamberArea = !*!"#*!%&! dAP represents the anterior-
to-posterior diameter and dSW represents the septum-to-free wall diameter. This formula 
was derived from the formula to calculate the area of a circle. All results are reported as 
mean ± standard deviation. Differences between groups were assessed by one-way or 
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two-way ANOVA and a Bonferroni’s post-hoc test was used to assess significant 
differences between groups. A p-value< 0.05 was accepted as significant. Correlation 
analysis was done using a Spearman’s test. 
The mean age for all groups was 28 ± 10 years. Both EMS and IPAH patients had severe 
pulmonary hypertension (56 ± 14 mmHg in IPAH versus 78 ± 14 mmHg in EMS, 
p=0.023). Figure 8C-E illustrates that the RV in both groups of patients responded to 
pressure-overload with significant hypertrophy as evidenced by increased RV wall 
thickness. Interestingly, EMS patients also exhibited increased left ventricular (LV) wall 
thickness at the base and middle levels but not at the apex level (Figure 8F-H). In 
contrast to what has been reported by cardiac magnetic resonance in patients with 
increased RV afterload secondary to chronic thromboembolic pulmonary 
hypertension(89), we did not find a reduction in LV wall thickness in the group of 
patients with IPAH. Figure 9A-C illustrates the correlation between the wall thickness at 
the base, middle and apex levels with their respective RV-chamber area. Patients with 
IPAH developed significant RV hypertrophy compared to control right ventricles but 
significantly less hypertrophy compared to EMS patients. Most importantly, compared to 
EMS group, the RV of IPAH patients had significantly less hypertrophy (RV thickness) 
in relationship to the RV-chamber area (Figure 9A-C) and this relationship between area 
and wall thickness seemed to be more disproportionate at the apex level.  
It should be noted, however, that EMS patients had significantly a higher mean 
pulmonary arterial pressure and this finding could in fact explain the differences in RV  
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Figure 8. Right and Left Ventricles Wall Thickness in Patients with Pulmonary Arterial 
Hypertension  
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Figure 8. A-B) Schematic representation and gross anatomy of the RV illustrating the 
location where each measurement level was taken. C-E) Right ventricular posterior wall, 
anterior wall and free wall thickness at base, middle or apex segment levels. F-H) Left 
ventricular posterior wall, anterior wall and free wall thickness at base, middle or apex 
segment levels. Figure was reprinted with permission of the American Thoracic Society. 
Copyright © 2013 American Thoracic Society Gomez-Arroyo J et al. Differences in 
Right Ventricular Remodeling Secondary to Pressure-Overload in Patients with 
Pulmonary Hypertension. Am J Respir Crit Care Med. 2013. In Press. 
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hypertrophy. However, as it can be appreciated in Figure 9F-H, the LV of these patients 
is also larger and thicker, which could suggest the presence of a stimuli, not directly 
associated with increased RV pressure-overload, that lead to generalized growth of the 
heart. However, to what extent the remodeling of the RV in EMS patients is independent 
of pressure-overload will remain to be investigated. Interestingly, despite the fact that the 
RV of EMS patients was exposed initially to volume and later by pressure-overload, the 
RV underwent concentric (Figure 9M) rather than eccentric hypertrophy. This is a 
particularly interesting finding given the fact that volume-overload of the left ventricle 
frequently leads to dilated cardiomyopathy. It is also important to underline that all 
patients in the EMS group had a post-tricuspid defect (patent ductus arteriosus) and our 
findings may not be true for all congenital heart defects leading to Einsenmenger 
physiology. For instance, it has been shown that pre-tricuspid defects (such as atrial 
septal defects) exhibit different cardiac remodeling compared to post-tricuspid defects 
(98). To further investigate cardiac remodeling in the two groups of patients, we analyzed 
collagen deposition by Masson Trichrome staining. We demonstrated that both 
conditions were associated with significant perivascular and interstitial RV fibrosis 
(Figure 9 K-L). However, EMS patients appear to exhibit less RV fibrosis, which could 
contribute to better diastolic function. The mechanisms underlying the difference in the 
amount of cardiac fibrosis will remain to be investigated. 
In the aggregate, based on the data derived from our study of patients with ESM 
and from the current literature, one could suggest that chronic, progressive 
pressure overload might be the initial component responsible for triggering 
maladaptive changes in the RV, however, not necessarily the only one. Other factors 
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such as ischemia, inflammation, oxidative damage, epigenetics and abnormal cardiac 
energetics could equally contribute to the development of RVF (Figure 7). 
 
Figure 9. Correlation Between Wall Thickness and Chamber Area in Patients with 
Pulmonary Arterial Hypertension 
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Figure 9. A-C) Correlation between free wall thickness and RV chamber area. 
Horizontal and vertical whiskers represent the standard error bars for both variables. J) 
Autopsy material shows the thin RV-free wall (asterisk) of a patient with idiopathic 
pulmonary hypertension (IPAH), compared to the RV of an Eisenmenger’s Syndrome 
patient (M). K-L) Micrographs of Masson Trichromatic-Stained slides illustrate 
significant collagen deposition (blue) in the RV of the IPAH patient compared to the 
EMS patient (O-P). Figure was reprinted with permission of the American Thoracic 
Society. Copyright © 2013 American Thoracic Society Gomez-Arroyo J et al. 
Differences in Right Ventricular Remodeling Secondary to Pressure-Overload in Patients 
with Pulmonary Hypertension. Am J Respir Crit Care Med. 2013. In Press.   
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3.4 Mechanisms of Right Ventricular Failure  
3.4.1 Right ventricular ischemia 
Patients with severe PAH can develop chest pain which may be due to RV 
ischemia(241). Wolferen et al (239) have shown changes in the right coronary artery 
blood flow pattern in patients with PAH, while Gómez, Sandoval and collaborators 
employed stress myocardial scintigraphy using technetium sestamibi to demonstrate RV 
ischemia associated with a RV end-diastolic pressure elevation(83). Unfortunately human 
histological studies of the RV from patients with chronic severe PAH are unavailable, 
and it has never been demonstrated whether the ratio of RV muscle-to-capillary density, 
in patients with severe PAH, is altered as it has been reported in LV failure or in 
experimental RVF(25). Hein et al studied LV tissue biopsies obtained at the time of heart 
surgery for aortic stenosis valve replacement, and described capillary rarefaction and 
discuss their finding of autophagy. In order to explain RV ischemia in the setting of PAH, 
investigators have pointed towards increased RV-wall stress (92) and myocardial fibrosis, 
but it is presently unclear whether RV-wall microcirculation impairment, RV wall stress, 
RV fibrosis – or all these factors in combination – conversely contribute to RV 
myocardial ischemia.  In the SU5416/ chronic hypoxia (Su/Hx) model of severe PAH and 
RV failure (to be discussed in Chapter 4) (25), Bogaard et al. have demonstrated a 
dramatic reduction in the number of perfused myocardial capillaries using in vivo tomato-
lectin endothelial cell (EC) labeling. Histologically we have also showed diffuse 
myocardial fibrosis(25). Capillary rarefaction has also been reported in the monocrotaline 
(MCT) model of PAH(86). Surprisingly, the capillary density in the RV from rats with 
pulmonary artery banding (mechanically induced RV hypertrophy) is only mildly 
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decreased [17]. We asked whether the Su/Hx model of PAH presents with additional 
functional alterations of the remaining RV capillaries. Thus, we used electron microscopy 
to show damaged EC in cardiac capillaries (Figure 10).  
Based on our results, we propose three mechanisms that could account for the capillary 
rarefaction observed in experimental RVF: 1) EC apoptosis and/or 2) Endothelial cell 
mesenchymal transformation, as proposed by Zeissberg et al(268). 3) Insufficient 
angiogenesis in a context of rapid myocardial hypertrophy. EC death could be partially 
explained by a decreased expression of the angiogenic protein vascular endothelial 
growth factor (VEGF), as it has been observed in the failing RV from Su/Hx animals(25). 
This hypothesis is largely based on the data generated by Eli Keshet’s group, which has 
shown that genetically engineered, reversible reduction of VEGF expression in the mouse 
myocardium results in capillary rarefaction, suggesting that VEGF signaling is necessary 
for the maintenance of myocardial capillaries(140). Handoko et al and others have also 
reported decreased VEGF and RV-capillary rarefaction in rats treated with MCT(86, 
168). Taken together, the work from several laboratories supports the notion that there 
are microcirculatory problems in the failing RV. However, whether impaired 
microcirculation function is sufficient to explain the rest of maladaptive changes 
observed in the failing RV remains to be investigated.        
3.4.2 Inflammation 
As mentioned in Chapter 2, the role of a dysregulated immune system in the 
pathobiology of human PAH has become more apparent in recent years (90, 158, 251). 
Interestingly, only one single study has reported leukocyte infiltration in the right 
ventricles obtained from patients with idiopathic PAH (IPAH) and PAH associated with 
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systemic sclerosis (SScPAH) (165). The authors reported a higher number of CD45+ and 
CD68+ cells in SScPAH when compared with RV samples from IPAH patients. 
Although inflammatory cells have been localized in the RV from rats with 
monocrotaline-induced PAH(81, 86), no systematic study has been undertaken to 
examine the role of inflammatory cells or inflammatory mediators in RV failure. A recent 
experimental study of LV failure in mice generated a novel concept of a toll-like receptor 
9 (TLR-9) – dependent failure component.  In this model of chronic severe LV pressure 
overload mitochondrial DNA from damaged heart cells generated a cardiac inflammatory 
response via TLR 9(163). 
3.4.3 Oxidative Stress 
Oxidative cell damage and oxidant-dependent transcriptional control occur and 
participate in inflammatory organ and tissue responses.  Little is known about the role of 
oxidant stress in RV failure with the exception of the important study of Yet et al(264).  
These authors exposed hemeoxygenase-1 KO mice to 5 weeks of chronic hypoxia and 
found that the RV, but not the LV was damaged and dilated.  Thus, it appears that the 
HO-1 function is required for a successful adaptation of the RV to pressure overload.  
The expression of HO-1 in the RV tissue from the Su/Hx pulmonary hypertensive rats is 
reduced, perhaps reflecting an impaired response to oxidant stress(25). 
3.4.4 MicroRNA 
Several recent publications have demonstrated microRNA dependent regulation of gene 
expression in association with pulmonary artery cell growth (44, 57, 180) and plasma 
microRNA expression patterns after acute myocardial infarcts or in patients with right 
heart failure (185). In mouse models, miRNAs play a role in the development of heart 
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Figure 10. Electron Microscopy Demonstrating Damaged Capillaries in Right 
Ventricular Failure Tissue  
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Figure 10. Micrographs obtained by electron microscopy demonstrate the presence of 
“blebbing” (A, arrow) and holes (B, arrow) which are a representation of endothelial cell 
damage of the microvessels of RV tissue obtained from rats with severe pulmonary 
hypertension and right ventricular failure. Figure C is a microphotograph of RV tissue 
obtained from a rat with RV failiure, stained with a Masson-Trichromatic staining which 
marks collagen in blue. 
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failure and the literature on cardiac microRNAs is still expanding(238).  The transition of 
the RV from hypertrophy to failure has been investigated in the rat Su/Hx model and we 
reported a decrease in miR 21,34c, 133a and 139-3p in Su/Hx-induced RV failure when 
compared to PAB-induced RV hypertrophy(55).  More recently Reddy et al reported RV-
specific microRNA expression changes in a murine model(185). Unfortunately, the 
mechanisms by which miRNAs could affect gene and protein expression during RVF, are 
incompletely understood.  
3.4.5 Other mechanisms: Apoptosis, fibrosis and mitochondrial dysfunction 
Indeed, other mechanisms could contribute to the development of RV failure, by directly 
affecting the contractile machinery. For instance, Bogaard et al. in our group has 
demonstrated that RV tissue obtained from animals with severe RVF exhibit positive 
Terminal deoxynucleotidyl transferase dUTP nick end (TUNEL) staining which is 
utilized to label cells with severe DNA damage and serves as a surrogate marker for 
cellular apoptosis(26). Cell death could potentially contribute to the formation of 
replacement fibrosis which has been demonstrated in human and experimental RV failure 
(Figure 9 and 10). Abnormal cardiac metabolism has long been recognized as a problem 
in chronic left heart failure(156, 220). Similarly, data derived from experimental models 
of PH suggest that the failing RV is also characterized by a certain degree of “metabolic 
remodeling”. In the SU/Hx rat model, the RV exhibits increased expression of glycolysis-
related genes(55), whereas dysfunctional RV hypertrophy in the monocrotaline rat model 
of PH is associated with increased glycolysis enzymatic rates(176). Unfortunately, a 
complete characterization of RV “metabolic remodeling” in human PAH is still lacking. 
Positron emission tomography studies have shown increased accumulation of the glucose 
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analog 18F-2-Deoxy-2-Fluoro-D-Glucose (18-FDG) in the RV of PAH patients(35, 161). 
However, 18-FDG uptake studies have multiple limitations and the physiological 
interpretation is not straightforward (i.e 18-FDG uptake studies do not directly measure 
glycolysis). RV oxygen consumption can also be measured by [11C]-acetate PET 
scanning(259).  However, such studies are limited to a few specialized centers and are 
difficult to perform(249). Based on these studies, we sought to characterize the metabolic 
transcriptional profile and mitochondrial function of RV tissue in normal, adaptive and 
maladaptive RV hypertrophy. The results are presented and discussed in Chapter 5.   
3.5 Summary and Conclusion  
Right heart failure is characterized by morphological and functional changes.  We wish to 
advance the concept that the RV afterload by itself is insufficient as an explanation of the 
mechanism of RV failure. Other factors should be taken into account when studying and 
treating RVF, as they pose a critical paradox: While the remodelled lung circulation in 
PAH is characterized by angiogenesis, apoptosis-resistance and cell proliferation 
(Chapter 2), the failing RV suffers from ischemia(83), capillary rarefaction and 
cardiomyocyte apoptosis(25), conditions that could be worsened by pharmacotherapy 
targeting pulmonary vascular remodelling.  
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CHAPTER 4 
 
4.1 Introduction 
Animal models of disease are of pivotal importance for the investigation of normal organ 
function, the pathobiology of frequent and rare disorders as well as for preclinical proof 
of principle treatment studies.  As mentioned in the previous Chapters, it has been 
increasingly noticed that there is a substantial gap between our knowledge of left 
ventricular and right ventricular failure (RVF) mechanisms and that the concepts of RVF 
mechanisms have been mainly adapted from models of left ventricle failure or 
extrapolated from models of acute RVF(246).  
Different animal models of pulmonary hypertension have been described many 
investigators and therefore, the aim of this Chapter is to briefly describe the current 
models of adaptive and maladaptive RV hypertrophy with or without lung vascular 
remodeling. This Chapter also provides the rationale for using the SU5416/hypoxia 
model for the experiments conducted for this dissertation and discusses the pros and cons 
of the other models such as the Monocrotaline-injury rat model. Lastly, we discuss the 
limitations of genetically engineered mice for the study of PH and RV failure.  
4.2 The Monocrotaline-injury Model of Pulmonary Hypertension in Perspective 
For the past three decades, two rat models have been central to the investigation of 
pulmonary hypertension (PH): The chronic hypoxia exposure model and the 
monocrotaline (MCT) lung injury model (215). Although the mechanisms of hypoxia-
induced vascular remodeling are understood to some degree, the complex obliterative 
lesions found in human patients with severe PAH do not develop in this rodent model 
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(248). The monocrotaline rat model continues to be a frequently investigated model of 
PAH as it offers technical simplicity, reproducibility and low cost compared to other 
models of PAH. While the MCT rat model has contributed to a better understanding of 
vascular remodeling in pulmonary hypertension. However, multiple features of the 
“monocrotaline syndrome” do not resemble human PAH: liver failure, lung injury and 
myocarditis. Therefore, based on a literature review and our current data we questioned 
whether this model remained productive as a preclinically relevant model of severe 
plexogenic PAH. 
4.2.1 Monocrotaline pyrrole toxicity and the “monocrotaline syndrome” 
Monocrotaline (MCT) is an 11-membered macrocyclic pyrrolizidine alkaloid derived 
from the seeds of the Crotalaria spectabilis plant (Figure 11A and B). The MCT 
alkaloid is activated to the reactive pyrrole metabolite dehydromonocrotaline (MCTP) in 
the liver, a reaction that is highly dependent on CYP3A4 (cytochrome p450) (187, 257). 
Specific metabolic inducers of this cytochrome increase the MCTP production by the rat 
liver, whereas specific anti-CYP3A4 antibodies inhibit it (114, 187). When ingested, 
MCT induces a syndrome (Table 2) characterized – among other manifestations – by 
pulmonary hypertension, pulmonary mononuclear vasculitis (acute necrotizing 
pulmonary arteritis in about one-third of the animals) and right ventricular hypertrophy 
(117, 125). 
Although it has been reported that MCT injures pulmonary endothelial cells (190) (117), 
the exact toxicological mechanisms by which MCT initiates lung toxicity remain unclear.  
 
 
	   58	  
Table 2.  
 
Characteristic Dose 
range 
(mg/kg) 
Reference 
Acute lung injury 60 -100   (58, 122, 188, 200, 216) 
Interstitial pulmonary fibrosis 2.4 - 100 (91, 145, 146) 
Necrotizing pulmonary 
arteritis 
Not 
quantified 
(117, 125, 257) 
Pulmonary hypertension 45 - 60  (27, 117, 159, 176, 198, 200, 266, 267) 
RV hypertrophy 45 - 60 (27, 34, 86, 117, 159, 176, 198, 200, 266, 
267) 
Myocarditis 50 - 60 (4, 34, 86) 
Hepatic venooclusive disease 60 - 300 (41-43, 47, 48, 51, 60, 138, 142, 170, 256, 
257) 
	   59	  
Lee and Sehgal, have shown that pulmonary arterial endothelial cells (PAEC) exposed to 
MCT develop megalocytosis characterized by an enlarged Golgi apparatus, displacement 
of endothelial nitric oxide synthase and decreased cell-surface/caveolar nitric oxide 
(128). MCT-treated endothelial cells demonstrate marked disruptions of intracellular 
membrane trafficking that affect several cell membrane proteins (204). Huang and 
Mathew have reported that MCT-induced loss of membrane proteins, results in the 
activation of proliferative and antiapoptotic factors, and deregulation of nitric oxide 
signaling, leading to lung vascular changes (100). The initial MCT-induced endothelial 
cell damage has also been linked to BMPRII (Bone Morphogenetic Protein Receptor II) 
dysfunction and BMP signaling disruption, as well as increased expression of 
intracellular elements involved in the sequestration and inhibition of the BMPR II activity 
(184). Nakayama and Wilson demonstrated that in human PAEC, the monocrotaline 
pyrrole significantly induced the Nrf2-mediated stress response pathway and increased 
caspase-3 activation (154). 
Paradoxically, although there is vast evidence to suggest that MCT elicits PAEC 
dysfunction in multiple levels, the MCT PAH model is characterized predominantly by 
pulmonary arterial medial hypertrophy (Figure 11D) but not by endothelial cell-mediated 
angioobliteration, as it is present in the human disease or in the SU5416/hypoxia model 
of severe PAH (Figure 11E). It remains unclear whether an initial MCT-induced damage 
of pulmonary endothelial cells stimulates smooth muscle cell proliferation and/or 
endothelial cell mesenchymal transition; it is also elusive whether endothelial cell 
dysfunction is a consequence of non-PAEC damage or systemic inflammation triggered 
by MCT exposure. A detailed mechanistic explanation connecting the initial endothelial 
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cell injury and subsequent medial hypertrophy is still missing. Another major concern is 
the relation between the kinetics of MCT and development of pulmonary hypertension. 
MCT causes a short intense insult with a rapid loss of the starting compound because 
MCTP is rapidly degraded in aqueous solutions such as plasma (32, 63, 257). Of interest, 
significant changes in pulmonary artery pressures, medial thickness of small pulmonary 
arteries and RV hypertrophy do not occur until the third or fourth week after MCT 
exposure (124, 235). This issue has been partially explained by the accumulation of 
MCTP in erythrocytes, where it conserves its capability to interact with lung tissue (63, 
166, 257). Furthermore, although a time-dependent effect of MCT has been described 
(88, 235), an adequate dose-response study has not yet been reported.  
Many publications have demonstrated pulmonary vessel remodeling in MCT-treated rats 
and dogs, leading to pulmonary hypertension (84, 215, 257). Mitchel Botney (164) 
originally described that when used in combination with pneumonectomy (a “second 
hit”), MCT-treated rats developed angioobliterative changes in the pulmonary vasculature 
resembling those of human disease or the SU5416/hypoxia rat model (255). However, 
plexiform-like vascular lesions have not been described after a “single hit” of 
monocrotaline alone, while other pathological changes have been reported as a 
consequence of MCT exposure. MCT not only injures the pulmonary arteries, but also 
induces alveolar edema, alveolar septal cell hyperplasia and occlusion of pulmonary 
veins (58, 126). MCT-induced interstitial pulmonary fibrosis has also been described in 
mice (with variable doses and timepoints) (58, 91). Electron micrographs of MCT-treated 
animals, revealed degeneration of both lung endothelial and type I epithelial cells, as well 
as marked interstitial hypercellularity and fibrosis (145, 146). Hayashi and Hayashi 
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reported that a single dose of 100 mg/kg, is sufficient to induce severe pulmonary fibrosis 
and/or interstitial pneumonia in mice (91), whereas other investigators have reported that 
pulmonary fibrosis seems to be only a late manifestation of monocrotaline exposure (58). 
The MCT pyrrole has also been described as an anti-mitotic agent (47, 174). In 
astrocytes, the MCT pyrrole can induce DNA damage by generating DHP-derived DNA 
adducts, which induce DNA-crosslinks, DNA-celullar protein conjugates and apoptosis 
(154, 208, 253). MCT-induced DNA damage is reflected in persistent cell cycle arrest 
and is responsible for the cyto- and karyomegaly (megalocytosis) described in 
pneumocytes, human pulmonary endothelial cells, glial cells and hepatocytes of MCT-
treated animals (128, 208, 256, 257). Particularly, type II pneumocytes seem to be highly 
affected by MCT-induced mitotic inhibition (260), which is partially mediated by altered 
polyamine metabolism (20). Confirming these previously reported data, when compared 
to the SU5416/hypoxia model of angioobliterative pulmonary hypertension, the MCT-
treated animals demonstrate marked perivascular edema (Figure 11F), significant 
alveolar septal thickening (Figure 11G), and type I pneumocyte megakariocytosis 
(Figure 11H). 
4.2.2 Monocrotaline-induced myocarditis 
MCT treated rats develop significant pulmonary hypertension and marked right 
ventricular (RV) hypertrophy (Figure 12 A, also see references (27, 117, 176, 198, 225). 
Traditional concepts suggest that the RV dysfunction of MTC-treated rats is a direct 
consequence of pressure overload. Interestingly, despite having lower pulmonary artery 
pressure and a similar degree of RV dysfunction compared to the SU5416/hypoxia model 
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of pulmonary hypertension (Figure 12 B-C), MCT treated rats exhibit a significantly 
higher mortality (Figure 12 D). Several investigators have utilized MCT to induce 
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Figure 11. The monocrotaline pyrrole and the lung changes characteristic of the 
monocrotaline syndrome 
 
 
 
 
 
 
 
 
Nakayama et al. (46) demonstrated that, in human PAEC, the
monocrotaline pyrrole significantly induced the Nrf2-mediated
stress response pathway and increased caspase-3 activation.
Paradoxically, although there is vast evidence to suggest that
MCT elicits PAEC dysfunction on multiple levels, the MCT PAH
model is characterized predominantly by pulmonary arterial me-
dial hypertrophy (Fig. 1D) but not by endothelial cell-mediated
angioobliteration, which is present in the human disease or in the
SU5416/hypoxia model of severe PAH (Fig. 1E). It remains
unclear whether an initial MCT-induced damage of pulmonary
endothelial cells stimulates smooth muscle cell proliferation
and/or endothelial cell mesenchymal transition; it is also elusive
whether endothelial cell dysfunction is a consequence of non-
PAEC damage or systemic inflammation triggered by MCT ex-
posure. A detailed mechanistic explanation connecting the initial
endothelial cell injury and subsequent medial hypertrophy is still
missing. Another major concern is the relation between the kinet-
ics of MCT and development of PH. MCT causes a short intense
insult with a rapid loss of the starting compound because MCTP
is degraded rapidly in aqueous solutions such as plasma (9, 22,
84). Of interest, significant changes in pulmonary artery pressures,
medial thickness of small pulmonary arteries, and RV hypertro-
phy do not occur until the 3rd or 4th week after MCT exposure
(35, 77). This issue has been explained partially by the accumu-
lation of MCTP in erythrocytes, where it conserves its capability
to interact with lung tissue (22, 53, 84). Furthermore, although a
time-dependent effect of MCT has been described (26, 77), an
adequate dose-response study has not yet been reported. Table 2
shows the various degrees of PH achieved with a standard dose of
60 mg/kg. Kasahara et al. (31) also discovered that prior induction
of CYP3A, via facilitating the conversion of MCT to its active
pyrrole, potentiated the development of PH.
Many publications have demonstrated pulmonary vessel re-
modeling in MCT-treated rats and dogs, leading to PH (Table 2)
Fig. 1. A: Crotalaria spectabilis, image re-
produced with permission of Wendy Van-
Dyk Evans, Bugwood.org. B: monocrotaline
pyrrole chemical structure, reproduced with
permission of chembase.com-chemical com-
pounds database. Monocrotaline-treated rats
(D) exhibit pulmonary vascular media hyper-
trophy and mononuclear cell infiltration
compared with control rats (C). In contrast to
monocrotaline-treated rats, the model of
SU5416/hypoxia (E), characterized by ab-
normal endothelial cell proliferation, shows
complete vascular obliteration. In addition to
the vascular changes, monocrotaline-treated
rats exhibit marked perivascular edema (F,
blue line), alveolar septal thickening (G, long
arrow; arrowhead marks a normal septa), and
megalocytosis of type I pneumocytes (H,
long arrows; arrowhead marks a normal type
I pneumocyte nucleus).
Table 1. The monocrotaline syndrome
Characteristic Dose Range, mg/kg Ref. No.
Acute lung injury 60–100 20, 33, 62, 66, 74
Interstitial pulmonary fibrosis 2.4–100 29, 43, 44
Necrotizing pulmonary arteritis Not quantified 32, 36, 84
Pulmonary hypertension 45–60 8, 32, 49, 56, 65, 66, 86, 87
RV hypertrophy 45–60 8, 10, 25, 32, 49, 56, 65, 66, 86, 87
Myocarditis 50–60 1, 10, 25
Hepatic venooclusive disease 60–300 13–17, 19, 21, 39, 40, 54, 83, 84
RV, right ventricle.
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Figure 11. A: Crotalaria spectabilis, image re- produced with permission of Wendy Van- 
Dyk Evans, Bugwood.org. B: monocrotaline pyrrole chemical structure, reproduced with 
permission of chembase.com-chemical com- pounds database. Monocrotaline-treated rats 
(D) exhibit pulmonary vascular media hyper- trophy and mononuclear cell infiltration 
compared with control rats (C). In contrast to monocrotaline-treated rats, the model of 
SU5416/hypoxia (E), characterized by ab- normal endothelial cell proliferation, shows 
complete vascular obliteration. In addition to the vascular changes, monocrotaline-treated 
rats exhibit marked perivascular edema (F, blue line), alveolar septal thickening (G, long 
arrow; arrowhead marks a normal septa), and megalocytosis of type I pneumocytes (H, 
long arrows; arrowhead marks a normal type I pneumocyte nucleus).
	   65	  
pulmonary hypertension, assuming that MCT has no direct cardiac effect; however, 
others have investigated the potential role of load-independent maladaptive mechanisms 
that could contribute to RV failure in MCT-treated rats. For instance, in addition to RV 
hypertrophy, MCT treatment has been associated with increased 67Galium uptake by 
scintigraphy (34) and marked neutrophil migration into the RV myocardium, even during 
early stages of the monocrotaline syndrome (34). Whether this neutrophil infiltration was 
a consequence of RV pressure overload or consequence of a direct cardiac effect (perhaps 
microvascular endothelial cell damage) of monocrotaline remains undetermined. 
Handoko et al have also demonstrated a widespread leukocyte infiltration of the right 
ventricle in MCT-treated rats (86). Our own data confirm the presence of multiple 
inflammatory cell foci throughout the RV (Figure 12 F-G). When characterized by 
immunohistochemistry, the majority of the leukocyte infiltrates were positive for CD20, a 
marker for B-lymphocytes (Figure 12 K), while CD68 (a macrophage marker) was 
negative. CD8 (a cytotoxic T-cell marker) was positive as well, but to a lesser extent. 
These results suggest perhaps that monocrotaline induces a lymphocytic myocarditis. We 
also observed, marked infiltration of inflammatory cells within the left ventricle, 
associated with coronary arteriolar wall thickening (Figure 12 H) and marked 
perivascular fibrosis (Figure 12 I). The MCT-induced myocarditis may be responsible 
for significant left ventricular systolic dysfunction and impaired diastolic relaxation, also 
described by Akhavein and Rohlicek (4). Benoist and collaborators have described a pro-
arrhytmogenic substrate in the hearts of MCT-treated animals (21). Whether MCT-
induced myocarditis or arrhythmias (21, 144) are the cause of death in rats – which can 
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Figure 12. Changes in the Right Ventricle Associated with Monocrotaline Exposure 
 
 
 
 
 
 
tional concepts suggest that the RV dysfunction of MTC-treated
rats is a direct consequence of pressure overload. Interestingly,
despite having lower pulmonary artery pressure and a similar
degree of RV dysfunction compared with the SU5416/hypoxia
model of PH (Fig. 2, B and C), MCT-treated rats exhibit a
significantly higher mortality (Fig. 2D). Several investigators have
used MCT to induce PH, assuming that MCT has no direct
cardiac effect; however, others have investigated the potential role
of load-independent maladaptive mechanisms that could contrib-
ute to RV failure in MCT-treated rats. For instance, in addition to
RV hypertrophy, MCT treatment has been associated with in-
creased 67Galium uptake by scintigraphy (10) and marked neu-
trophil migration into the RV myocardium, even during early
stages of the MCT syndrome (10). Whether this neutrophil infil-
tration was a consequence of RV pressure overload or conse-
quence of a direct cardiac effect (perhaps microvascular endothe-
lial cell damage) of MCT remains undetermined. Handoko et al.
(25) have also demonstrated a widespread leukocyte infiltration of
the right ventricle in MCT-treated rats. Our own data confirm the
presence of multiple inflammatory cell foci throughout the RV
Fig. 2. Both monocrotaline (MCT) and SU5416/hypoxia animals develop pulmonary hypertension, however, MCT-treated rats present with a lower degree of
pulmonary hypertension compared with the SU5416/hypoxia model (A). Both models develop a similar degree of right ventricular (RV) dysfunction assessed
by increased RV internal diameter (B) and decreased tricuspid annular planar systolic excursion (TAPSE, C), two heart rate-independent variables to evaluate
RV function by echocardiogram. Although the pulmonary artery pressure is lower in MCT-treated rats, and RV dysfunction is similar in both models,
MCT-treated rats exhibit a higher mortality rate compared with the SU5416/hypoxia model (D). Rats treated with a dose of 160 mg/kg or higher develop liver
alterations consistent with hepatic venooocclusive disease [E, reproduced with permission of Frank Snow (19)]. Histological analysis of MCT-treated right
ventricles demonstrated a severe inflammatory infiltrate in the RV (F and G). A similar inflammatory infiltrate was present in the left ventricle of MCT-treated
rats (H, arrows) and was associated with medial hypertrophy of coronary arterioles (H, arrowhead) and marked perivascular fibrosis (I). Immunohistochemistry
reveals that the majority of the inflammatory infiltrates are prominently positive for the B cell marker CD20 (K), negative for CD68! (J), and identifies few CD8!
cells (L). These results are consistent with an MCT-induced lymphocytic myocarditis. SuHx, SU5416/hypoxia-exposed rats; mPAP, mean pulmonary arterial
pressure; RVID, right ventricular internal diameter.
Perspectives
L366 MONOCROTALINE MODEL IN PERSPECTIVE
AJP-Lung Cell Mol Physiol • doi:10.1152/ajplung.00212.2011 • www.ajplung.org
 on April 9, 2012
ajplung.physiology.org
Downloaded from
 
	   67	  
Figure 12. Both monocrotaline (MCT) and SU5416/hypoxia animals develop pulmonary 
hypertension, however, MCT-treated rats present with a lower degree of pulmonary 
hypertension compared with the SU5416/hypoxia model (A). Both models develop a 
similar degree of right ventricular (RV) dysfunction assessed by increased RV internal 
diameter (B) and decreased tricuspid annular planar systolic excursion (TAPSE, C), two 
heart rate-independent variables to evaluate RV function by echocardiogram. Although 
the pulmonary artery pressure is lower in MCT-treated rats, and RV dysfunction is 
similar in both models, MCT-treated rats exhibit a higher mortality rate compared with 
the SU5416/hypoxia model (D). Rats treated with a dose of 160 mg/kg or higher develop 
liver alterations consistent with hepatic venooocclusive disease [E]. Histological analysis 
of MCT-treated right ventricles demonstrated a severe inflammatory infiltrate in the RV 
(F and G). A similar inflammatory infiltrate was present in the left ventricle of MCT-
treated rats (H, arrows) and was associated with medial hypertrophy of coronary 
arterioles (H, arrowhead) and marked perivascular fibrosis (I). Immunohistochemistry 
reveals that the majority of the inflammatory infiltrates are prominently positive for the B 
cell marker CD20 (K), negative for CD68+ (J), and identifies few CD8+ cells (L). These 
results are consistent with an MCT-induced lymphocytic myocarditis. SuHx, 
SU5416/hypoxia-exposed rats; mPAP, mean pulmonary arterial pressure; RVID, right 
ventricular internal diameter.
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tolerate higher levels of RV afterload – remains undetermined but should be considered. 
Indeed, as mentioned in Chapter 3, although inflammatory cells have been found present 
in patients with pulmonary hypertension associated with systemic sclerosis(165), a 
mechanistic role for these cells is still incomplete and, conversely, they could serve as 
confounders for the development of RV failure.  
4.2.3 Limitations of the Monocrotaline-Injury Model of PAH: Do rats die with PH 
or from PH? 
As reviewed in the Chapter the monocrotaline rat model of pulmonary hypertension 
remains a model favored by many investigators, continues to impact preclinical PAH 
research (215), and a significant amount of time and funding continues to be invested in 
testing new drugs in this model (245). We are skeptical and of the opinion that the MCT 
model is not an appropriate model of human severe PH. Pulmonary vasoconstriction 
seems to be an important mechanistic component of the MCT-model (37, 143, 162, 202), 
and while that is shared in a certain subpopulation of patients with PAH (those 
documenting a large vasoconstriction component), pulmonary interstitial edema, 
myocarditis and hepatic venoocclusive disease (not to mention renal alterations (123)), 
which are part of the monocrotaline syndrome, are certainly not associated with the 
human forms of severe PAH (renal insufficiency is however a late manifestation (205)). 
Whereas the “two hits” model of monocrotaline/pneumonectomy can reproduce the 
pertinent pulmonary vascular pathology of human PAH, the other components of the 
monocrotaline syndrome may be cofounding. Also importantly, in contrast to the 
SU5416/hypoxia model (225), a very large number of drugs and compounds have either 
prevented or improved pulmonary hypertension in the MCT-alone (single-hit) model. 
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Paradoxically the animals, when untreated, die from undetermined causes. Hence the 
question: do MCT-treated rats die with PH or from PH? As a preclinical model of severe 
PAH, the MCT-alone model may be misleading as the particular syndrome associated 
with the development of PH (after a single injection of MCT) and the successful 
treatment of the MCT syndrome with practically any drug investigated (215), may have 
little in common with human forms of severe PH.  
4.3 Pulmonary artery banding: A model for Adaptive (functional) Right Ventricular 
Hypertrophy 
Many researchers have utilized the pulmonary artery banding (PAB) model to study the 
effects of mechanically-induced pressure-overload of RV. As mentioned in Chapter 3, 
increasing impedance, and therefore the afterload of the RV, by means of a band around 
the pulmonary artery would theoretically lead to RV dysfunction and eventually RV 
failure. Indeed, the transverse aortic constriction model is commonly used to reproduce 
systemic hypertension and left ventricular failure(12). Because the RV seems to adapt to 
increased pressure overload in a certain group of patients (mainly patients with 
Eisenmnger Syndrome, as studied in Chapter 3), Bogaard et al. (25) revisited the rat PAB 
model and compared the measurements obtained with the SU5416/hypoxia model, a 
model of severe pulmonary hypertension and RVF (see below). Interestingly, and in 
contrast to what would be expected, the PAB rats were able to tolerate high RV systolic 
pressures for a remarkably long time and TAPSE (tricuspid annular plannar systolic 
excursion), a heart-rate independent measurement of RV longitudinal contractility 
commonly used to evaluate RV function in patients with PAH, was similar to that of 
control rat RVs (3.25mm in PAB versus 3.46 in controls). In order to explain why the RV 
	   70	  
of PAB rats was more ‘resilient’, microarray-based gene expression analysis of the 
compensated rat RVH was performed. This analysis allowed the characterization of a 
‘RV failure transcriptional signature’(55).  Following PAB surgery, rats showed an 
increased expression of IGF-1 (insulin-like growth factor-1) mRNA, normal levels of 
phosphorylated Akt and VEGF protein levels, as well as and an increased amount of 
apelin (another pro-angiogenic factor) when compared to RV tissues from rats with RVF 
(SU5416/hypoxia rats)(25). These results were in line with what Faber et al. reported 
when evaluating right and left ventricular function in PAB rat(64). The authors 
demonstrated that 6 weeks of pressure overload resulted in enhanced baseline RV 
contractility while LV baseline contractility remained unaffected. In contrast, Fang, 
Archer and collaborators showed that 4 weeks after PAB, the cardiac output and treadmill 
distance were significantly reduced in the PAB vs. control animals(65).  Possible 
explanations for this discrepancy could be the differences in pulmonary artery lumen 
reduction and the time allowed for RV adaptation.   
Another interesting feature are the changes in the RV when compared to the LV 
subjected to pressure-overload in rodents. The Stanford pediatric cardiology group 
performed PAB in mice and then analyzed the RV and LV tissues with mRNA 
microarrays(234).  Animals with moderate pulmonary stenosis had a 50% survival of >50 
days. Importantly, the right ventricular end-diastolic pressure increased 6 hours 
postoperatively in mice with severe stenosis, but remained within the normal range in the 
animals with moderate outflow tract stenosis. Furthermore, the authors demonstrated a 
differential expression of genes between the pressure-overloaded right ventricles when 
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compared to the left counterparts. Altogether, the published data suggest that PAB can be 
used as a model of RV pressure-overload with associated adaptive hypertrophy. 
4.4 The SU5416/hypoxia rat model of pulmonary arterial hypertension: A brief 
summary 
The combined VEGF receptor 1 (Flt) and 2 (KDR) blocker, SU5416, was one of the first 
agents discovered by screening for growth inhibitory activity of cultured endothelial cells 
incubated with the potent angiogenic VEGF ligand (68). Kindly provided by Dr. Peter 
Hirth (Sugen, South San Francisco, CA), for preclinical studies, SU5416 was tested with 
the hypothesis that inhibition of VEGF signaling would result in pulmonary emphysema. 
Indeed, a single subcutaneous injection of 20 mg/kg of SU5416 caused airspace 
enlargement and mild PH in adult rats (115). Unexpectedly, rats injected with SU5416 
(20 mg/kg) were exposed to chronic hypoxia in a hypobaric chamber, as an attempt to 
worsen the airspace enlargement. The results of these experiments were published in 
2001 (223). Surprisingly, the combination of SU5416 and chronic hypoxia (hereafter 
SUHx) resulted in the development of severe PAH which was not reversible when the 
animals were returned to Denver altitude (223) or in later experiments to sea level 
(Figure 13) (25). The PH was associated with angioobliterative pulmonary lesions which 
were preventable by treating the animals concomitantly with a pan-caspase inhibitor, 
indicating that apoptosis was necessary for the development of pulmonary vascular 
lesions (223). This rat model has served as a model for preclinical drug studies designed 
to examine whether the PH and pulmonary vascular disease in the SuHx rats could be 
reversed once established.  
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Figure 13.  Comparison between a normal lung vessel and the vascular lesions present in 
the SU5416/hypoxia rat model of severe pulmonary arterial hypertension.  
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Figure 13. Microphotographs showing the histological differences in the lung 
vasculature between controls (A), SuHx (B) and Pulmonary Artery Banding (PAB) (C). 
	   74	  
Because in this rat model the PH is severe, is accompanied by plexiform-like lessions and 
is largely refractory to treatment, it was concluded that the SUHx rat model of 
angioobliterative severe PH had a number of features which resembled the human 
disease.  Moreover, Abe et al has shown the histopathological similarities of the SUHx 
lung vascular lesions in comparison to the plexiform lesions in human disease (1). In 
addition to severe PH, rats treated with SU5416 and exposed to chronic hypoxia also 
develop severe RV failure characterized by a cardiac output reduction, decreased TAPSE, 
increased RV diastolic diameter, capillary rarefaction, RV fibrosis and cardiomyocyte 
apoptosis (25, 27, 162).  
The SUHx model has been modified to uncover immunological mechanisms in the 
pathobiology of severe PAH. We have shown that treatment of athymic rats with SU5416 
is sufficient to cause severe angioobliterative PAH— indicating that hypoxia is not 
necessary (224), and that early immune reconstitution with rat regulatory T lymphocytes 
prevents the development of severe PAH (222, 224). For further information regarding 
the SuHx model the reader is referred to ((25, 194, 195, 223)). 
4.5 Mouse Models of Right Ventricular Failure: Problems and Prospects 
The advent and development of genetically modified mice, as tools to dissect cellular and 
molecular signaling pathways, created an understandable desire to generate mouse 
models for PH studies. In recent years a considerable number of transgenic mice have 
been generated in order to investigate mechanisms of pulmonary hypertension (See Ref 
(82)). In particular, the report of associations between mutations in the BMPR2 gene with 
both familiar and idiopathic forms of pulmonary arterial hypertension (PAH) (101, 137, 
157, 218), led to multiple attempts to generate novel animal models of PAH. In addition 
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to BMPR2 knock out (KO) mice, researchers have targeted other genes suspected to be 
involved in the pathogenesis of PAH. Very likely the transgenic mouse studies have 
strongly influenced the way we think of the pathogenesis of PAH and helped shift the 
early mechanical concepts of pressure – and flow – dependency, towards disease models 
built on cell-to-cell interactions, immune dysregulation, metabolic changes and abnormal 
cell phenotypes (50, 149, 181, 183, 224, 251, 262). However, although somewhat useful 
for the study of lung vascular remodeling, mice exhibit multiple limitations as a model of 
right ventricular failure.  
RV hypertrophy is easy to measure by separating the RV-free wall from the rest of the 
heart (70). In rats, the RVSP is strongly correlated with the RV/LV+S (162) suggesting 
that the RV responds to an increased afterload with a corresponding degree of 
hypertrophy. Rat models of PAH – such as the SU5416/hypoxia and monocrotaline-
injury models – generate robust RV hypertrophy (mean RV/LV+S 0.67-0.76) (25, 80). In 
contrast to rat models, only mice overexpressing interleukin-6 seem to develop a 
comparable degree of hypertrophy (average RV/LV+S 0.69) and pulmonary hypertension 
(214). When plotting data extracted from the reviewed mouse PH studies (Figure 14B-
D), there seems to be an “uncoupling” between RVSP and RV/LV+S for the majority of 
PH-mouse studies, even after hypoxia exposure. For example, Xu et al (261) 
demonstrated that mice lacking the adenosine A2A receptor develop spontaneous PH 
(RVSP 39 mmHg), however the RV/LV+S was only 0.26, a value that is within normal 
limits for C57BL6/J WT mice (219). In contrast, Chen and collaborators (39) reported 
that mice overexpressing 
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Figure 14. Brief analysis of the hemodynamics and right ventricular hypertrophy of mice 
models of pulmonary hypertension 
 
  
 
was ubiquitous and severe, the RVSP was not elevated (range
21–29 mmHg) and there were no signs of right heart hyper-
trophy. Thus, at least in the mouse, severe pulmonary vascular
remodeling does not necessarily cause severe pulmonary arte-
rial hypertension.
Right Ventricular Failure in Transgenic Mouse Models of
Pulmonary Hypertension
RVF is the leading cause of death and the main determinant
of survival in patients with PAH (7, 83). Intriguingly, whereas
the mechanisms of pulmonary vascular remodeling have been
extensively studied in both mouse and rat models of PAH, the
mechanisms underlying RVF remain largely elusive (9, 110).
RV hypertrophy is easy to measure by separating the RV free
wall from the rest of the heart (28). In rats, RVSP strongly
correlates with the RV/LV!S (72), suggesting that the RV
responds to an increased afterload with a corresponding degree
of hypertrophy. Rat models of PAH, such as the SU5416/
hypoxia and monocrotaline-injury models, generate robust RV
hypertrophy (mean RV/LV!S 0.67–0.76) (11, 35). In contrast
to rat models, only the IL6-OE mice seem to develop a
comparable degree of hypertrophy (average RV/LV!S 0.69)
and PH (94). When plotting data extracted from the reviewed
mouse PH studies (Fig. 1, B–D), there seems to be an “uncou-
pling” between RVSP and RV/LV!S for the majority of PH
mouse studies, even after hypoxia exposure. For example, Xu
et al. (122) demonstrated that mice lacking the adenosine A2A
receptor develop spontaneous PH (RVSP 39 mmHg); however,
Fig. 1. A: C57BL6 mouse. B: correlation between right ventricular systolic pressure (RVSP) and right ventricle (RV) to left ventricle (LV) plus septum (S) ratio
(RV/LV!S) in mouse pulmonary hypertension (PH) models exposed to normoxia and hypoxia, compared with the combination of SU5416 and chronic hypoxia
(SuHx) and monocrotaline (MCT)-injured rat models. C: correlation between RVSP and RV/LV!S in mouse models exposed to normoxia. Pearson coefficient
0.32, P " 0.150. D: correlation between RVSP and RV/LV!S in mouse models exposed to hypoxia. If all mouse models are included, the Pearson coefficient
is 0.82, P " 0.0008. However, the correlation seems to be driven by an outlier, the IL6-OE mice (red dot). Thus, if the latter is not included in the statistical
calculations, the coefficient becomes nonsignificant (r " 0.58, P " 0.057) (E). F: hematoxylin and eosin (HE)-stained lung section of a pulmonary vessel
obtained from wild-type C57BL6 mice chronically exposed to ovalbumin. The mice develop severe pulmonary arterial muscularization without pulmonary
hypertension. The vascular remodeling does not involve endothelial cell proliferation (G; brown staining is smooth muscle actin and blue is von Willebrand
factor). F and G are reprinted from Daley et al. (2008), doi:10.1084/jem.20071008.
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Figure 14 A: C57BL6 mouse. B: correlation between right ventricular systolic pressure 
(RVSP) and right ventricle (RV) to left ventricle (LV) plus septum (S) ratio (RV/LV+S) 
in mouse pulmonary hypertension (PH) models exposed to normoxia and hypoxia, 
compared with the combination of SU5416 and chronic hypoxia (SuHx) and 
monocrotaline (MCT)-injured rat models. C: correlation between RVSP and RV/LV+S in 
mouse models exposed to normoxia. Pearson coefficient 0.32, P <0.150. D: correlation 
between RVSP and RV/LV+S in mouse models exposed to hypoxia. If all mouse models 
are included, the Pearson coefficient is 0.82, P < 0.0008. However, the correlation seems 
to be driven by an outlier, the IL6-OE mice (red dot). Thus, if the latter is not included in 
the statistical calculations, the coefficient becomes nonsignificant (r =0.58, P < 0.057) 
(E). F: hematoxylin and eosin (HE)-stained lung section of a pulmonary vessel obtained 
from wild-type C57BL6 mice chronically exposed to ovalbumin. The mice develop 
severe pulmonary arterial muscularization without pulmonary hypertension. The vascular 
remodeling does not involve endothelial cell proliferation (G; brown staining is smooth 
muscle actin and blue is von Willebrand factor). F and G are reprinted from Daley et al. 
(2008), doi:10.1084/jem.20071008 
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connective tissue growth factor (CTGF) generate modest PH (average RVSP 22 mmHg 
versus 10 mmHg in WT controls) but develop significant RV hypertrophy (RV/LV+S 
0.42).  
Three of the published mouse models of PH have provided unpredicted and puzzling 
results which ought to be followed-up to better understand the integrated response of the 
lung circulation/heart axis, in the setting of PAH and chronic hemodynamic stress. For 
instance, Daley et al (50) reported very pronounced pulmonary artery muscularization, 
but no RV hypertrophy. In contrast, the studies of Shifren et al (206) demonstrate that 
mice lacking elastin develop impressive elevation of RVSP without RV hypertrophy. 
Finally, in hemeoxygenase-1 knock out mice, Yet et al demonstrated that after chronic 
hypoxia exposure, mice did not develop RV hypertrophy, but developed RV dilatation 
(264). All together, these last three studies exemplify that in mice: 1) Severe 
muscularization does not necessarily indicate pulmonary hypertension 2) PH is not 
always translated into RV hypertrophy 3) RV remodeling could happen in the absence of 
PH. Whether increased pulmonary arterial pressure and right ventricular remodeling are 
two mechanistically distinct processes which are usually coupled in PAH remains to be 
investigated. 
4.6 Summary and Conclusions 
Animal models serve as a powerful tool to evaluate human disease. Unfortunately, none 
of the current models is perfect and each one of the presented in this Chapter offers 
unique, and perhaps, complementary features for the researcher interested in studying RV 
failure. The pulmonary artery banding model in rats and mice could offer tremendous 
opportunities to study genes or proteins required for RV adaptation to chronic pressure 
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overload. Conversely, models of established RV failure such as monocrotaline or 
SU5416/hypoxia have been used to describe the mechanisms potentially involved in the 
transition from adaptive to maladaptive RV hypertrophy and can therefore serve to 
identify and study key molecular players involved in the reversal of RV failure.  
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CHAPTER 5 
 
 
5. 1 Generation of Animal Models 
5.1.2 SU5416/Hypoxia model 
Male Sprague-Dawley rats (weight 200-250 g) received a single injection of SU5416 
suspended in 0.5% (w/v) carboxymethylcellulose sodium, 0.9% (w/v) sodium chloride, 
0.4% (w/v) polysorbate 80, and 0.9% (v/v) benzyl alcohol in deionized water, according 
to our protocol and previously published literature(79, 223), at a dose of 20 mg/kg 
subcutaneously and were exposed in a hypoxia (nitrogen dilution) chamber simulating an 
approximate altitude of 5000 m. for 4 weeks. As previously described, the RV in the 
SuHx rat model responds to pulmonary hypertension with a robust degree of 
hypertrophy, followed by dysfunction and failure(162). The RV in this rat model is 
characterized by fibrosis, capillary rarefaction and cardiomyocyte apoptosis(25), which 
are associated with decreased cardiac output, markedly dilated RV and decreased 
exercise capacity(26). Also, as previously described, the SuHx RV dysfunction model 
reproduces some features of human RV dysfunction, such as paradoxical septal 
movement and RV dilatation.  
5.1.2 Pulmonary artery banding 
Male Sprague-Dawley rats (weight 180-200 g) were anesthetized with isoflurane 
inhalation (5% and 2%, respectively, in oxygen-enriched room air). After intubation, the 
animals are mechanically ventilated with the use of a volume-controlled respirator. 
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Positive endexpiratory pressure was maintained at 4 cmH2O. A left thoracotomy as 
performed, where the pulmonary artery was carefully dissected free from the aorta. A silk 
thread was then positioned underneath the pulmonary artery, while we also placed an 8-
gauge needle is placed alongside the pulmonary artery. A suture was tied tightly around 
the needle, and the needle rapidly removed to produce a fixed constricted opening in the 
lumen equal to the diameter of the needle. After the banding, the thorax was closed in 
layers, and postoperative pain relief was obtained by applying buprenorphine (15µg/kg 
s.c.). For more information about the procedure please refeer to Bogaard, et at. 
Circulation 2009 (25). The PAB rats were sacrificed to collect organs 6 weeks after the 
surgery, to allow for significant hypertrophy as reported by Bogaard et al(24, 25). As a 
model of strictly mechanical RV pressure overload, the PAB rat model demonstrates 
preserved RV function despite generating significantly high RV afterload and 
hypertrophy(24, 25) (See Chapter 4). Thus, the PAB-model was utilized as a model of 
non-dysfunctional RV hypertrophy.  
5.2 Human samples 
Human RV tissue samples were obtained from 4 patients diagnosed with PAH and RVF 
that underwent cardiac transplantation. All human samples were kindly donated by the 
Bosch Institute, University of Sydney, Sydney, Australia. Control RV samples were 
obtained from a normal donor heart, carefully matching age and gender. Clinical 
information regarding the human samples can be found Table 3.  
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Table 3. Demographic and clinical information of patients with right ventricular 
dysfunction and pulmonary hypertension 
Patient  
 
Age Gender NYHA 
Class 
Clinical 
Data 
Control  
 
42 Female I Brain death due to 
subarachnoid 
hemorrhage. No 
previous cardiac or 
pulmonary disease. 
EMS 1 21  Female II Large VSD and pulmonary hypertension.  
 
EMS 2 
 
46 Female IV Large VSD and pulmonary hypertension.  
PAH 1  
 
38 Female IV Familiar IPAH, mean pulmonary pressure 
80 mmHg, wedge pressure 10, cardiac 
index 1.76. Negative vasoreactive test. No 
specific PAH treatment.  
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Table 3. Demographic and clinical information of patients with right ventricular 
dysfunction and pulmonary hypertension. Heart samples from free RV wall were 
obtained after cardiac transplantation, immediately frozen and stored. NYHA = New York 
Heart Association Functional Classification at the moment of cardiac transplantation; 
EMS =  Eisenmenger’s Syndrome; IPAH =  Idiopathic Pulmonary Arterial Hypertension; 
VSD = Ventriculoseptal defect 
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5. 3 Echocardiography 
Doppler echocardiography was performed using the Vevo770 imaging system 
(VisualSonics, Toronto, Canada) directly after the hypoxic exposure (baseline) and again 
4 weeks later after treatment. Superficial anesthesia with ketamine/xylazine was used to 
obtain two-dimensional, M-mode and Doppler imaging in both long axis and short-axis 
views, using a 30-MHz probe. Measurements were made of the RV inner diameter in 
diastole (RVID; long axis) and tricuspid annular plane systolic excursion (TAPSE; long 
axis). The presence of pulmonary hypertension before treatment was evaluated by 
measuring the pulmonary artery acceleration time and mid-systolic notching with pulsed-
wave Doppler recordings, as previously reported (235).  
5.4 Hemodynamic measurements 
Four weeks after SU5416 administration or four weeks after the first dose of carvedilol 
(eight weeks after SU5416 injection), hemodynamic measurements were made using a 
4.5 mm conductance catheter (Millar Instruments, Houston, TX) and the Powerlab data 
acquisition system (AD Instruments, Colorado Springs, CO). The rats were anesthetized 
with an intramuscular injection of ketamine at a dose of 100mg/kg and xylazine 15 
mg/kg. Rats were then were intubated through tracheotomy and placed in a supine 
position. After a median sternotomy the RV outflow tract was punctured with a 23G 
needle and the catheter was introduced ante grade to measure pulmonary artery pressures.  
5.5. Tissue preparation for molecular analysis 
 Upon sacrifice, the right lung and the total heart were removed. The RV was carefully 
dissected from the rest of the heart to measure the RV/LV+S. RV weight over left 
ventricle and septum weight (LV/+S) weight is the standard assessment for hypertrophy, 
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as previously reported(25, 79, 82). After dissection the lung, RV and LV+S tissues were 
frozen with liquid nitrogen until the isolation of mRNA and protein was performed. The 
left lung was inflated with 0.5% low-melting agarose at a constant pressure of 25cm H2O, 
fixed in 10% formalin for 48 hours and used for histological evaluation of the lungs and 
IHC analysis, as reported previously(25, 109).    
5.6 Gene expression studies 
Using the FastPrep®- 24 instrument (MP Biomedicals, Solon, OH), 25mg of RV or LV 
or Lung tissue were homogenized with Triazol® (Qiagen, Valencia, CA) in Lysing 
Matrix D impact-resistant 2ml tubes (MP Biomedicals, Solon, OH). mRNA was carefully 
isolated using a RNeasy (Qiagen, Valencia, CA) isolation kit according to manufacturers 
protocol. Total RNA (1 µg) was reverse transcribed into first complimentary DNA 
(cDNA) using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA). First strand cDNA was diluted 10 times and RT-QPCR performed 
using Power SYBR® Green PCR Master Mix (Applied Biosystems) along with murine 
specific primers (Table 4).  
All PCR reactions were performed with a LightCycler480 PCR system (Roche 
Diagnostics, Meylan, France). The cycling parameters were the following: initial 
denaturation at 95°C for 15 min, followed by 50 cycles of denaturation at 94°C for 15s, 
annealing at 55°C for 15 s, and extension at 72°C for 15 s. The α-actinin 1 and 18 S 
genes were used as the reference gene for mRNA relative quantification. All gene 
expression results were normalized to controls, and expressed as mean± SEM unless 
otherwise specified.   
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5.7 Western Blotting 
Whole cell lysate from isolated right ventricle was prepared using RIPA (Radio-
Immunoprecipitation Assay) buffer (Sigma, St. Louis, MO), and the protein 
concentration was determined using BioRad Protein DC Protein Assay (BioRad, 
Hercules, CA). Thirty micrograms of whole cellular protein per lane was separated by 
SDS-PAGE with a 4-12% Bis-Tris NUPAGE gel (MES SDS running buffer) and blotted 
onto a PVDF membrane. The membrane was incubated with blocking buffer (5% non-fat 
dry milk/PBS 0.1%/Tween 20) at room temperature for 1 hour. The membrane was then 
probed with the primary antibodies diluted in blocking buffer overnight at 4˚C. 
Subsequently, membranes were incubated with horseradish peroxidase-conjugated anti-
mouse or anti-rabbit antibody diluted 1:1000 in blocking buffer. Blots were developed 
with ECL (PerkinElmer, Waltham, MA) on GeneMate Blue Basic Autorad Films 
(BioExpress, Kaysville, UT). Blots were scanned and densitometry analysis was done 
with ImageJ (National Institutes of Health 1997-2011, Bethesda, MD; 
http://imagej.nih.gov/ij). Rabbit anti-PGC1α antibody was acquired from Cell Signaling 
Technology, Inc., Beverly, MA. Rabbit anti-ACADM and ACADVL antibody were 
acquired from Abcam plc, Cambridge, MA. Rabbit anti-PPARα antibody, ND4L and 
CytB were purchased from Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and rabbit 
anti-estrogen related receptor alpha (EPR46Y) was purchased from Millipore, Billerica, 
MA.  
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Table 4. List of Primers Used 
Gene 
NCBI 
Gene 
Ref. 
Forward Sequence Reverse Sequence 
α-actinin 1 81634 5' 
TCAGTTGGAAGGATGGT
CTTG 3' 
5' 
AAGGCTGTGTTCAGGTTTGT
G 3' 
ACADM 24158 5' 
GACGGAGCAGCAGAAAG
AGTT 3' 
5' 
CTTGATGAGAGGGAACGGG
TA 3' 
ACADVL 25363 5' 
AAGTGAATGACCCTGCC
AAGA 3' 
5' 
ATGCCCCCAGTTCTTTGAGT
C 3'  
ACADS 64304 5' 
CTGGATTGTGCCGTGAA
GTAC 3' 
5' 
GCTTGAACTGGATGTTTTGG
A 3' 
ACSL1 25288 5' 
GGGTACTACTGAGGGTG
TCCG 3' 
5' 
CTCTGGAAGCCATCGTACAT
C 3' 
CD36 29184 5' 
GTTATTGGTGCTGTCCTG
GCT 3' 
5' 
CCGTTTTCACCCAGTTTTTG
A 3' 
COUP- 11398 5' 5' 
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TF1 4 CTTTTGCTTCGTCTCCCTT
CC 3' 
ATGGGGGTTTTACCTACCAA
A 3' 
CPT-1α 25757 5' 
GGCATGATCGCAAAGAT
CAGT 3'  
5' 
GCCACCCAGAGCCCTGTAC
CA 3' 
CPT-1β 25756 5' 
AAGAACACGAGCCAACA
AGCA 3' 
5' 
TACCATACCCAGTGCCATCA
C 3' 
CPT-2 25413 5' 
GCTGCCTATCCCTAAACT
TGA 3' 
5' 
AACGCTTCTGTTCTCCTGAA
C 3' 
CS 17058
7 
5' 
CTGAGTGCCAGAAACTG
CTAC 3' 
5' 
GTGAGAGCCAAGAGACCTG
TT 3' 
ERRα 29370
1 
5' 
CACAAGGAGGAGGAGGA
TGG 3' 
5' 
AGGCGTTTGGGTAGAGAGC
T 3' 
ERRγ 36089
6 
5' 
TCCCCAGACCAAGTGTG
AATA 3' 
5' 
AGTGATACCCAGAGGCGAT
GT 3' 
GLUT-1 24778 5' 
TTCCTGCTCATCAATCGT
AAC 3' 
5' 
ACCCTCTTCTTTCATCTCCT
G 3' 
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Hexokinas
e 1 
25058 5' 
TGATGGAGGTGAAGAAG
AGGC 3' 
5' 
GGCAGCATTTTGACAGTAG
CT 3' 
Hexokinas
e 2 
25059 5' 
GAAGATGATTAGCGGGA
TGTA 3' 
5' 
TAAGGAGTTCTGGGCTGAG
TT 3' 
IDH1 24479 5' 
CACACAGTTCCTTCCAAA
TGG 3' 
5' 
GCGTCCATCATACTTCTTCA
G 3' 
PDHb 28995
0 
5' 
GCTGAGATTTGTGCGAG
AATT 3' 
5' 
CGTAAGGCATAGGGACATC
AG 3' 
PDK-1 89813 5' 
CGAAACAGACATCATAA
TGTG 3' 
5' 
GAATATGAGGATGTGCTGG
TT 3' 
PGC-1α 83516 5' 
ACCCCAGAGTCACCAAA
TGA 3' 
5' 
GCAGTTCCAGAGAGTTCCA
C 3' 
PPAR-α 25747 5' 
GGTCCTCTGGTTGTCCCC
TT 3' 
5' 
GTGAGTTACGCCCAAATGC
A 3' 
PPAR-δ 25682 5' 
AACTTCAGCAGCCTCTTC
5' 
ACCAGCAGTCCGTCTTTGTT
	   91	  
CTC 3' G 3' 
PPAR-γ 25664 5' 
CGGTTGATTTCTCCAGCA
TT 3' 
5' 
TCGCACTTTGGTATTCTTGG 
3' 
SP-1 24790 5' 
AGCAGCAATACCACCCT
TACA 3' 
5' 
GACAGTTGAGCAGCATTCA
CA 3' 
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5.8 Isolation of mitochondria  
Isolation of a single population of cardiac mitochondria was conducted as described 
previously (217), except that approximately 100 mg of right ventricle tissue were used. 
Briefly, tissue was washed in a modified Chappell-Perry (CP) buffer (buffer CP1 at pH 
7.4: 100 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM MgSO4⋅7H2O, 1 mM ATP), dried 
with Whatman filter paper, weighed, minced and homogenized in CP1 buffer using a 
polytron tissue blender (Kinematica, Bohemia, NY). The homogenate was supplemented 
with 5 mg/g (wet weight) trypsin (#T0303, Sigma-Aldrich), incubated with stirring for 15 
min at 4 oC followed by addition of 3 ml of CP2 buffer (CP1 buffer containing 0.2% BSA 
(#A7030, Sigma-Aldrich) to attenuate trypsin activity). Digested tissue was further 
homogenized by two strokes using a digital steady-stirring tight Teflon pestle/glass tube 
homogenizer set at 600 rpm (Fisher Scientific, Pittsburgh, PA). Undigested tissue and 
heavier cell fractions in the remaining volume were pelleted by centrifugation at speed 
500g for 10 min at 4 oC. The mitochondria-containing supernatant was centrifuged at 
3000g for 10 min at 4 oC. The mitochondrial pellet was washed with 1 ml of KME buffer, 
pH 7.4 (100 mM KCl, 50 mM MOPS, 0.5 mM EGTA). Mitochondria were re-suspended 
in KME and used within 4 h after isolation or frozen. The protein concentration was 
measured by Lowry (134) using BSA as a standard and sodium deoxycholate as a 
detergent. 
5.9 Mitochondrial oxidative phosphorylation  
Oxygen consumption by intact mitochondria was measured using a Clark-type oxygen 
electrode (Strathkelvin Instruments, North Lanarkshire, UK) at 30 oC in respiration buffer 
at pH 7.4 (80 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM KH2PO4, 1 mg/ml defatted 
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BSA) as previously described (38, 132). Briefly, substrates for complex I (20 mM 
glutamate), complex II (20 mM succinate with 7.5 µM rotenone), and complex IV (1 mM 
N,N,N′,N′-tetramethyl-p-phenylenediamine (TMPD)/20 mM L- ascorbate with 7.5 µM 
rotenone) were used and state 3 (0.2 mM ADP-stimulated), state 4 (ADP-limited) 
respiration, respiratory control ratio (RCR), maximal rate of state 3 respiration (2 mM 
ADP), and ADP/O ratio were determined. 
5.10 Chromatography Electrospray Ionization Tandem Mass Spectrometry  
Eicosanoids were analyzed from frozen heart samples as follows. Briefly the frozen heart 
tissues were thawed on ice and homogenized using an Omni TH tissue homogenizer to 
obtain a 10% (w/v) solution in PBS. 200 µl of the solution thus obtained was diluted 1ml 
of LCMS grade ethanol containing 10 ng of each internal standard and 0.05% BHT. The 
internal standards used were, (d4) 6k PGF1α, (d4) 8-iso PGF2α, (d4) PGF2α, (d4) PGE2, 
(d4) PGD2, (d4) LTB4, (d4) TXB2, (d4) LTC4, (d5) LTD4, (d5) LTE4, (d8) 5-
hydroxyeicosatetranoic acid (5HETE), (d8) 15-hydroxyeicosatetranoic acid (15HETE), 
(d8) 14,15 epoxyeicosatrienoic acid, (d8) Arachidonic Acid, and (d5) Eicosapentaenoic 
acid. The mixture thus obtained was agitated to homogeneity using a bath sonicator and 
the resultant suspension was incubated in the dark at 4 0C for 5 hours with periodic 
sonication. Following incubation, the insoluble fraction was precipitated by centrifuging 
at 6000g for 20 minutes and the supernatant was transferred into a new glass tube. This 
supernatant was dried under vacuum followed by reconstitution in 100 µl of 50:50 
EtOH:dH2O for quantitation via LC/MS/MS.  A 30 minute reversed-phase LC method 
utilizing a Kinetex C18 column (150 x 2.1mm, 1.7µm) was used to separate the 
eicosanoids at a flow rate of 200µl/min at 50°C.  The column was equilibrated with 100% 
	   94	  
Solvent A [acetonitrile:water:formic acid (10:90:0.02, v/v/v)] for five minutes and then 
10 µl of sample was injected.  100% Solvent A was used for the first minute of 
elution.  Solvent B [acetonitrile:isopropanol (50:50, v/v)] was increased in a linear 
gradient to 25% Solvent B to 3 minutes, to 45% until 11 minutes, to 60% until 13 
minutes, to 75% until 18 minutes, and to 100% until 20 minutes.  100% Solvent B was 
held until 25 minutes, then was decreased to 0% in a linear gradient until 26 minutes, and 
then held until 30 minutes.  The eicosanoids were analyzed using a hybrid triple 
quadrapole linear ion trap mass spectrometer (QTRAP5500® ABSciex) via multiple-
reaction monitoring in negative-ion mode.  Eicosanoids were monitored using precursor 
→ product MRM pairs.  The mass spectrometer parameters used were: curtain gas: 30; 
CAD: High; ion spray voltage: -3500V; temperature: 500°C; Gas 1: 40; Gas 2: 60; 
declustering potential, collision energy, and collision cell exit potential vary per 
transition.  
5.11 Statistical analysis 
Differences between groups were assessed with one-way or two-way ANOVA or 
Kruskall-Wallis tests. Bonferroni’s and Dunn’s post-hoc tests were used to assess 
significant differences between groups. A p-value < 0.05 was accepted as significant. 
Correlation analysis was done with Spearman’s test. Results are reported as means±SEM, 
or fold-change mean±SEM unless specified otherwise. Four-to-six rats were used per 
group, unless otherwise specified. Statistical analysis was done with PASW V.18 (IBM, 
Armonk, New York) and GraphPad Prism (La Jolla, CA). 
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CHAPTER 6 
 
6.1 Introduction 
As discussed in Chapter 2 and 3 pulmonary arterial hypertension (PAH) is a severe and 
often rapidly progressive group of diseases which are characterized by a chronically and 
frequently progressive increase in the right ventricular (RV) afterload(197). Increased RV 
afterload is partially compensated by RV hypertrophy but eventually leads to RV 
dysfunction (RVD), RV failure and untimely death, regardless of medical treatment(197). 
Human and experimental chronic left heart dysfunction is characterized by decreased 
oxidative metabolism(156), abnormal mitochondrial respiration(189) and impaired 
mitochondrial biogenesis(113). These changes have in part been explained by a 
deregulated expression of critical transcription factors such as the peroxisome 
proliferator-activated receptor (PPAR) alpha(16), the estrogen-related receptor (ERR) 
alpha(108) and the master regulator of oxidative metabolism, the PPAR-gamma 
coactivator-1alpha (PGC-1α)(12).  
Akin to left heart failure, it has been postulated that RVD is characterized by abnormal 
energy metabolism(186, 231). Studies in animal models have demonstrated that RVD 
exhibits an increased expression of glycolysis-related genes(54) and increased enzymatic 
glycolysis rate(176). However, is largely unknown to what extent this switch in cardiac 
bioenergetics (also known as metabolic remodeling(236)) involves changes in fatty acid 
oxidation (FAO), whether metabolic remodeling is a response to chronic pressure 
overload, or to what extent mitochondrial structure and function are also compromised in 
RVD. Thus, we sought to 1) characterize the metabolic gene expression profile associated 
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with RV dysfunction, 2) determine whether pressure overload is sufficient to explain 
metabolic gene remodeling, 3) assess the structure and function of mitochondria in the 
dysfunctional RV.  
6.2 Results 
6.2.1 RV dysfunction is characterized by a load-independent downregulation of 
PGC-1α, PPAR-α  and ERR-α .  
Drake et al. have previously reported that dysfunctional RVs from SuHx-rats, 
differentially express multiple gene signalling pathways when compared with non-
dysfunctional hypertrophied RVs(55). Importantly, we reported that RVD is associated 
with gene expression changes that suggest an abnormal metabolism, with a particularly 
strong signal relating to the peroxisome proliferator-activated receptor (PPAR) signaling 
pathways. Therefore, as a first step, we measured the expression of PGC-1α, a direct 
coactivator and master regulator of the PPAR family of transcription factors. PGC-1α 
regulates oxidative metabolism and many aspects of mitochondrial biology(67).     
Western blots of protein samples obtained from SuHx RV tissues showed a significantly 
decreased amount of PGC-1α protein (Figure 15A). qPCR analysis revealed a significant 
downregulation of PGC-1α mRNA levels (Figure 15B) indicating that the change in 
PGC-1α expression also occurred on the transcription level. Decreased PGC-1α gene 
expression was accompanied by a decreased expression of the ERR-α and PPAR-α genes 
(Figure 15B). To evaluate whether pure mechanical RV pressure-overload was sufficient 
to downregulate PGC-1α expression, we measured PGC-1α transcript levels in PAB-RV 
tissues and found that the expression of PGC-1α, ERR-α and PPAR-α was not 
	   98	  
Figure 15. Gene and protein expression of PGC-1α, ERR-α and PPAR-α in SuHx RV 
tissue and its relationship with RV function. 
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PPAR family of transcription factors. PGC-1α regulates oxida-
tive metabolism and many aspects of mitochondrial biology.21
Western blots of protein samples obtained from SuHx RV 
tissues showed a significantly decreased amount of PGC-1α 
protein (Figure 1A). Quantitative polymerase chain reac-
tion analysis revealed a significant downregulation of PGC-
1α mRNA levels (Figure 1B), indicating that the change in 
PGC-1α expression also occurred on the transcription level. 
Decreased PGC-1α gene expression was accompanied by a 
decreased expression of the ERR-α and PPAR-α genes (Figure 
1B). To evaluate whether pure mechanical RV pressure-over-
load was sufficient to downregulate PGC-1α expression, we 
measured PGC-1α transcript levels in PAB-RV tissues and 
found that the expression of PGC-1α, ERR-α, and PPAR-α 
was not significantly decreased in the nonfailing hypertro-
phied RVs of PAB rats, despite the high RV pressure and RV 
hypertrophy (Figure 1B). Figures 1C and Figure S2A and S2B 
(available in the online-only Data Supplement) illustrate that 
PGC-1α (R2=0.72; p=0.001), PPAR-α (R2=0.72, P=0.001), 
and ERR-α (R2=0.76; P=0.002) transcript levels strongly 
correlated with the tricuspid annular plane systolic excursion, 
a heart rate–independent variable of RV function.
We have described previously that SU5416 treatment 
alone does not induce RVD and has a limited impact on gene 
expression.20 However, because decreased expression of PGC-
1α could be a direct effect of the combination of SU5416 and 
hypoxia rather than a consequence of RVD, we measured the 
expression of PGC-1α 1 week after the SuHx protocol had 
been initiated. At 1 week no RVD is present and, indeed, as 
shown in Figure 1D, PGC-1α expression is not decreased 
in the right ventricle or in the left ventricle. In addition, we 
measured the expression of PGC-1α in rat lung tissues after 
4 weeks of SuHx, a time point where plexiform-like lesions 
have already formed, and we found a significant increase 
in PGC-1α expression (Figure 1E). To further evaluate a 
potential toxic effect of SU5416 in the setting of RV pressure 
overload, we examined the RV gene expression of PAB 
animals exposed to SU5416 and found no change in the PGC-
1α, ERR-α, or PPAR-α mRNA transcript levels (Figure S2C). 
Next, we measured the expression of PGC-1α in LV tissue 
Figure 1. A, Western blots on SU5416/
hypoxia (SuHx) right ventricular (RV) whole 
tissue lysates show a downregulation of 
peroxisome proliferator-activated receptor 
(PPAR)-γ coactivator-1α (PGC-1α), estro-
gen-related receptor (ERR)-α, and PPAR-α 
on the protein level. B, Quantitative reverse 
transcription-polymerase chain reaction 
mRNA expression analysis from right 
 ventricles of control, SuHx, and pulmonary 
artery banding (PAB) animals. Compared 
with controls and PAB, SuHx-RV tissue 
exhibits decreased PGC-1α transcript 
 levels along with a decreased expression of 
the nuclear receptors ERR-α and PPAR-α. 
C, PGC-1α correlation with right ventricular 
function (tricuspid annular plannar sys-
tolic excursion [TAPSE]). D, Quantitative 
 polymerase chain reaction analysis shows 
no change in PGC-1α expression in RV and 
left ventricle (LV) of SuHx rats at 1 week 
after SuHx had been initiated. E, mRNA 
expression of PGC-1α in SuHx lung tissue. 
F, PGC-1α, ERR-α, and PPAR-α mRNA 
transcript levels in human RV samples. 
Data are shown in fold changes±SEM over 
controls; **P<0.001; #P<0.0001.
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Figure 15.  A, Western blots on SU5416/ hypoxia (SuHx) right ventricular (RV) whole 
tissue lysates show a downregulation of peroxisome proliferator-activated receptor 
(PPAR)- coactivator-1α (PGC-1α), estrogen-related receptor (ERR)-α, and PPAR-α on 
the protein level. B, Quantitative reverse transcription-polymerase chain reaction mRNA 
expression analysis from right ventricles of control, SuHx, and pulmonary artery banding 
(PAB) animals. Compared with controls and PAB, SuHx-RV tissue exhibits decreased 
PGC-1α transcript levels along with a decreased expression of the nuclear receptors 
ERR-α and PPAR-α. C, PGC-1α correlation with right ventricular function (tricuspid 
annular plannar systolic excursion [TAPSE]). D, Quantitative polymerase chain reaction 
analysis shows no change in PGC-1α expression in RV and left ventricle (LV) of SuHx 
rats at 1 week after SuHx had been initiated. E, mRNA expression of PGC-1α in SuHx 
lung tissue. F, PGC-1α, ERR-α, and PPAR-α mRNA transcript levels in human RV 
samples. Data are shown in fold changes±SEM over controls; **P<0.001; #P<0.0001. 
Reproduced with permission from Gomez-Arroyo J, et al. Metabolic gene remodeling 
and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to 
pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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significantly decreased in the non-failing hypertrophied RVs of PAB rats, despite the 
high RV pressure and RV hypertrophy (Figure 15B). Figures 15C and Figure 16 2A-B 
illustrate that PGC-1α (R2=0.72, p=0.001), PPAR-α (R2=0.72, p=0.001) and ERR-α 
(R2=0.76, p=0.002) transcript levels strongly correlated with the tricuspid annular plane 
systolic excursion (TAPSE), a heart-rate independent variable of RV function.  
We have previously described that SU5416 treatment alone does not induce RV 
dysfunction and has a limited impact on gene expression(55). However, because 
decreased expression of PGC-1α could be a direct effect of the combination of SU5416 
and hypoxia rather than a consequence of RVD, we measured the expression of PGC-1α 
at one week after the SuHx protocol had been initiated. At one week no RVD is present 
and indeed, as shown in Figure15D, PGC-1α expression is not decreased in the RV or in 
the LV. In addition, we measured the expression of PGC-1α in rat lung tissues after four 
weeks of SuHx, a time-point where plexiform-like lesions have already formed, and we 
found a significant increase in PGC-1α expression (Figure 15E). To further evaluate a 
potential toxic effect of SU4516 in the setting of RV pressure overload, we examined the 
RV gene expression of PAB animals exposed to SU4516 and found no change in the 
PGC-1α, ERR-α or PPAR-α mRNA transcript levels (Figure 16C). Next, we measured 
the expression of PGC-1α in LV tissue obtained from animals sacrificed four weeks after 
initiation of the SuHx protocol. Although somewhat decreased, the SuHx-LV tissue did 
not show a significant change in PGC-1α expression (Figure 16D). In the aggregate, the 
data indicates that the decreased expression of PGC-1α is unlikely due to a toxic effect of 
SU5416.   
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Figure 16.  
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Figure 16. Gene expression of PGC1α  and other nuclear receptors involved in fatty 
acid transition from fetal to adult hearts. Scatter-plot illustrating correlation between 
TAPSE and mRNA expression of ERR-α (A) and PPAR-α (B). RT-PCR analysis reveals 
no difference in the gene expression of PGC-1α, PPAR-α or ERR-α in the PAB model 
after exposure to SU5416 (C) or in SuHx left ventricle tissue (D). E) mRNA transcript 
levels of transcription factors other than PGC-1α that regulate cardiac energetics. N= 4-8 
per group. Data are shown in fold-change mean ± SEM. * p=<0.05, #p=<0.001. 
Reproduced with permission from Gomez-Arroyo J, et al. Metabolic gene remodeling 
and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to 
pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144. 
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Because nuclear receptors other than PGC-1α have been implicated in phenotypic 
metabolic changes which occur during normal cardiac development, we decided to 
evaluate the expression of the estrogen related receptor gamma (ERR-γ), and of the 
transcription factors COUP-TF1 and SP1 (5, 191). QPCR analysis showed that the 
expression of these transcription factors was not affected in dysfunctional RV tissues 
(Figure 16E). Lastly, to examine whether the changed expression of the metabolic gene 
pattern was also observed in human myocardium, we examined the gene expression of 
PGC-1α, PPAR-α and ERR-α in RV tissue samples from patients with PAH. Indeed, we 
found a comparable expression pattern in the human RV tissue as we had observed in the 
SuHx RV rat tissue (Figure 15F).  
6.2.2 Dysfunctional RV hypertrophy is characterized by decreased expression of 
genes involved in fatty acid and glucose oxidation  
Figure 17A illustrates that multiple PGC-1α/PPAR-α/ERR-α target genes encoding 
critically important proteins, required for fatty acid transport into the cardiomyocytes and 
into the mitochondria, were downregulated in the SuHx dysfunctional RVs. In addition, 
the expression of genes encoding proteins required for beta-oxidation (ACADM, 
ACADVL and ACADS) was decreased (Figure 17B). Western blot analysis confirmed 
the decreased expression of ACADM and ACADVL in RVD (Figure 17C). Supporting 
the observation of normal expression of PGC-1α/PPAR-α/ERR-α, non-failling 
hypertrophied (PAB) RVs demonstrated a normal expression of ACADM and a 
significantly increased expression of ACADS and ACADVL. These Acyl-CoA 
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Figure 17.  
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obtained from animals killed 4 weeks after initiation of the 
SuHx protocol. Although somewhat decreased, the SuHx-LV 
tissue did not show a significant change in PGC-1α expression 
(Figure S2D). In the aggregate, the data indicate that the 
decreased expression of PGC-1α is unlikely attributed to a 
toxic effect of SU5416.
Because nuclear receptors other than PGC-1α have been 
implicated in phenotypic metabolic changes that occur during 
normal cardiac development, we decided to evaluate the expres-
sion of the ERR-γ and of the transcription factors COUP-TF1 
and SP1.22,23 Quantitative polymerase chain reaction analysis 
showed that the expression of these transcription factors was 
not affected in dysfunctional RV tissues (Figure S2E). Lastly, 
to examine whether the changed expression of the meta-
bolic gene pattern was also observed in human myocardium, 
we examined the gene expression of PGC-1α, PPAR-α, and 
 ERR-α in RV tissue samples from patients with PAH. Indeed, 
we found a comparable expression pattern in the human RV tis-
sue as we had observed in the SuHx RV rat tissue (Figure 1F).
Dysfunctional RV Hypertrophy Is Characterized 
by Decreased Expression of Genes Involved in Fatty 
Acid and Glucose Oxidation
Figure 2A illustrates that multiple PGC-1α/PPAR-α/ERR-α 
target genes encoding critically important proteins, required 
for fatty acid transport into the cardiomyocytes and into the 
mitochondria, were downregulated in the SuHx dysfunctional 
right ventricles. In addition, the expression of genes encod-
ing proteins required for β-oxidation (acyl-coenzyme A [CoA] 
dehydrogenase, C-4 to C-12 straight chain [ACADM], acyl-
CoA dehydrogenase, very long chain [ACADVL], and acyl-
CoA dehydrogenase, C-4 to C-8(6) short chain [ACADS]) 
was decreased (Figure 2B). Western blot analysis confirmed 
the decreased expression of ACADM and ACADVL in RVD 
(Figure 2C). Supporting the observation of normal expression 
of PGC-1α/PPAR-α/ERR-α, nonfailing hypertrophied (PAB) 
right ventricles demonstrated a normal expression of ACADM 
and a significantly increased expression of ACADS and 
ACADVL. These acyl-CoA dehydrogenases are required to 
metabolize medium, short, and long fatty acids, respectively.
In accordance with our previous reports,20 dysfunctional RV 
hypertrophy in the SuHx rats was characterized by increased 
expression of GLUT1 and hexokinase 1; these 2 genes play an 
important role in glycolysis (Figure 2D). In contrast, we found a 
downregulation of genes that encode enzymes involved in aero-
bic glucose catabolism, such as the genes encoding the Krebs 
cycle enzymes citrate synthase and  isocitrate dehydrogenase. 
Furthermore, the β subunit of pyruvate dehydrogenase, an impor-
tant link between glycolysis and glucose oxidation, showed a 
50% decreased mRNA expression, whereas the gene expression 
of pyruvate dehydrogenase kinase, an enzyme  controlling pyru-
vate dehydrogenase activity, was upregulated. Conversely, non-
failing hypertrophied PAB RVs exhibited a normal expression 
of glycolysis-related genes, a significantly lower expression of 
pyruvate  dehydrogenase kinase, and  normal expression of isoci-
trate dehydrogenase and citrate synthase (Figure 2D).
RVD Is Characterized by Abnormal  
Mitochondrial Ultrastructure, Impaired 
Mitochondrial Respiration, and Abnormal 
Mitochondrial Biogenesis
PGC-1α regulates mitochondrial biogenesis along with oxi-
dative metabolism.21 Therefore, we sought to explore abnor-
malities in mitochondrial biology. PGC-1α exerts pleiotropic 
effects by direct coactivation of an array of nuclear and non-
nuclear receptors used in the control of cellular metabolism.21 
Among them, transcription factor A, mitochondrial (TFAM), 
Figure 2. A, mRNA levels of genes encod-
ing key rate-limiting enzymes involved in 
fatty acid transport into the cell (CD36) and 
transport into the mitochondria (ACSL1, 
CPT1α, CPT1β, and CPT2) were decreased. 
B, Genes encoding a family of acyl-coen-
zyme A (CoA) dehydrogenases specific for 
fatty acid β-oxidation (ACADS, ACADM, 
and ACADVL) also were downregulated 
in dysfunctional SU5416/hypoxia (SuHx) 
right ventricles but significantly increased 
in pulmonary artery banding (PAB) right 
ventricular (RV) tissue. C, Western blotting 
on cytosolic protein extracts obtained from 
RV tissue lysate shows decreased protein 
expression of ACADM and ACADVL in 
SuHx-RV tissue. D, Genes encoding key 
rate-limiting enzymes for aerobic glucose 
oxidation (Kreb cycle) were downregulated, 
whereas genes encoding enzymes neces-
sary for glycolysis were upregulated. Data 
are shown in fold changes±SEM over con-
trols; *P<0.01; #P<0.0001.
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Figure 17. Gene and protein expression of PGC-1α   target genes required for fatty 
acid oxidation. mRNA levels of genes encod- ing key rate-limiting enzymes involved in 
fatty acid transport into the cell (CD36) and transport into the mitochondria (ACSL1, 
CPT1α, CPT1β, and CPT2) were decreased. B, Genes encoding a family of acyl-coen- 
zyme A (CoA) dehydrogenases specific for fatty acid à-oxidation (ACADS, ACADM, and 
ACADVL) also were downregulated 
in dysfunctional SU5416/hypoxia (SuHx) right ventricles but significantly increased in 
pulmonary artery banding (PAB) right ventricular (RV) tissue. C, Western blotting on 
cytosolic protein extracts obtained from RV tissue lysate shows decreased protein 
expression of ACADM and ACADVL in SuHx-RV tissue. D, Genes encoding key rate-
limiting enzymes for aerobic glucose oxidation (Kreb cycle) were downregulated, 
whereas genes encoding enzymes neces- sary for glycolysis were upregulated. Data are 
shown in fold changes±SEM over con- trols; *P<0.01; #P<0.0001. Reproduced with 
permission from Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial 
dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial 
hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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dehydrogenases are required to metabolize medium, short and long fatty acids, 
respectively.  
In accordance with our previous reports(55), dysfunctional RV hypertrophy in the SuHx 
rats was characterized by increased expression of GLUT1 and Hexokinase-1; these two 
genes play an important role in glycolysis (Figure 17D). In contrast, we found a 
downregulation of genes that encode enzymes involved in aerobic glucose catabolism, 
such as the genes encoding the Krebs cycle enzymes citrate synthase and isocitrate 
dehydrogenase. Furthermore, the beta subunit of pyruvate dehydrogenase – an important 
link between glycolysis and glucose oxidation – showed a 50% decreased mRNA 
expression, whereas the gene expression of pyruvate dehydrogenase kinase (PDK-4), an 
enzyme controlling pyruvate dehydrogenase activity was upregulated. Conversely, non-
failing hypertrophied PAB RVs exhibited a normal expression of glycolysis-related 
genes, a significantly lower expression of PDK-4 and normal expression of isocitrate 
dehydrogenase and citrate synthase (Figure 17D).   
6.2.3 RVD is characterized by abnormal mitochondrial ultrastructure, impaired 
mitochondrial respiration and abnormal mitochondrial biogenesis.   
PGC-1α regulates mitochondrial biogenesis along with oxidative metabolism(67). 
Therefore, we sought to explore abnormalities in mitochondrial biology. PGC-1α exerts 
pleiotropic effects by direct coactivation of an array of nuclear and non-nuclear receptors 
employed in the control of cellular metabolism(67). Among them, TFAM regulates 
mitochondrial DNA replication and maintenance, and is required for cellular and 
mitochondrial viability(118, 240). Associated with the decreased expression of PGC-1α, 
SuHx-RVD tissue had a decreased expression of TFAM (Figure 18A). Because, reduced 
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Figure 18. 
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regulates mitochondrial DNA replication and maintenance 
and is required for cellular and mitochondrial viability.24,25 
Associated with the decreased expression of PGC-1α, SuHx-
RVD tissue had a decreased expression of TFAM (Figure 3A). 
Because reduced TFAM mRNA levels are associated with 
alterations in mitochondrial biogenesis, we measured the 
expression of Top1mt, POGL2, and POLRMT, a set of genes 
that encode enzymes required for the replication of mtDNA 
and mitochondrial biogenesis.4,25 All 3 of the genes were 
downregulated in dysfunctional (SuHx) RV hypertrophy but 
not in PAB-induced RV hypertrophy, as illustrated in Figure 
3A. To test for decreased mtDNA transcription, we measured 
the expression of 2 mtDNA-encoded proteins, NADH-ubiqui-
none oxidoreductase subunit 4L and cytochrome B. These 2 
proteins are subunits of the mitochondrial electron-transport 
chain complexes I and III, respectively. As illustrated in Fig-
ure 3B, the relative protein expression of NADH-ubiquinone 
oxidoreductase subunit 4L and cytochrome B was signifi-
cantly decreased in SuHx-RVs.
High-power magnification electron microscopy 
demonstrated that the mitochondrial ultrastructure in RVD 
tissue was highly abnormal. In comparison to controls (Figure 
3C), mitochondria in SuHx RVs were consistently abnormal 
in shape and size and clumped together in clusters (Figure 
3D). Although clustering of mitochondria was also present 
in the PAB RVs (Figure 3E, arrow), the overall distribution 
of mitochondria was similar to that of control RVs. On 
isolation, RVD tissues exhibited a significantly decreased 
amount of mitochondria, as evidenced by mitochondrial yield 
and by citrate synthase activity (Figure 4A and 4B). Isolated 
mitochondria were studied by respirometry to evaluate the 
efficiency of oxidative phosphorylation. RVF mitochondria 
demonstrated a significantly decreased ADP-stimulated (state 
3) respiration rate when using glutamate (Figure 4C) but not 
when using succinate as electron donors to complexes I and II, 
respectively (Table S2). The complete respirometry results are 
depicted in Table S2.
Because mitochondrial dysfunction could contribute 
to the generation of reactive oxygen species (ROS), we 
measured the levels of 8-isoprostane (8-isoProstaglandin 
F2α) in RVD tissues. 8-Isoprostane has been proposed as a 
marker of antioxidant deficiency and enhanced oxidative 
stress.26 Analysis from liquid chromatography-tandem mass 
spectrometry of SuHx RV tissue demonstrated no change 
in the amount of 8-isoprostane in comparison with controls 
(Figure S3A) but increased levels in the lungs (Figure S3B). 
However, although the amount of ROS generated might have 
not been sufficient to cause significant lipid peroxidation in 
whole RV tissues, ROS could still induce damage. mtDNA 
is particularly susceptible to ROS-induced damage,27 and 
a common marker of mtDNA damage is the formation of 
7,8-dihydro-8-oxoguanine, a mutagenic base byproduct that 
Figure 3. A, mRNA transcript levels of 
genes required for mitochondrial bio-
genesis and mitochondrial DNA (mtDNA) 
replication and transcription. B, Western 
blotting of right ventricular (RV) tissue dem-
onstrates a significantly decreased protein 
expression of mtDNA-encoded proteins in 
SU5416/hypoxia (SuHx)-RV dysfunction. C 
and D, Electron microscopy demonstrates 
abnormal ultrastructure of mitochondrial 
in RV dysfunction. Data are shown in fold 
changes±SEM compared with controls; 
*P<0.01; #P<0.0001.
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Figure 18. Changes in mitochondrial biology in RV failure tissue. mRNA transcript 
levels of genes required for mitochondrial bio- genesis and mitochondrial DNA (mtDNA) 
replication and transcription. B, Western blotting of right ventricular (RV) tissue 
demonstrates a significantly decreased protein expression of mtDNA-encoded proteins in 
SU5416/hypoxia (SuHx)-RV dysfunction. C and D, Electron microscopy demonstrates 
abnormal ultrastructure of mitochondria in RV dysfunction. Data are shown in fold 
changes±SEM compared with controls; *P<0.01; #P<0.0001. Reproduced with 
permission from Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial 
dysfunction in failing right ventricular hypertrophy secondary to pulmonary arterial 
hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144.
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TFAM mRNA levels is associated with alterations in mitochondrial biogenesis, we 
measured the expression of Top1mt, POGL2 and POLRMT, a set of genes that encode 
enzymes required for the replication of mtDNA and mitochondrial biogenesis(113, 118). 
All three genes were downregulated in dysfunctional (SuHx) RV hypertrophy but not in 
PAB-induced RV hypertrophy as illustrated in Figure 18A. To test for decreased mtDNA 
transcription, we measured the expression of two mtDNA-encoded proteins proteins: 
NADH-ubiquinone oxidoreductase subunit 4L (ND4L) and cytochrome B (CytB). These 
two proteins are subunits of the mitochondrial electron-transport chain complexes I and 
III respectively. As illustrated in Figure 18B, the relative protein expression of ND4L 
and CytB was significantly decreased in SuHx-RVs.  
High-power magnification electron microscopy demonstrated that the mitochondrial 
ultrastructure in RVD tissue was highly abnormal. In comparison to controls (Figure 
18C), mitochondria in SuHx RVs were consistently abnormal in shape and size, and 
clumped together in clusters (Figure 18D). Although clustering of mitochondria was also 
present in the PAB RVs (Figure 18E, arrow), the overall distribution of mitochondria 
was similar to that of control RVs. Upon isolation, RVD tissues exhibited a significantly 
decreased amount of mitochondria, as evidenced by mitochondrial yield and by citrate 
synthase activity (Figure 19A-B). Isolated mitochondria were studied by respirometry to 
evaluate the efficiency of oxidative phosphorylation. RVF-mitochondria demonstrated a 
significantly decreased ADP-stimulated (State 3) respiration rate when utilizing 
glutamate (Figure 19C) but not when utilizing succinate as electron donors to complex I 
and II, respectively.  
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Figure 19 
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results from direct exposure of DNA to ROS.28 Figure 5 
shows 8-oxo-G–positive staining in dysfunctional RV tissues, 
particularly in the endomyocardial area.
Discussion
RV failure is a common consequence of severe chronic pul-
monary hypertension and the most frequent cause of death 
in patients with PAH.1 Although RVD plays an important 
prognostic role in patients with PAH,29,30 there are relatively 
few experimental data shedding light on the mechanisms of 
chronic RVD and failure.31,32 Although it has been proposed 
that RVD is associated with metabolic gene remodeling,8 a 
comprehensive metabolic gene profile of the failing right ven-
tricle is still lacking.
Here we demonstrate that dysfunctional RV hypertrophy, 
in rats and patients with PAH, exhibits a significant reduction 
in the expression of PGC-1α and its corresponding nuclear 
receptors (PPAR-α and ERR-α). Interestingly, the change in 
PGC-1α expression seems to be largely independent of the 
RV pressure-overload and hypertrophy. Moreover, multiple 
PGC-1α target genes encoding proteins required for fatty 
acid metabolism were significantly decreased in expression in 
RVD tissues. Particularly, the expression of genes encoding 
the acyl-CoA dehydrogenases, which are specific for fatty 
acid β-oxidation, was significantly decreased in dysfunctional 
SuHx-RV hypertrophy but not in adaptive PAB-RV hypertrophy. 
Conversely, functional PAB-RV hypertrophy was associated 
with a high expression of ACADS and ACADVL, the latter 
being the most important heart acyl-CoA dehydrogenase 
for FAO. Altogether, the gene and protein expression data 
suggest that, in RVD, FAO is impaired on multiple levels. 
Along with the metabolic gene remodeling, we show evidence 
for an abnormal mitochondrial ultrastructure and decreased 
mitochondrial respiration at the level of complex I of the 
electron transport chain. Moreover, RVD is characterized by 
decreased expression of genes encoding proteins required for 
mitochondrial biogenesis, such as TFAM, Top1mt, POGL2, 
and POLRMT. RVD also demonstrated a significantly low 
mitochondrial yield in comparison with control RVs. Finally 
Figure 4. A, Amount of mitochondrial 
protein per 100 mg of right ventricular 
(RV) tissue. SU5416/hypoxia (SuHx) and 
pulmonary artery banding (PAB) RV tis-
sues demonstrate significantly decreased 
mitochondrial yield when compared with 
control RV tissue. B, Whole tissue citrate 
synthase activity assay demonstrates that 
SuHx has a reduced oxidative capacity 
when compared with control RV. C, State 3 
respiration with complex I substrate (gluta-
mate) is significantly decreased in SuHx RV 
dysfunction when compared with control 
or PAB RV tissues. The lines in the box-
and-whiskers plots illustrate the median, 
whereas the + sign illustrates the mean. 
*P<0.01; #P<0.0001.
Figure 5. Immunofluorescence shows 
increased 7,8-dihydro-8-oxoguanine (green) 
in right ventricular dysfunction (RVD) tissue 
vs SU5416/hypoxia (SuHx)-RVD.
	   111	  
Figure 19: A, Amount of mitochondrial protein per 100 mg of right ventricular (RV) 
tissue. SU5416/hypoxia (SuHx) and pulmonary artery banding (PAB) RV tis- sues 
demonstrate significantly decreased mitochondrial yield when compared with control RV 
tissue. B, Whole tissue citrate synthase activity assay demonstrates that SuHx has a 
reduced oxidative capacity when compared with control RV. C, State 3 respiration with 
complex I substrate (gluta- mate) is significantly decreased in SuHx RV dysfunction 
when compared with control or PAB RV tissues. The lines in the box- and-whiskers plots 
illustrate the median, whereas the + sign illustrates the mean. *P<0.01; #P<0.0001. 
Reproduced with permission from the published from Gomez-Arroyo J, et al. Metabolic 
gene remodeling and mitochondrial dysfunction in failing right ventricular hypertrophy 
secondary to pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–
144.
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Since mitochondrial dysfunction could contribute to the generation of reactive oxygen 
species (ROS), we measured the levels of 8-isoprostane (8-isoProstaglandin F2α) in RVD 
tissues. 8-Isoprostane has been proposed as a marker of antioxidant deficiency and 
enhanced oxidative stress(151). Analysis from LC tandem mass spectrometry of SuHx 
RV tissue demonstrated no change in the amount of 8-isoprostane in comparison to 
controls (Figure 20A) but increased levels in the lungs (Figure 20B). However, whereas 
the amount of ROS generated might have not been sufficient to cause significant lipid 
peroxidation in whole RV tissues, ROS could still induce damage. mtDNA is particularly 
susceptible to ROS-induced damage(207) and a common marker of mtDNA damage is 
the formation of 7,8-dihydro-8-oxoguanine (8-oxoG), a mutagenic base byproduct that 
results from direct exposure of DNA to ROS(18). Figure 21 shows that 8-oxo-G positive 
staining in dysfunctional RV tissues, particularly in the endomyocardial area.   
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Figure 20 
 
 
Figure 20. LC-tandem mass spectrometric measurement of 8-iso- PGF-2α (8-
isoprostane) in the RV (A) and lung (B) tissue of SuHx rats. N= 4 rats per group. There 
were no statistically significant differences between groups. Reproduced with permission 
from Gomez-Arroyo J, et al. Metabolic gene remodeling and mitochondrial dysfunction 
in failing right ventricular hypertrophy secondary to pulmonary arterial hypertension. 
Circ Heart Fail. 2013 Jan 1;6(1):136–144. 
 
 
 
 
 
 
 
 
 
Supplemental Figure 3. LC-tandem mass spectrometric measurement of 8-iso-
PGF-2α (8-isoprostane) in the RV (A) and lung (B) tissue of SuHx rats. N= 4 rats per 
group. There were no statistically significant differences between groups.  
 
Legends for Supplemental Video 
Supplemental Video 1. This video clip was obtained while performing an 
echocardiogram of a rat exposed to SU5416/hypoxia (RVD model). The clip 
illustrates the degree of RV dysfunction. Note the significant dilatation of the RV, the 
paradoxical septal movement and the important restriction of the left ventricle during 
systole and diastole.  
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Figure 21.  
 
 
 
Figure 21. Immunofluorescence shows increased 7,8-dihydro-8-oxoguanine (green) in 
right ventricular dysfunction (RVD) tissue vs SU5416/hypoxia (SuHx)-RVD. 
Reproduced with permission from Gomez-Arroyo J, et al. Metabolic gene remodeling 
and mitochondrial dysfunction in failing right ventricular hypertrophy secondary to 
pulmonary arterial hypertension. Circ Heart Fail. 2013 Jan 1;6(1):136–144. 
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results from direct exposure of DNA to ROS.28 Figure 5 
shows 8-oxo-G–positive staining in dysfunctional RV tissues, 
particularly in the endomyocardial area.
Discussion
RV failure is a common consequence of severe chronic pul-
monary hypertension and the most frequent cause of death 
in patients with PAH.1 Although RVD plays an important 
prognostic role in patients with PAH,29,30 there are relatively 
few experimental data shedding light on the mechanisms of 
chronic RVD and failure.31,32 Although it has been proposed 
that RVD is associated with metabolic gene remodeling,8 a 
comprehensive metabolic gene profile of the failing right ven-
tricle is still lacking.
Here we demonstrate that dysfunctional RV hypertrophy, 
in rats and patients with PAH, exhibits a significant reduction 
in the expression of PGC-1α and its corresponding nuclear 
receptors (PPAR-α and ERR-α). Interestingly, the change in 
PGC-1α expression seems to be largely independent of the 
RV pressure-overload and hypertrophy. Moreover, multiple 
PGC-1α target genes encoding proteins required for fatty 
acid metabolism were significantly decreased in expression in 
RVD tissues. Particularly, the expression of genes encoding 
the acyl-CoA dehydrogenases, which are specific for fatty 
acid β-oxidation, was significantly decreased in dysfunctional 
SuHx-RV hypertrophy but not in adaptive PAB-RV hypertrophy. 
Conversely, functional PAB-RV hypertrophy was associated 
with a high expression of ACADS and ACADVL, the latter 
being the most important heart acyl-CoA dehydrogenase 
for FAO. Altogether, the gene and protein expression data 
suggest that, in RVD, FAO is impaired on multiple levels. 
Along with the metabolic gene remodeling, we show evidence 
for an abnormal mitochondrial ultrastructure and decreased 
mitochondrial respiration at the level of complex I of the 
electron transport chain. Moreover, RVD is characterized by 
decreased expression of genes encoding proteins required for 
mitochondrial biogenesis, such as TFAM, Top1mt, POGL2, 
and POLRMT. RVD also demonstrated a significantly low 
mitochondrial yield in comparison with control RVs. Finally 
Figure 4. A, Amount of mitochondrial 
protein per 100 mg of right ventricular 
(RV) tissue. SU5416/hypoxia (SuHx) and 
pulmonary artery banding (PAB) RV tis-
sues demonstrate significantly decreased 
mitochondrial yield when compared with 
control RV tissue. B, Whole tissue citrate 
synthase activity assay demonstrates that 
SuHx has a reduced oxidative capacity 
when compared with control RV. C, State 3 
respiration with complex I substrate (gluta-
mate) is significantly decreased in SuHx RV 
dysfunction when compared with control 
or PAB RV tissues. The lines in the box-
and-whiskers plots illustrate the median, 
whereas the + sign illustrates the mean. 
*P<0.01; #P<0.0001.
Figure 5. Immunofluorescence shows 
increased 7,8-dihydro-8-oxoguanine (green) 
in right ventricular dysfunction (RVD) tissue 
vs SU5416/hypoxia (SuHx)-RVD.
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6.3 Discussion 
Right ventricular failure is a common consequence of severe chronic pulmonary 
hypertension and the most frequent cause of death in patients with PAH(197). Although 
RV dysfunction plays a important prognostic role in patients with PAH(237, 244), there 
are relatively few experimental data shedding light on the mechanisms of chronic RV 
dysfunction (RVD) and failure(23, 246). Whereas it has been proposed that RVD is 
associated with metabolic gene remodeling(231), a comprehensive metabolic gene profile 
of the failing RV is still lacking. 
Here we demonstrate that dysfunctional RV hypertrophy – in rats and patients with PAH 
– exhibit a significant reduction in the expression of PGC-1α and its corresponding 
nuclear receptors (PPAR-α and ERR-α). Interestingly, the change in PGC-1α expression 
appears to be largely independent of the RV pressure overload and hypertrophy. 
Moreover, multiple PGC-1α target genes encoding proteins required for fatty acid 
metabolism were significantly decreased in expression in RVD tissues. Particularly, the 
expression of genes encoding the acyl-CoA dehydrogenases which are specific for fatty 
acid β-oxidation, was significantly decreased in dysfunctional SuHx-RV hypertrophy but 
not in adaptive PAB-RV hypertrophy. Conversely, functional PAB-RV hypertrophy was 
associated with a high expression of ACADS and ACADVL, the latter being the most 
important heart acyl-CoA dehydrogenase for FAO. Altogether the gene and protein 
expression data suggest that in RVD, FAO is impaired on multiple levels (Figure 22). 
Along with the metabolic gene remodeling, we show evidence for an abnormal 
mitochondrial ultrastructure and decreased mitochondrial respiration at the level of 
complex I of the electron transport chain. Moreover, RVD is characterized by decreased 
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Figure 22.  
 
 
 
Figure 22. Schematic representation of the multiple steps affected in fatty acid 
metabolism during right ventricular failure (black stars). ETC= Electron transport chain.   
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expression of genes encoding proteins required for mitochondrial biogenesis such as 
TFAM, Top1mt, POGL2 and POLRMT. RVD also demonstrated a significantly low 
mitochondrial yield in comparison to control RVs. Finally we demonstrate that RVD 
exhibits high levels of 7,8-dihydro-8-oxoguanine, consistent with ROS-induced DNA 
damage.  
We decided to focus on central transcriptional regulators such as PGC-1α and its 
corresponding nuclear receptors ERR-α and PPAR-α, because multiple gene knockout 
studies have illustrated that these proteins play an important role during the functional 
bioenergetic adaptation of the heart to pressure overload(67, 237, 244). PGC-1α is 
preferentially expressed in tissues with high oxidative capacity and coordinates several 
biological processes of mammalian energy metabolism by activating genes involved in 
cellular uptake and mitochondrial oxidation of fatty acids(179). Heart tissue obtained 
from PGC-1α knockout mice displays a reduced palmitoyl-L-carnitine state 3 respiration, 
suggesting reduced FAO, and a reduction in the amount of ATP generated per oxygen 
consumed (131). Of equal importance, in the absence of PGC-1α, the expression of 
mitochondrial genes in the heart is suppressed, the activities of mitochondrial enzymes 
are altered and ATP production is reduced (11). As it has been shown in models of left 
heart failure(11, 12, 130), the SuHx model of severe PAH and RVD is characterized by 
reduced PGC-1α expression. We consider this reduced expression as a central component 
of RV metabolic remodeling. Whereas downregulation of PGC-1α is a feature of 
dysfunctional hypertrophy, it remains unclear what drives the downregulation of PGC-1α 
expression during RVD. As the SuHx model is characterized by capillary rarefaction(25), 
ischemia and hypoxia could potentially drive the metabolic remodeling. However, PGC-
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1α expression is not decreased until RVD occurs. Because PGC-1α expression is an HIF-
independent hypoxia-inducible gene(10), it is unlikely that the downregulated expression 
of PGC-1α and the associated metabolic remodeling profile would be entirely explained 
by hypoxia or by HIF activation. Whereas decreased PGC-1α mRNA expression has 
been reported in human left heart failure (203), recent studies using samples of left 
ventricles obtained from patients with heart failure have demonstrated a relatively normal 
expression of PGC-1α(113). Perhaps these discrepant results may be explained by 
different drug treatments of the patients with LV failure.  
Whereas impaired glucose oxidation has been well characterized in the monocrotaline-
injury model of RVD, changes in fatty acid metabolism are less clear(177). In our study, 
the downregulation of PGC-1α, ERR-α, and PPAR-α expression was coupled to a 
decreased expression of genes encoding FA transport proteins and FAO, which suggests 
to us that FA catabolism in the failing RVs is likely compromised on the levels of 
regulation, transport and catabolism. Others have reported that changes in FAO occur in 
the monocrotaline-injury model of PH, mainly in CPT-1β  expression(33), and few case 
reports have shown reduced uptake of radiolabeled fatty acid analogues in the RV of 
patients with PAH(121). However, it remains unclear whether the changes in FA 
metabolism are beneficial or detrimental in the overall function of the RV. In the left 
ventricle, multiple studies have shown that the rate FAO is preserved or increased in 
physiological/adaptive hypertrophy, and that FAO decreases during the progression of 
heart failure(3). Similarly, we demonstrate a normal/increased expression of ACADM, 
ACADS and ACADVL in adaptive PAB-RV hypertrophy. These results are supported by 
the data of Fang and Archer, who demonstrated that rats with PAB-RV hypertrophy 
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exhibit higher rates of FAO(65). We postulate that along with capillary rarefaction, 
fibrosis and ROS-induced damage, mitochondrial metabolic remodeling in RVD is 
pathological. It has been reported that FAO inhibition may have a therapeutic 
potential(65) however, it will remain to be tested whether further inhibition of FAO is 
beneficial in the model of SuHx RVD.  
While it has been reported that RVD is associated with mitochondrial 
hyperpolarization(152), a comprehensive analysis of mitochondrial respiration in RVD is 
still lacking. Here we demonstrate that RVD is associated with significant mitochondrial 
dysfunction, reduced mitochondrial yield and reduced overall oxidative capacity. 
Surprisingly, although the expression of PGC-1α and TFAM was unchanged in PAB-RV 
hypertrophy, mitochondrial yield and citrate synthase activity were similarly decreased in 
both SuHx-RVD and PAB-RV hypertrophy. Because PGC-1α regulates mitochondrial 
biogenesis, our results would suggest an “uncoupling” between PGC-1α expression and 
mitochondrial biogenesis in adaptive PAB-RV hypertrophy. Yet, abnormal mitochondrial 
biogenesis can occur in the presence of normal PGC-1 levels(113). We speculate that 
preserved PGC-1α and TFAM expression could explain the better preserved 
mitochondrial respiration in PAB-RV hypertrophy when compared to SuHx-RVD, as 
both proteins play a critical role in mitochondrial function(67, 118).  
6.4 Study Limitations and Future Directions 
We do not know whether a decrease of in PGC-1α expression is a consequence or a cause 
of RVF. Nonetheless, our results show that decreased PGC-1α gene expression is not 
explained by a toxic effect of SU5416, hypoxia or RV pressure overload. Several 
mechanisms may participate in the downregulation of PGC-1α expression in RVD and 
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the associated gene metabolic remodeling. We did not explore whether the metabolic 
remodeling-dependent gene and protein expression profile affects enzymatic activity.  
6.5 Conclusions 
Our data illustrate that right ventricular dysfunction is associated with a complex 
multilevel disturbance of fatty acid oxidation and mitochondrial respiration that are not 
entirely explained by pressure overload or hypertrophy. We propose that RV metabolic 
remodeling is a consequence of decreased PGC-1α expression. To what extent metabolic 
remodeling or mitochondrial dysfunction is of functional importance for the development 
of RVD remains to be investigated.  
6.6 Clinical Perspective 
Our experiments demonstrate that in the setting of severe pulmonary arterial 
hypertension, load-independent alterations of cardiac energy metabolism and 
mitochondrial efficiency are associated with RVD. Because RV failure determines the 
outcome in patients with severe PAH, the cellular and molecular mechanisms which 
underlie RVF need to be understood for they could be reversible. As we design RV-
targeted therapies, the use of metabolic modulators should aim to restore not only 
substrate utilization but also mitochondrial function. 
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CHAPTER 7 
7.1 Introduction 
As it was discussed in Chapter 3, studying the mechanisms that contribute to the 
development of right ventricular failure is critical in order to develop new therapeutic 
strategies. Although we characterized the transcriptional profile in maladaptive RV 
hypertrophy (Chapter 6), we still do not know whether these changes in fatty acid 
oxidation are indeed adaptive or maladaptive or whether the use of metabolic modulators 
could improve function of the failing RV. Therefore, in this chapter, we sought to:  
1) Evaluate whether further blockade of fatty acid oxidation improved function of the failing 
right ventricle. 
2) Evaluate whether other metabolic modulators that do not affect substrate utilization but 
rather mitochondrial biogenesis improved function of the failing right ventricle. 
3) Evaluate whether treatment with the adrenergic receptor blocker, carvedilol, modified the 
metabolic transcriptional profile observed in maladaptive RV hypertrophy. 
7.2 Pharmacotherapies Used 
7.2.1 Etomoxir (D-enantiomer) treatment 
A group of SuHx animals was treated with the fatty acid oxidation blocker Etomoxir. 
Etomoxir was purchased as a D-enantiomer from Sigma-Aldrich (St Louis, MO). It was 
dissolved in PBS pH 7.4 (phosphate buffered saline 1x) and administered 
intraperitoneally in a standard dose of 7 mg/kg/day (equivalent to 15mg/kg/day of 
racemic Etomoxir) (133, 201, 233) for 2 weeks, starting once RV failure was established 
(as confirmed by echocardiogram). The D-enantiomer of etomoxir was used because it is 
more accurate to quantify and administer when compared to the racemic form. 
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7.2.2 Resveratrol treatment 
Resveratrol dissolved in with propylene glycol and water 50/50 was orally administered 
10mg/kg daily by oral gavage for 4 weeks starting once RV failure was established (as 
confirmed by echocardiogram).  
7.2.3 Recombinant human TFAM treatment 
A recombinant human mitochondrial transcription factor A (rhTFAM) produced and 
purified by Gencia Corporation, (Charlottesville, VA), kindly shared by Dr. James 
Bennett and collaborators. rhTFAM was stored in 50% sorbitol, and dialyzed against 5% 
glycerol in 1x PBS then filtered through 10,000 Amicon ultracentrifugal filter units 
(MWCO) right before injection. rhTFAM was administered at a dose of .67mg/kg and 
injected intravenously through rat tail vein once per week for 4 weeks.  
7.2.4 recombinant human TFAM protein sequence and characteristics 
For detailed information about the recombinant protein please refer to Reference (110, 
227). Briefly, RhTFAM is a translational fusion protein is composed by an HA epitope 
placed after an 11-Arginine protein transduction domain (PTD) which facilitates 
cytosolic escape of transduced protein after macropinocytosis(110). rhTFAM includes an 
N-terminal protein transduction domain to allow rapid translocation across cell 
membranes, followed by an SOD2 mitochondrial localization signal to stimulate uptake 
through the TOM-TIM mitochondrial translocases. RhTFAM enters the mitochondrial 
compartment of cells rapidly and can also transport mtDNA cargo into mitochondria. The 
nucleotide sequence corresponding to PTD-HA-MLS-TFAM is shown below:  
 [6X-His]-[SUMO3]-[11Arg PTD]–[HA]-[SODMLS]-[MatureTFAM] 
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[MGHHHHHHGG]-[MSEEKPKEGVKTENDHINLKVAGQDGSVVQ 
FKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLE 
MEDEDTIDVFQQQTGG]-[RRRRRRRRRRR]-[GEGDIMGEWGNEIFGAI 
AGFLGGE]-[MLSRAVCGTSRQLPPVLGYLGSRQ]-[SSVLASCPKKPVSSY LR 
FSKEQLPIFK AQNPDAKTTELIRRIAQRWR ELPDSKKKIYQD 
AYRAEWQVYKEEISRFKE QLTPSQIM SLEKEIMD KHLKRKAM TKKKEL 
TLLGKPKRPRSAYN VYVAERFQEA KGDSPQEKLK TV KENWKNLS 
DSEKELYIQH AKEDETRYHN EMKSWEEQ MIEVG RKD LLRRTIKKQR 
KYGAEEC) KGDSPQEKLK TVKENWKNLS DSEKELYIQH AKEDETRYHN 
EMKSWEEQ MIEVGRKD LLRRTI KKQR KYGAEEC](110). 
7.2.5 Adrenergic Receptor Blockage treatment 
Carvedilol treatment has been shown to improve RV function in experimental PAH (27). 
One group of SuHx (n=4-6) and one group of MCT (n=4-6) animals were treated with 
carvedilol (15mg/kg; Sigma-Aldrich, St Louis, MO) dissolved in 20% DMSO and water 
and administered once daily per oral gavage for 4 weeks, starting after RV failure was 
confirmed by echocardiogram. Another group of SuHx rats was treated with a β-1 
selective adrenergic receptor blocker (metoprolol). Metoprolol was administered in a 
dose of 150 mg/kg/day, dissolved in the drinking water. Both carvedilol and metoprolol 
doses have been validated previously (27). 
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Results and Discussions for Each Pharmacological Approach 
7.3 Pharmacological inhibition of fatty acid β-oxidation with Etomoxir does not 
improve function nor prevent deterioration of right ventricular function.  
To begin to address whether the changes in metabolic substrate utilization in the failing 
RVs, described in Chapter 6, were an adaptative or a maladaptative mechanism, we 
treated a group of SuHx animals (with established RVF assessed by echocardiogram) 
with a standarized dose of etomoxir (133, 201, 233), a potent carnitine-
palmitoyltransferase-1 (CPT-1) blocker. CPT-1 catalyses a rate-limiting (133) regulated 
step in mitochondrial transport of fatty acids, and failing RVs exhibit a residual 
expression of CPT-1 that could be targeted (Figure 17) . Therefore, we reasoned that 
pharmacological blockade of this enzyme would further reduce FAO in failing RVs, and 
if indeed a reduction in fatty acid oxidation in the setting of RVF were beneficial, we 
would expect an improvement in RV function after etomoxir treatment. Statistical 
analysis revealed that after 2 weeks of treatment with etomoxir or vehicle, there was a 
significant deterioration of RV function over time (p=0.013) but no significant difference 
in TAPSE or RV systolic area between vehicle and etomoxir treated groups (Figure 23A-
B). At the time of post-treatment echocardiogram and cardiac catheterization, etomoxir 
treatment did not show any improvement in RV function, nor did it modify pulmonary 
hypertension (Figure 23C-H). Importantly, etomoxir treatment did not halt the 
deterioration of RV function observed over time in the SuHx model (27, 162). 
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Figure 23.  
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Figure 23. SuHx rats were treated with Etomoxir or Vehicle at a dose 7 mg/kg/day for 2 
weeks after the animals had established RVF as assessed by echocardiogram. Paired T-
test reveals an overall significant deterioration in TAPSE (A) and RV systolic area (B) in 
both groups. Short-axis cardiac ultrasound illustrates the RV diastolic area (blue line) 
from a normal rat (C), when compared with a SU5416/hypoxia rat treated with vehicle 
(D) or treated with etomoxir (E). There was no significant difference in the RV diastolic 
area between etomoxir-treated and vehicle-treated groups. Separate group analysis at the 
time of sacrifice did not show any significant differences in TAPSE (C) or MPAP (D) 
between vehicle-treated versus etomoxir-treated animals. N= 4-8 per group. Data are 
shown in mean ± SEM. 
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Etomoxir was first described as a metabolic modulator for the treatment of acute heart 
failure (133) with the rationale that during experimental myocardial infarction, an 
overactive 5' AMP-activated protein kinase (AMPK) would drive excessive FAO, which 
in turn would result in greater mitochondrial reactive oxygen species formation (133, 
233). In these earlier studies, blockade of FAO by etomoxir resulted in improved 
functional capacity of the left ventricle, even in a model of LV chronic pressure-overload 
(233).  Based on these findings, one would predict that chronic etomoxir treatment would 
have a beneficial effect in RV function. Interestingly, SuHx failing RVs treated with 
etomoxir did not show improved RV function, etomoxir did not lower the pulmonary 
artery pressure or decrease RV hypertrophy. More importantly, etomoxir treatment did 
not prevent the progression of RVF which is observed in this model (162). These findings 
suggest that inhibition of FAO might not be an effective therapeutic strategy for RVF in 
the setting of severe PAH. 
Conversely, multiple studies have shown that the rate of fatty acid oxidation is preserved 
or increased in physiological/adaptive left ventricular hypertrophy, and that it decreases 
during the progression of heart failure (156). In a similar fashion, as shown in Chapter 6, 
rats with adaptive RV hypertrophy after pulmonary artery banding have increased rates of 
fatty acid oxidation (157). Multiple clinical trials evaluating the role of fatty acid 
oxidation blockers have been designed (158), however, none of these metabolic 
modulators have become a cornerstone in the treatment of heart failure. Moreover, no 
clinical trial has evaluated the role of metabolic modulators for PAH-associated RV 
failure. Recently, a clinical trial studying dichloroacetate, a mitochondrial modulator, has 
been started but it has not yet been concluded (ClinicalTrials.gov Identifier 
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NCT01083524). All together, our data would not support the use of fatty acid oxidation 
blockade to treat RV failure.  
7.4 Resveratrol treatment does not improve function nor prevent deterioration of 
right ventricular function 
Resveratrol (trans-3,5,4’-trihydroxystilbene) is a polyphenolic compound and naturally 
occurring phytoalexin, has been designated the active agent. Resveratrol is a potent 
inducer of sirtuins expression and it has been shown to be cardioprotective during 
myocardial infarction in rats through induction of VEGF and HO-1 enhancing 
neovascularization(112). Resveratrol can directly stimulate NADH dehydrogenases, and 
more specifically mitochondrial complex I activity, therefore increasing mitochondrial 
NAD+/NADH ratio(52). The NAD-dependent histone deacetylase sirtuin1 (SIRT1) is a 
key regulator of lifespan in lower organisms and mice, and plays an important role in 
cardiac energy metabolism. Several studies have shown that SIRT1 has pivotal 
cardioprotective roles (153). For instance, it has been reported that upregulation of SIRT1 
gene expression inhibits apoptosis, protects against oxidative stress and delays the 
progression of aging in the mouse heart (6, 7). Moreover, Hsu et al have demonstrated 
that cardiac-specific overexpression of SIRT1 protects from ischemia/reperfusion injury 
(99). Furthermore, SIRT1 modulates fatty acid oxidation mainly through deacetylation of 
PGC-1α (73) which increases PGC-1α activity and expression (autoregulatory 
expression)(36). SIRT1 not only plays a critical role in regulating energy substrate 
utilization, but also uniquely regulates angiogenesis signaling.  
Activation of SIRT1 by the natural phenol resveratrol has also been shown to improve 
health and survival of mice on a high-caloric diet (19). Moreover, synthetic SIRT1 
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activators –such as SRT1720 –have been shown to protect from diet-induced metabolic 
by predominantly by enhancing FAO (66). SRT1720 another activator of SIRT1 
promotes energy expenditure and enhanced expression of PGC-1α and PPAR-α (66). We 
initially demonstrated that RV failure tissue is characterized by decreased expression of 
SIRT1 protein in both humans and rats RVs (Figure 24A-B). Thus, we hypothesized that 
treatment with resveratrol would increase SIRT1 protein levels and induce PGC-1α 
expression and improve RV function. Interestingly, four weeks of resveratrol treatment 
did not improve nor prevented the progression of RV failure (Figure 24C) and in 
contrast, right ventricular systolic pressure was significantly increased (mean RVSP  
105±10 mmHg).   
Multiple studies have demonstrated the beneficial effects of resveratrol and a group of 
investigators has even reported that resveratrol treatment ameliorates the pulmonary 
hypertension caused by monocrotaline exposure(46). However, as discussed in Chapter 4, 
whether the improvement in RV function in this model was attributed to partial 
improvement of pulmonary hypertension (which is rather common in the monocrotaline-
injury model) or whether resveratrol has direct beneficial effects on the RV was not 
investigated or discussed by the authors. Our results demonstrate that resveratrol 
treatment was not sufficient to improve the function of the RV but rather worsened the 
disease and increase the pulmonary artery pressure. These results are interesting because 
PAH is an angiogenic disease where VEGF plays an important role. As mentioned 
previously, resveratrol can induce VEGF expression and therefore contribute to 
angiogenesis. However, whether this is the mechanism whereby resveratrol worsened 
pulmonary hypertension in the SU5416/hypoxia remains to be investigated.   
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Figure 24.  
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Figure 24. Protein levels of SIRT1 are decreased in SUHX rat RV tissue (A) and human 
RV tissue (B).  Function of the RV ventricle pre and post resveratrol treatment (C).
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7.5 Treatment with rhTFAM induces significant upregulation of rat TFAm and 
PGC-1α  transcript levels and improves RV longitudinal contractility 
The mitochondrial transcription factor A, is an essential component for the maintenance 
and replication of mitochondrial DNA(118). Thomas, Bennett and collaborators have 
demonstrated that rhTFAM can stimulate mitochondrial biogenesis, and restore ATP 
levels in cell models of Parkinson’s disease(227).  Furthermore, the have demonstrated 
that systemic treatment of young adult mice with rhTFAM stimulates mitochondrial 
biogenesis, increases mitochondrial respiration in brain, heart and muscle tissues and 
increases brain mitochondrial ATP synthesis while reducing ROS-induced damage to 
proteins(227). Therefore, because maladaptive RV hypertrophy in the SU5416/hypoxia 
model is characterized by decreased TFAm expression, abnormal mitochondrial 
biogenesis and by ROS-induced damage of DNA, we hypothesized that treatment with 
rhTFAM would improve the abnormal changes in mitochondrial biology and therefore 
improve RV function in the SU5416/hypoxia model of RVF. 
 Although we had originally plan to treat the animals for 4 weeks, we could not 
continue the treatment for more than one week. However, the results were encouraging as 
we demonstrated that SU5416/hypoxia animals treated with rhTFAM had an 
improvement in TAPSE and, perhaps more importantly, exhibited a significant increase 
in rat TFAM and PGC-1α transcript levels (Figure 25). Indeed, our findings are 
interesting because this is perhaps the first time a genetically engineered agent 
specifically designed to modify mitochondrial biogenesis has been utilized to treat RV 
failure. However, we should still evaluate whether rhTFAM improved RVF via induction 
of PGC-1α, whether it modified the changes in mitochondrial ultrastructure and function 
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observed in maladaptive RV hypertrophy (described in Chapter 6) and, perhaps most 
importantly, evaluate how is rhTFAM inducing the expression of rat TFAM and PGC-1α 
transcript levels.  
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Figure 25.  
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Figure 25. Although not significant, treatment with rhTFAM was sufficient to improve 
the longitudinal contractility of the RV as assessed by tricuspid annular plane systolic 
excursion (TAPSE) and cardiac output (A and B). Furthermore, rhTFAM treatment 
significantly induced the gene expression of rat TFAM and PGC-1α, as evaluated by 
qPCR. 
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7.6 Treatment with the adrenergic receptor blocker carvedilol reverses the 
metabolic transcriptional profile and improves mitochondrial respiratory efficiency  
We have reported that treatment with the non-selective adrenergic receptor antagonist 
carvedilol reverses established RVF in two different rat models of PAH 
(SU5416/hypoxia and monocrotaline-induced PAH), and that this improvement in RV 
function was associated with reduced hypertrophy and improved capillary density of the 
RV myocardium((26)). These changes were partially explained by an effect of carvedilol 
in the expression of genes that could be potentially relevant for the adaptive response of 
the RV to chronic pressure overload(26). However, the mechanisms by which carvedilol 
reverses maladaptive RV hypertrophy remain largely incomplete. Carvedilol has been 
shown to have pleiotrophic cardioprotective effects beyond heart-rate control. Indeed, a 
spectrum of anti-inflammatory, antioxidant, and anti-apoptotic actions of carvedilol have 
been reported in vitro and in vivo(135, 265). Based on microarray analysis, we have 
previously reported that RVF, in contrast to functional, compensated RV hypertrophy, is 
characterized by a distinct gene expression profile(55).  The set of differentially 
expressed genes was designated “RVF-prediction set”, and we speculated that these 
genes might play a critical role in the transition between adaptive hypertrophy and 
failure. Based on a similar approach, Drake and the rest of our group performed an in-
depth array assessment to show that carvedilol treatment affects the expression of a 
number of genes from the RVF prediction set(56). An initial analysis of carvedilol-
treated RVs showed that the gene expression profile mostly resembled that of the RVF 
tissue. However, an analysis beyond the boundaries of the prediction set revealed a small 
group of genes that were differentially expressed after carvedilol treatment (Figure 26). 
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In particular, we found a strong signal from mitochondrial dysfunction Ingenuity 
canonical pathway (Figure 27A). We examined the effect of carvedilol treatment on the 
expression of PGC-1α, ERR-α and PPAR-α, and their corresponding target genes and 
indeed found that carvedilol treatment restored PGC-1α, ERR-α, PPAR-α gene 
expression (Figure 27B-C), whereas the treatment with metoprolol had no effect on 
PGC-1α or PPAR-α gene expression. Furthermore, carvedilol treatment increased FAO 
genes expression towards control levels (Figure 28A).  
Similar to what we did in Chapter 6, we measured respiration of mitochondria isolated 
from RV tissue obtained from rats treated with carvedilol. Figure 28B demonstrates that 
mitochondria obtained from SuHx-RVs had significantly reduced ADP/O ratio, which 
measures mitochondrial respiratory efficiency. A lower ADP/O ratio represents higher 
oxygen consumption per unit of ADP provided. Next, because impaired mitochondrial 
respiration would be reflected in decreased ATP production, we indirectly assessed 
decreased ATP levels by measuring the activation (phosphorylation) of the AMP-
activated protein kinase (AMPK). Mammalian AMPK is sensitive to the cellular 
AMP/ATP ratio and is activated by metabolic stresses that inhibit ATP production (87). 
Figure 28 illustrates that carvedilol treatment improved the mitochondrial ADP/O ratio 
and restored the protein levels of phosphorylated AMPK, which suggests that carvedilol 
treatment improves mitochondrial function and restores ATP levels.   
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Figure 26
with median centering to identify differentially expressed genes.
Briefly, the SAM algorithm for a two-class comparison is as follows.
First, the relative difference in expression between two sets of samples
is calculated for each gene; this is the observed relative difference. To
calculate the expected relative difference, data labels are permuted
and the relative difference is calculated for each gene. The expected
relative difference for a gene will be the average relative difference
across all permutations. The observed relative difference is plotted
against the expected relative difference. Genes that fall outside of a
threshold value, !, will be called significant. !-Values were chosen to
give an acceptable false discovery rate (FDR) of " 5%. For each
gene, we report the FDR-equivalent P value, the q value as a
percentage. The q value is defined as the minimum FDR of a given
individual test at which a gene may be called significant.
The gene list was clustered by hierarchical clustering methods in
Cluster 3.0 (9) and visualized in Java Tree View (39). Based on
literature search results and pathway analysis results obtained using
Ingenuity Pathway Analysis [(IPA); Ingenuity Systems, Redwood
City, CA] and the PANTHER classification system (30, 44), we
selected genes for confirmation by quantitative RT-PCR.
For prediction analyses, raw expression data files were uploaded
into R (36) and normalized with the marray package (50) by the
Lowess normalization algorithm and then exported to BRB Array
Tools. Lowess intensity-dependent normalization was used to adjust
for differences in labeling intensities of the Cy3 and Cy5 dyes. The
adjusting factor varied over intensity levels (40). We identified genes
that were differentially expressed between the three classes by an F
test, using an #-level of 0.0001 for univariate testing, and performing
1,000 permutations for multivariate analysis.
The class prediction model was developed using diagonal linear
discriminant analysis (37), nearest neighbor classification (7), and
nearest centroid classification. The models incorporated genes that
were previously deemed significant. We estimated the prediction error
of each model using leave-one-out cross-validation (LOOCV) as
described by Simon et al. (42). For each LOOCV training set, the
entire model building process was repeated, including the gene selec-
tion process. We also evaluated whether the cross-validated error rate
estimate for a model was significantly less than one would expect
from random prediction. The class labels were randomly permuted,
and the entire LOOCV process was repeated. The significance level is
the proportion of the random permutations that gave a cross-validated
error rate no greater than the cross-validated error rate obtained with
the real data. We used 2,000 random permutations.
We have previously described a set of 450 genes that were most
discriminatory between normal RVs, adaptive nondysfunctional hy-
pertrophic RVs (induced by chronic hypoxia PH), and failing RVs
(induced by SU5416/hypoxia), and we designated this group of genes
SuHx + Carv                                  SuHx
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Fig. 2. Cluster for class comparison analysis
between SU5416/hypoxia RV (failure) and
SU5416/hypoxia$ carvedilol RV microarray
data sets. 489 probes were called significant at
an # " 0.001 level and multivariate permu-
tation testing gives a false discovery rate "
5%. Red represents greater relative expres-
sion than reference RNA, and green repre-
sents less relative expression than reference
RNA.
Table 2. Top five canonical pathways of subcluster 1
Pathway Name P Value
Regulation of eIF4 and p70S6k signaling 1.98 % 10&4
Glucocorticoid receptor signaling 2.61 % 10&4
Ceramide signaling 4.04 % 10&4
EGF signaling 4.94 % 10&4
eIF2 signaling 5.68 % 10&4
eIF, eukaryotic initiation factor.
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Figure 26. Cluster for class comparison analysis between SU5416/hypoxia RV (failure) 
and SU5416/hypoxia + carvedilol RV microarray data sets. 489 probes were called 
significant at an α< 0.001 level and multivariate permutation testing gives a false 
discovery rate < 5%. Red represents greater relative expression than reference RNA, and 
green represents less relative expression than reference RNA. Reproduced with 
permission from the publisher from Drake JI, Gomez-Arroyo JG, et al. Chronic 
carvedilol treatment partially reverses the right ventricular failure transcriptional profile 
in experimental pulmonary hypertension. Physiol. Genomics. 2013 Apr 30. 
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Indeed, carvedilol treatment not only increased PGC-1α gene and protein expression but 
also the expression of PGC-1α co-activated nuclear receptors ERR-α and PPAR-α as well 
as their corresponding target genes and the fact that metoprolol, a selective β2 blocker, 
did not restore PGC-1α gene expression could suggest a β2 or perhaps an α receptor-
dependent response. However, there are other pharmacological differences between 
metoprolol and carvedilol. As a G-coupled protein receptor, the adrenergic receptor can 
also bind non-classical intracellular proteins such as β-arrestins (53). The β-arrestin-
dependent signaling is largely ligand dependent and, in contrast to metoprolol, carvedilol 
is a biased agonist that can transactivate different intracellular pathways (258). However, 
whether the effects of carvedilol treatment observed in this study are β-arrestin dependent 
remains unclear. Furthermore, it remains to be investigated whether carvedilol reversed 
the transcriptional profile by directly affecting PGC-1α expression or whether PGC-1α 
transcript levels and mitochondrial function normalized after carvedilol improved the 
overall cardiac function. Nevertheless, disregarding whether it is a cause or consequence, 
our findings are interesting, because they suggest that there are set of genes that 
normalize when RV failure is treated (including the mitochondrial function genes), 
suggesting that these genes and/or signaling pathways are indeed critical for the reversal 
of RV failure.  
Conclusions  
The first decade of the 21st century finds the community of PAH trialists and researchers 
in a peculiar situation: The available drugs have some impact on patient survival but do 
not alter the remodeled lung circulation and in contrast, effective treatments targeting the 
lung vessels could have detrimental effects on the failing RV. Because there are 
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contrasting priorities within the different cell populations of heart and lungs, the 
development of PAH treatments that both reduce pulmonary vascular resistance and 
improve RV function is not straightforward. For instance, we demonstrated that although 
treatment with resveratrol could have had beneficial effects on the RV, non-selective 
effects in other organs, such as the lung, could worsen the disease. Specific support of 
RV contractility can perhaps be accomplished directly with carvedilol or modulators of 
mitochondrial biology such as rhTFAM, but further investigations are warranted.   
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Figure 27 
 
 
 
 
 
 
several member genes of this signaling pathway were de-
creased in expression after carvedilol treatment.
Metabolism, mitochondrial function, and oxidative stress
response. Subcluster 2 was made up of 207 probes that repre-
sented 192 different genes (Fig. 2). Figure 4 illustrates the
different biological processes, of which cellular, metabolic,
and developmental processes, as well as cellular component
organization pathways, were the most abundant. The top five
canonical pathways for the genes in this cluster are listed in
Table 3. Several of these pathways, including the peroxisome
proliferator-activator receptor (PPAR) signaling, PPAR!/reti-
noid X receptor-! activation, and nuclear respiratory factor
(Nrf)2-mediated oxidative stress response, represent metabolic
processes of critical importance for adequate heart function
(10). PPAR-! and -" are both coactivated by the PPAR
coactivator-1 alpha (PGC-1!). Both PGC-1! and PPAR-! are
preferentially expressed in tissues with high oxidative capacity,
such as the heart (10). Through coactivation of PPAR-! and
estrogen-related receptor alpha (ERR-!), PGC-1! activates
genes involved in the cellular uptake and mitochondrial oxi-
A
B
Normal               SuHx
SuHx+
-Carv
Fig. 6. A: canonical pathway analysis identified the pathways from the Ingenuity Pathway Analysis library of canonical pathways that were most significant to
the dataset. The P value for the mitochondrial dysfunction canonical pathway is 5.16 # 10$3. Genes are colored based on fold-change comparison between the
SU5416/hypoxia % carvedilol (treated) RV and the SU5416/Hypoxia (failing) RV. Red indicates a relatively higher expression in the treated RV than the failing
RV, and green indicates a relatively higher expression in the failing RV than the treated RV. B: microarray gene expression of genes encoding proteins involved
in mitochondrial dysfunction in subcluster 2. The first 3 major columns on the left labeled “normal,” “SuHx,” and “SuHxCarv” denote expression in the normal,
SU5416/hypoxia, and SU5416/hypoxia% carvedilol RVs. Red coloration indicates increased expression compared with the average normal RV expression level,
while green indicates reduced expression. The small columns represent different animals treated with the same condition. The last major column to the right of
the gray line labeled “-” denotes the difference in expression between the SU5416/hypoxia % carvedilol and SU5416/hypoxia RVs. Red coloration indicates
increased expression in the SU5416/hypoxia RV with carvedilol treatment compared with an untreated SU5416/hypoxia RV, and green indicates reduced
expression in the SU5416/hypoxia % carvedilol RV compared with the SU5416/hypoxia RV.
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in Fig. 2. Subcluster 1 was composed of 282 probes that
corresponded to 275 different genes. The top five canonical
pathways for genes in this cluster are listed in Table 2. Two of
the top canonical pathways, regulation of eukaryotic initiation
factor (eIF)4, p70S6k signaling and eIF2 signaling, were also
categorized as cellular processes. eIF-2 and 4 are both required
for the initiation of translation, and it is known that cardiac
hypertrophy requires an increase in protein synthesis by indi-
vidual cardiomyocytes (43). Thus, cardiac hypertrophy devel-
opment likely requires greater activity of the eIFs, and indeed
in a model of cardiac hypertrophy caused by chronic alcohol
intake, eIF2 levels were shown to be increased (24). In our
microarray dataset, several of the eIF genes were decreased in
expression after carvedilol treatment.
A reduction in genes encoding proteins involved in the
development of cardiac hypertrophy (Fig. 2, subcluster 1, and
Fig. 3) is reflected in the experimental data, which show that
carvedilol reduces hypertrophy in the SuHx RV (3). Of partic-
ular importance to pulmonary hypertension are the genes
hypoxia-inducible factor 1 alpha (HIF-1!), and angiopoietin-2
(Ang2). HIF-1! expression was decreased 2.1-fold in the SuHx"
Carv RV compared with the SuHx RV. Increased expression of
HIF-1a was found in the hearts of patients with PAH (26). Four
and a half LIM domains 2 (FHL2) was decreased 2.3-fold in
the SuHx RV. A decrease in FHL2 expression occurs in human
left ventricular heart failure and is associated with a reduction
in activity of phosphofructokinase 2 nd adenylate cy las (4).
Ang2 is also known to play a role in PAH. Ang2 has proan-
giogenic properties when expressed in high concentrations (31)
or in combination with VEGF (25, 52). Patients with idiopathic
PAH have increased plasma levels of Ang2, and these levels
correlate with a low cardiac index and high pulmonary vascular
resistance (22). Ang2 expression decreased 2.3-fold in the
SuHx" Carv RV compared with the SuHx RV. A reduction in
the expression of these genes, as seen in the SuHx" Carv RV,
could lead to reduced cardiac hypertrophy and improved myo-
cardial function.
We found that the ceramide signaling and glucocorticoid
receptor signaling pathways were two of the top five canonical
pathways in this subcluster (Table 2). Ceramide is considered
injurious to the heart (34), while glucocorticoid receptors have
been shown to play a role in postmyocardial infarction heart
remodeling (23). Several genes of these pathways were de-
creased in expression in the SuHx " Carv RV relative to the
SuHx RV. To a lesser extent, the sphingosine-1-phosphate
signaling pathway was affected by carvedilol treatment as
Table 3. Top five canonical pathways of subcluster 2
Pathway Name P Value
PPAR signaling 2.59 # 10$5
PPAR!/RXR! activation 5.75 # 10$4
Agrin interactions at neuromuscular junction 8.10 # 10$4
NRF2-mediated oxidative stress response 8.76 # 10$4
Prostate cancer signaling 1.56 # 10$3
PPAR, peroxisome proliferator-activator receptor; RXR, retinoid X r cep-
tor; NRF, nuclear respiratory factor.
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Fig. 5. A: quantitative real-time PCR analysis
of PPAR coactivator (PGC)-1!, estrogen-re-
lated receptor (ERR)-!, and peroxisome prolif-
erator-activator receptor (PPAR)-! in control,
failing (SuHx), carvedilol-treated (carvedilol),
and metoprolol-treated (metoprolol) RVs (*P %
0.01, #P % 0.001). B: Top: quantitative real-
time PCR analysis of PGC-1! in control, fail-
ing (SuHx), and carvedilol-treated (carvedilol)
RVs (*P % 0.01) Bottom: Western blot analy-
sis of PGC-1! in failing (SuHx) and carvedilol-
treated (carvedilol) RVs. C: quantitative real-
time PCR analysis of the PGC-1! downstream
genes CD36, ACSL1, CPT1!, CPT1&, CPT2,
and ACADM in control, failing (SuHx), and
carvedilol-treated (carvedilol) RVs (*P% 0.01,
#P % 0.001). D: mitochondrial efficiency mea-
sured as ADP/O ratio in control, failing (SuHx),
and carvedilol-treated (carvedilol) RVs (*P %
0.01).
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in Fig. 2. Subcluster 1 was composed of 282 probes that
corresponded to 275 different genes. The top five canonical
pathways for genes in this cluster are listed in Table 2. Two of
the top canonical pathways, regulation of eukaryotic initiation
factor (eIF)4, p70S6k signaling and eIF2 signaling, were also
categorized as cellular processes. eIF-2 and 4 are both required
for the initiation of translation, and it is known that cardiac
hypertrophy requires an increase in protein synthesis by indi-
vidual cardiomyocytes (43). Thus, cardiac hypertrophy devel-
opment likely requires greater activity of the eIFs, and indeed
in a model of cardiac hypertrophy caused by chronic alcohol
intake, eIF2 levels were shown to be increased (24). In our
microarray datas t, several of the eIF genes were decreased in
expression after carvedilol treatment.
A reduction in genes encoding protein involved in the
development of cardiac hypertrophy (Fig. 2, subcluster 1, and
Fig. 3) is reflected in the experimental data, which show that
carvedilol reduces hypertrophy in the SuHx RV (3). Of partic-
ular importance to pulmonary hypertension are the genes
hypoxia-inducible factor 1 alpha (HIF-1!), and angiopoietin-2
(Ang2). HIF-1! expression was decreased 2.1-fold in the SuHx"
Carv RV compared with the SuHx RV. Incre sed xpression of
HIF-1a was found in the hearts of patients with PAH (26). Four
and a half LIM domains 2 (FHL2) was decreased 2.3-fold in
the SuHx RV. A decrease in FHL2 expression occurs in human
left ventricular heart failure and is associated with a reduction
i a tivity of phosphofructokinase 2 and adenylate cyclase (4).
Ang2 is also known to play a role in PAH. A g2 has proan-
giogenic properties when expressed in high concentrations (31)
or in combination with VEGF (25, 52). Patients with idiopathic
PAH have increased plasma levels of Ang2, and these levels
correlate with a low cardiac index and high pulmonary vascular
resistance (22). Ang2 expression decreased 2.3-fold in the
SuHx" Carv RV compared with the SuHx RV. A reduction in
the expression of these genes, as seen in the SuHx" Carv RV,
could lead to reduced cardiac hypertrophy and improved myo-
cardial function.
We found that the ceramide signaling and glucocorticoid
receptor signaling pathways were two of the top five canonical
pathways in t is subcluster (Table 2). Ceramide is considered
injurious to the heart (34), while glucoc rticoid recepto s have
be n shown to play a role in postmyocardial infarction heart
remodeling (23). Several genes of these pathways were de-
creased in expression in the SuHx " Carv RV relative to the
SuHx RV. To a lesser extent, the sphingosine-1-phosphate
signaling pathway was affected by carvedilol treatment as
Table 3. Top five canonical pathways of subcluster 2
Pathway Name P Value
PPAR signaling 2.59 # 10$5
PPAR!/RXR! activation 5.75 # 10$4
Agrin interactions at neuromuscular junction 8.10 # 10$4
NRF2-mediated oxidative stress r sp nse 8.76 # 10$4
Prostate cancer signaling 1.56 # 10$3
PPAR, peroxisome proliferator-activator receptor; RXR, retinoid X recep-
tor; NRF, nuclear respiratory factor.
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Fig. 5. A: quantitative re l-time PCR analysis
f P AR coactivato (PGC)-1!, estrogen-re-
lated recepto (ERR)-!, and peroxisome prolif-
erator-activator receptor (PPAR)-! in control,
failing (SuHx), carvedilol-treated (c rvedilol),
and metoprolol-treated (metoprolol) RVs (*P %
0.01, #P % 0.001). B: Top: quantitative real-
time PCR analysis of PGC-1! in contro , fail-
ing (SuHx), and carvedilol-treated (carvedilol)
RVs (*P % 0.01) Bottom: Western blot analy-
sis of PGC-1! in failing (SuHx) and carvedilol-
treated (carvedilol) RVs. C: quantitative real-
time PCR analysis of the PGC-1! downstream
genes CD36, ACSL1, CPT1!, CPT1&, CPT2,
and ACADM in control, failing (SuHx), and
carvedilol-treated (carvedilol) RVs (*P% 0.01,
#P % 0.001). D: mitochondrial efficiency mea-
sured as ADP/O ratio in control, failing (SuHx),
and carvedilol-treated (carvedilol) RVs (*P %
0.01).
454 CARVEDILOL PARTIALLY REVERSES RVF GENE EXPRESSION PATTERN
Physiol Genomics • doi:10.1152/physiolgenomics.00166.2012 • www.physiolgenomics.org
 at Virginia C
om
m
onw
ealth U
niv on August 5, 2013
http://physiolgenom
ics.physiology.org/
D
ow
nloaded from
 
	   144	  
 
Figure 28 
 
in Fig. 2. Subcluster 1 was composed of 282 probes that
corresponded to 275 different genes. The top five canonical
pathways for genes in this cluster are listed in Table 2. Two of
the top canonical pathways, regulation of eukaryotic initiation
factor (eIF)4, p70S6k signaling and eIF2 signaling, were also
categorized as cellular processes. eIF-2 and 4 are both required
for the initiation of translation, and it is known that cardiac
hypertrophy requires an increase in protein synthesis by indi-
vidual cardiomyocytes (43). Thus, cardiac hypertrophy devel-
opment likely requires greater activity of the eIFs, and indeed
in a model of cardiac hypertrophy caused by chronic alcohol
intake, eIF2 levels were shown to be increased (24). In our
microarray dataset, several of the eIF genes were decreased in
expression after carvedilol treatment.
A reduction in genes encoding proteins involved in the
development of cardiac hypertrophy (Fig. 2, subcluster 1, and
Fig. 3) is reflected in the experimental data, which show that
carvedilol reduces hypertrophy in the SuHx RV (3). Of partic-
ular importance to pulmonary hypertension are the genes
hypoxia-inducible factor 1 alpha (HIF-1!), and angiopoietin-2
(Ang2). HIF-1! expression was decreased 2.1-fold in the SuHx"
Carv RV compared with the SuHx RV. Increased expression of
HIF-1a was found in the hearts of patients with PAH (26). Four
and a half LIM domains 2 (FHL2) was decreased 2.3-fold in
the SuHx RV. A decrease in FHL2 expression occurs in human
left ventricular heart failure and is associated with a reduction
in activity of phosphofructokinase 2 and adenylate cyclase (4).
Ang2 is also known to play a role in PAH. Ang2 has proan-
giogenic properties when expressed in high concentrations (31)
or in combination with VEGF (25, 52). Patients with idiopathic
PAH have increased plasma levels of Ang2, and these levels
correlate with a low cardiac index and high pulmonary vascular
resistance (22). Ang2 expression decreased 2.3-fold in the
SuHx" Carv RV compared with the SuHx RV. A reduction in
the expression of these genes, as seen in the SuHx" Carv RV,
could lead to reduced cardiac hypertrophy and improved myo-
cardial function.
We found that the ceramide signaling and glucocorticoid
receptor signaling pathways were two of the top five canonical
pathways in this subcluster (Table 2). Ceramide is considered
injurious to the heart (34), while glucocorticoid receptors have
been shown to play a role in postmyocardial infarction heart
remodeling (23). Several genes of these pathways were de-
creased in expression in the SuHx " Carv RV relative to the
SuHx RV. To a lesser extent, the sphingosine-1-phosphate
signaling pathway was affected by carvedilol treatment as
Table 3. Top five canonical pathways of subcluster 2
Pathway Name P Value
PPAR signaling 2.59 # 10$5
PPAR!/RXR! activation 5.75 # 10$4
Agrin interactions at neuromuscular junction 8.10 # 10$4
NRF2-mediated oxidative stress response 8.76 # 10$4
Prostate cancer signaling 1.56 # 10$3
PPAR, peroxisome proliferator-activator receptor; RXR, retinoid X recep-
tor; NRF, nuclear respiratory factor.
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Fig. 5. A: quantitative real-time PCR analysis
of PPAR coactivator (PGC)-1!, estrogen-re-
lated receptor (ERR)-!, and peroxisome prolif-
erator-activator receptor (PPAR)-! in control,
failing (SuHx), carvedilol-treated (carvedilol),
and metoprolol-treated (metoprolol) RVs (*P %
0.01, #P % 0.001). B: Top: quantitative real-
time PCR analysis of PGC-1! in control, fail-
ing (SuHx), and carvedilol-treated (carvedilol)
RVs (*P % 0.01) Bottom: Western blot analy-
sis of PGC-1! in failing (SuHx) and carvedilol-
treated (carvedilol) RVs. C: quantitative real-
time PCR analysis of the PGC-1! downstream
genes CD36, ACSL1, CPT1!, CPT1&, CPT2,
and ACADM in control, failing (SuHx), and
carvedilol-treated (carvedilol) RVs (*P% 0.01,
#P % 0.001). D: mitochondrial efficiency mea-
sured as ADP/O ratio in control, failing (SuHx),
and carvedilol-treated (carvedilol) RVs (*P %
0.01).
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in Fig. 2. Subcluster 1 was composed of 282 probes that
corresponded to 275 different genes. The top five canonical
pathways for genes in this cluster are listed in Table 2. Two of
the top canonic l pathways, regulati n of eukaryotic nitiation
factor (eIF)4, p70S6k sig aling and eIF2 sig aling, were also
categorized as cellular process s. eIF-2 and 4 are both required
for the nitiati n of translation, and it is known that cardiac
hypertrophy requires an incr ase in protein synthesis by indi-
vidu l cardiom ocytes (43). Thus, cardiac hypertrophy devel-
opment likely requires greater ac ivity of the eIFs, and in eed
in a model of cardiac hypertrophy caused by chroni alcohol
intake, eIF2 levels were shown to be incr ased (24). In our
microarray dataset, several of the eIF genes wer decr ased in
expression after carvedilol treatment.
A reductio in gen s encoding proteins in olved in the
development of cardiac hypertrophy (Fig. 2, subcluster 1, and
Fig. 3) is reflected in the xperimental data, w ic show that
carvedilol reduces hypertrophy in the SuHx RV (3). Of partic-
ular importance to pulmonary hypertension are the genes
hypoxia-inducible factor 1 alpha (HIF-1!), and angiopoietin-2
(Ang2). HIF-1! expression was decr ased 2.1-fold in the SuHx"
Carv RV compared with the SuHx RV. Incr ased expressi n of
HIF-1 was fou d in the hearts of patients with PAH (26). Four
and half LIM domains 2 (FHL2) was d cr ased 2.3-fold in
the SuHx RV. A d cr ase in FHL2 expressi n occurs in human
left ventricular heart failure and is associated with a reduction
in ac ivity of phosphofructokinase 2 an adenylate cyclase (4).
Ang2 i also known to pl y a role in PAH. Ang2 has proan-
iogenic rop rties when expr ssed in igh o centrations (31)
or in combination with VEGF (25, 52). Patients w th idiopathic
PAH have incr ased plasma levels of Ang2, and these levels
corr late with a low card ac index and igh pulmonary vascular
resistance (22). Ang2 expression d cr ased 2.3-fold in the
SuHx" Carv RV compared with the SuHx RV. A reduction in
the expressi n of these gene , as seen in the SuHx" Carv RV,
could lead to reduced cardiac hypertrophy and improved myo-
cardial function.
We found that th ceramide sig aling and glucocorticoid
receptor sig aling pathways were two of the top five canonical
pathways in this subcluster (Table 2). Ceramide is considered
injurious to t heart (34), while glucocorticoid receptors have
been shown to pl y a role in postmyocard al infarction heart
remodeling (23). Several genes of these pathways wer de-
cr ased in expression in the SuHx " Carv RV relative to the
SuHx RV. To a l ss r xtent, the sphingosine-1-phosphate
sig aling pathway w s affected by carvedilol treatment as
Table 3. Top five canonical pathways of subcluster 2
P thw y Name P Value
PPAR signaling 2.59 # 10$5
PPA !/RXR! activation 5.75 # 10$4
Agrin interactions at neuromuscular junction 8.10 # 10$4
NRF2-mediated oxidativ tr ss response 8.76 # 10$4
Prostate cancer signaling 1.56 # 10$3
PPAR, per xisome prolifer tor-activator receptor; RXR, retinoid X recep-
tor; NRF, nucl ar respiratory factor.
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Fig. 5. A: qu ntitative real-time PCR analysis
of PPAR co ctivator (PGC)-1!, estrogen-re-
lated receptor (ERR)-!, and per xisome prolif-
er tor- ctivator receptor (PPAR)-! i control,
failing (SuHx), carvedilol-treated (carvedilol),
and met prolol-treated (metoprolol) RVs (*P %
0.01, #P % 0.001). B: Top: qu ntitative real-
time PCR analysis of PGC-1! i contro , fail-
ing (SuHx), and carvedilol-treated (carvedilol)
RVs (*P % 0.01) Bottom: Western blot analy-
sis of PGC-1! n failing (SuHx) and carvedilol-
treated (carvedilol) RVs. C: qu ntitative real-
time PCR analysis of the PGC-1! downstream
genes CD36, ACSL1, CPT1!, CPT1&, CPT2,
and ACADM i control, failing (SuHx), and
carvedilol-treated (carvedilol) RVs (*P% 0.01,
#P % 0.001). D: mitochondrial fficiency mea-
sured as ADP/O ratio i contro , failing (SuHx),
and carvedilol-treated (carvedilol) RVs (*P %
0.01).
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Figure 27: A) Canonical pathway analysis identified the pathways from the Ingenuity 
Pathway Analysis library of canonical pathways that were most significant to the dataset. 
Genes are colored based on fold-change comparison between the SU5416/hypoxia + 
carvedilol (treated) RV and the SU5416/Hypoxia (failing) RV. Red indicates a relatively 
higher expression in the treated RV than the failing RV, and green indicates a relatively 
higher expression in the failing RV than the treated. . B) Quantitative real-time PCR 
analysis of PPAR coactivator (PGC)-1α, estrogen-related receptor (ERR)-α, and 
peroxisome proliferator-activator receptor (PPAR)-α in control, 0.5 failing (SuHx), 
carvedilol-treated (carvedilol), and metoprolol-treated (metoprolol) RVs (*P <0.01, #P 
<0.001). Reproduced with permission from the publisher from Drake JI, Gomez-Arroyo 
JG, et al. Chronic carvedilol treatment partially reverses the right ventricular failure 
transcriptional profile in experimental pulmonary hypertension. Physiol. Genomics. 2013 
Apr 30 
Figure 28: A) Quantitative real- time PCR analysis of the PGC-1α downstream  genes 
CD36, ACSL1, CPT1α, CPT1β, CPT2, and ACADM in control, failing (SuHx), and 
carvedilol-treated (carvedilol) RVs (*P <0.01, #P < 0.001). B) mitochondrial efficiency 
mea- sured as ADP/O ratio in control, failing (SuHx), and carvedilol-treated (carvedilol) 
RVs (*P <0.01). ). Reproduced with permission from the publisher from Drake JI, 
Gomez-Arroyo JG, et al. Chronic carvedilol treatment partially reverses the right 
ventricular failure transcriptional profile in experimental pulmonary hypertension. 
Physiol. Genomics. 2013 Apr 30 
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8. SUMMARY OF THE DISSERTATION AND FUTURE DIRECTIONS 
 
As mentioned throughout the dissertation, pulmonary arterial hypertension is a complex 
disease. However, the essence of the chapters of these thesis could be summarized in a 
few bullet points for any clinician or investigator interested in the study of PAH and the 
associated right ventricular failure: 
 
1. Whereas the recent years have seen a dramatic increase in the number of 
publications regarding new pathobiological hypotheses, mechanistic studies, pre-
clinical (experimental) trials and clinical studies evaluating biomarkers, mortality 
predictors and pharmacotherapies, PAH continues to be an incurable disease. 
Moreover, although multiple clinical trials and registries have demonstrated a 
shift in survival curves, the overall patient survival in the “modern era of targeted 
pharmacotherapies” remains incredibly low and the survival of “incident” PAH 
patients appears to be similar to that of the idiopathic PAH patients enrolled in the 
1981-1991 NIH registry.  
2. Patients with PAH (almost invariably) die from right ventricular failure. 
Therefore, characterizing and dissecting the mechanisms that underlie the 
transition between adaptive and maladaptive RV hypertrophy is critical for the 
development of new treatments. Current (and newly proposed) pharmacotherapies 
face a critical paradox: While the remodelled lung circulation in PAH is 
characterized by angiogenesis, apoptosis-resistance and cell proliferation, the 
failing RV suffers from ischemia, capillary rarefaction and cardiomyocyte 
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apoptosis, conditions that could be worsened by pharmacotherapy targeting the 
pulmonary vascular remodelling. 
3.  Current animal models of PAH are not perfect; however, far from being 
exclusive the animal models of chronic RV pressure-overload are complementary 
depending on what aspect of the disease the researcher is trying to reproduce.  
4. Pressure overload might not be sufficient to drive the stressed right ventricle into 
failure. Although our study of patients with Eisenmenger syndrome does not 
provide a mechanism to explain the adaptation to pulmonary hypertension in 
these patients, it generates multiple hypotheses. Furthermore, the analyses of 
animal models of adaptive RV hypertrophy in the pulmonary artery banding rats 
suggest that load (pressure)-independent mechanisms contribute to the 
development of right ventricular failure.  
5. Along with cardiomyocyte apoptosis, cardiac fibrosis, capillary rarefaction, right 
ventricular failure is characterized by load-independent, multilevel impairment of 
fatty acid oxidation and mitochondrial dysfunction. Whereas downregulation of 
PGC-1α could be responsible for the metabolic remodelling that we described in 
maladaptive right ventricular hypertrophy, further mechanistic studies are 
warranted. Contrary to what has been described for animal and human studies of 
left heart failure, we postulate that decreased fatty acid oxidation is secondary to a 
broader context of abnormal mitochondrial biology. Hence, metabolic modulators 
should focus on restoring the balance between mitochondrial biogenesis and 
turnover (mitophagy).  
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6. We cannot definitely conclude whether metabolic remodelling is a cause or 
consequence of right ventricular failure. However, the gene expression studies 
from rats treated with carvedilol, together with the metabolic transcriptional 
profile from animals with adaptive right ventricular hypertrophy after pulmonary 
artery banding, suggest that restoring fatty acids as the preferential substrate for 
the heart is indeed associated with compensated right ventricular function.  
 
As predicted many questions remain, but perhaps the most important question that could 
be derived from our research work is: Can prevention of right ventricular dysfunction 
prolong life? The results presented in this dissertation suggests that there are indeed 
mechanisms of RV failure that can be targeted with the goal to preserve RV function in 
the setting of severe PAH.  
 
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
✄ 
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